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ABSTRACT 
 
 Cysticercosis is a parasitic disease caused by the larva of the cestode Taenia solium. The 
objectives of this study were to estimate 1) the annual cost of neurocysticercoss (NCC) in 
outpatients and hospitalized patients, 2) the pre-hospitalization, hospitalization, and post-
hospitalization costs for hospitalized NCC patients, and 3) the total societal cost of cysticercosis 
in Mexico. In order to accomplish these objectives, a case series was conducted in two neurology 
referral hospitals in Mexico City. Information on presenting clinical manifestations, diagnostic 
tests, hospitalizations, surgical procedures, and other treatments received by NCC patients was 
collected from medical charts. A questionnaire was used to evaluate productivity losses and out-
of-pocket expenses related to NCC. In order to estimate the societal cost of cysticercosis, 
epidemiologic and economic parameters were obtained from the published literature, 
government reports, and interviews with ministry of health workers, primary care providers, and 
secondary care providers. 
 Interviews were conducted and medical charts reviewed for 224 NCC patients. The 
annual average per patient direct costs were U.S.$ 503 (95% CI: 414 – 592) and U.S.$ 438 (95% 
CI: 322 – 571) for outpatients without a history of hospitalization and/or surgery seen at the two 
referral hospitals. These costs increased to U.S.$ 2,506 (95% CI: 1,797 – 3,215) and U.S.$ 2,170 
(95% CI: 1,303 – 3,037) for patients with a history of hospitalization and/or surgery. The 
medical charts of 108 patients hospitalized for NCC were reviewed to estimate pre-
hospitalization, hospitalization, and post-hospitalization costs. The average per-patient pre-
hospitalization and hospitalization costs were U.S.$ 257 (95% CI: 185 – 329) and U.S.$ 2,576 
(95% CI: 2,244 – 2,908), respectively. Post-hospitalization costs decreased over time, with 
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estimates for the first five years post-hospitalization of U.S.$ 475 (95% CI: 423 – 527), U.S.$ 
228 (95% CI: 167 – 288), U.S.$ 157 (95% CI: 111 – 202), U.S.$ 150 (95% CI: 106 – 204), and 
U.S.$ 91 (95% CI: 27 – 154), respectively. The total 2012 monetary losses associated with 
people with NCC-associated epilepsy and NCC-associated severe chronic headaches, in Mexico, 
along with losses to the agriculture sector, was estimated to be U.S.$ 250,219,772 (95% CR: 
145,560,590 - 384,051,262). Cysticercosis continues to create health disparities and significant 
economic losses in Mexico. 
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CHAPTER I 
 INTRODUCTION AND LITERATURE REVIEW* 
 
Taenia solium (T. solium) cysticercosis is a cestode zoonosis with public health 
importance. Pigs are the intermediate hosts and become infected when they ingest T. solium eggs 
that are shed in the feces of infected humans. Ingested larvae hatch in the intestine of the pig, 
penetrate the intestinal mucosa, reach the blood stream and migrate to tissues, including muscle. 
Humans are the definitive hosts of T. solium and become infected with the intestinal adult 
tapeworm (taeniasis) by ingesting undercooked pork containing cysticerci. Humans can also 
become accidental intermediate hosts after ingesting T. solium eggs leading to cysticercosis. The 
condition is predominantly found and considered endemic in Latin American, Asian, and African 
countries where pigs are raised using traditional methods, meat inspection is insufficient, and 
sanitation is poor [1-3]. However, it is now increasingly being diagnosed in other regions such as 
the United States, Western Europe, and Canada due to an increasing flow of immigrants from 
endemic areas who may have taeniasis or cysticercosis [4-7].   
Neurocysticercosis (NCC) occurs when immature T. solium larvae migrate to the central 
nervous system. When NCC manifests, it is often in the form of epilepsy/seizures, 
hydrocephalus, severe chronic headaches, focal deficits, increased intracranial pressure, 
dementia, vasculitis, or stroke. Among these clinical manifestations, epilepsy/seizures, 
headaches, focal deficits and increased intracranial pressure are the most common [8,9]. The 
social consequences of NCC potentially include stigmatization, incapacitation, and 
___________________________________________________ 
*Part of this chapter is reprinted © 2013 Bhattarai R, Carabin H, Budke C. (2013) The Burden of Cysticercosis, Novel Aspects 
on Cysticercosis and Neurocysticercosis, Prof. Humberto Foyaca Sibat (Ed.), Published in InTech under CC BY 3.0 license. 
Available from: http://dx.doi.org/10.5772/51668.  
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decreased work productivity [10]. In endemic countries, the stigma associated with epilepsy may 
have a greater impact on patients’ lives than the clinical manifestations of the disease itself [11]. 
In addition, due to the reduction in quality of life and the psychological effects of the condition, 
work productivity might be further decreased [9,12,13]. 
In pigs, infection with the larval stage of the parasite results in the development of cysts 
in the skeletal muscles and less commonly in the heart, diaphragm, brain, and other organ 
systems. The presence of these cysts can lead to partial or full condemnation of the carcass and 
economic losses in areas where meat is inspected [2]. In some areas, pig traders look for the 
presence of cysts under the tongue before buying pigs, and will offer a lower price for infected 
animals [2,14]. This parasite can, therefore, reduce the household income of farmers.  
There is a need to evaluate the socioeconomic impact, or burden, of this condition on 
endemic communities. Both non-monetary and monetary methods can be employed [15]. These 
estimates may then be compared to other locally important health or agricultural conditions to 
prioritize disease control initiatives. Disease burden estimates can subsequently be used to 
compare alternative control strategies for cysticercosis, as well as other diseases affecting the 
population, through cost-utility and cost-benefit analyses. Although NCC is endemic in many 
areas of the world and is believed to be associated with considerable economic losses, very few 
studies have been conducted to evaluate the burden of NCC [16-20]. Therefore, more 
comprehensive studies are needed to estimate the actual burden of NCC in endemic areas in 
order to allocate resources for health interventions.  
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I.1 Life cycle 
The parasite needs two hosts to complete its life cycle. Humans are the definitive hosts of 
T. solium and pigs are the intermediate hosts. Pigs become infected when they ingest T. solium 
eggs that are shed in the feces of infected humans. Ingested larvae hatch in the pig’s intestine, 
penetrate the intestinal mucosa, reach the blood stream, and migrate to tissues, including muscle 
[21]. Humans become infected with the adult tapeworm (taeniasis) by ingesting undercooked 
pork containing T. solium cysticerci. Eggs and/or mature proglottids are regularly excreted by 
human tapeworm carriers. The adult parasite develops proglottids, which mature, become gravid, 
detach, and migrate to the anus or are passed in the stool. Adult worms can have more than 1,000 
proglottids. The eggs contained in the gravid proglottids are released after the proglottids are 
passed with the feces. A single adult parasite can  produce more than 50,000 eggs per proglottid 
[22]. Humans can also act as accidental intermediate hosts either by ingestion of food 
contaminated with feces/eggs or by autoinfection. After reaching the small intestine, eggs hatch 
and the embryos (oncospheres) migrate through the mucosa to enter the circulation, which then 
carries the larvae to various tissues, including the central nervous system (CNS), eyes, and 
striated muscle, leading to cysticercosis and/or (NCC [22] (Figure 1).  
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Figure 1: Life cycle of T. solium (Adapted from: [22]) 
 
I.2 Methods for evaluating the burden of zoonotic infections 
Taenia solium cysticercosis results in mortality, morbidity, and economic losses in 
affected human and animal populations. To evaluate the burden of cysticercosis, the monetary 
and non-monetary impacts of the disease on human health, agriculture, and society must be 
considered comprehensively [15]. Measuring the burden of cysticercosis is challenging because 
it requires various types of data from valid studies conducted in human and pig populations. 
Because of those challenges, it is recommended to focus the evaluation on a certain period and to 
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one geographical area where high quality epidemiological and clinical studies have been 
conducted, preferably in both pigs and humans. The disadvantage of such an approach is that the 
data cannot be generalized to other areas.  
Certain types of epidemiological data are required for the estimation of both the non-
monetary and the monetary burden of cysticercosis [15]. In humans, these data include the 
frequency of disease occurrence, the frequency and duration of each NCC-associated 
manifestation; NCC-associated mortality; the proportion of patients with NCC who seek care in 
clinics and hospitals of various levels; the proportion of patients who seek care from traditional 
healers; and the number (or incidence) of cases of NCC diagnosed after care has been sought. In 
pigs, the data required include the proportion of pigs that are inspected pre or post-mortem and 
the proportion of infected pigs diagnosed pre or post-mortem [15]. Such data may be found in 
the published/unpublished literature and national or regional databases. When some aspects of 
the data are unavailable, the opinion of local experts may be sought.  
In estimating the burden of NCC, there is the additional challenge that the internationally 
recognized definition of NCC requires the use of diagnostic imaging (computed tomography 
(CT) scan or magnetic resonance imaging (MRI)) or autopsy [23]. The absence of advanced 
diagnostic imaging facilities limits the evaluation of the burden of NCC in many areas of the 
world, and especially in the poorest regions where the disease is likely to be most prevalent. 
Serological tests are designed to measure the exposure to or current infection with cysticercosis 
[24], but can show low specificity and sensitivity in the diagnosis of NCC, depending on the 
number and stages of lesions present in the brain [25]. Therefore, test accuracy needs to be 
considered when evaluating frequency of infection [26]. 
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I.2.1 Measuring the non-monetary burden of cysticercosis 
Specific measures have been designed to estimate the non-monetary burden of human 
diseases [15,27]. One of the most informative measures of non-monetary burden is “utility”, a 
health economics concept which measures the preference that people have for certain health 
status along a continuum [28]. Utility theory arose from Jeremy Bentham's utilitarian 
philosophy, which was first proposed in 1789. Broadly speaking, utility has always been 
synonymous with preference, the more preferable an outcome, the greater the outcome’s "utility" 
[29]. Several Health Adjusted Life Years (HALYs) metrics have been developed as indicators of 
“utility”. HALYs are summary measures of population health that enable measures of mortality 
to be combined with measures of disability associated with each sequela (manifestation) of the 
disease of interest into one metric [28]. 
There are two types of HALYs that have been commonly used in estimating human 
burden of disease: Quality Adjusted Life Years (QALYs) and Disability Adjusted Life Years 
(DALYs). Even though QALYs and DALYs may be used to estimate utility, they were 
developed to serve different purposes. Where DALYs are meant to be used as an objective, 
population-based measure, QALYs are meant to be used as a subjective, individual-based 
measure of utility of health. DALYs are used to compare disease burdens in many different 
populations on a comparable basis. QALYs are used to assess individual preferences for various 
outcomes from complex interventions or measure the ability of the subject to perform some task 
or function. In addition, these measures use opposite scales. The DALY is a negative concept, 
with one DALY being the equivalent of one year lived completely disabled (analogous to death) 
whereas the QALY is a positive concept, with one QALY being the equivalent of one year of 
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healthy life [28]. Therefore, control strategies would aim to minimize DALYs and maximize 
QALYs. 
 
I.2.1.1 Quality Adjusted Life Years (QALYs) 
The ideal way of measuring quality of life is to attribute a utility, or a weighted 
preference for a certain health status. Utility is not only good for measuring the status of patients 
who have one clinical manifestation, but also for people suffering from several ailments. In 
theory, the utility of a health status is best measured with choice-based methods, which include 
uncertainty, such as the standard gamble method. Other choice-based methods, without 
uncertainty, include paired person-trade-off and time-trade-off techniques [29]. Utility measures 
are based on Paretian welfare economics, which requires that each individual be the judge of his 
or her own welfare. However, in practice, these methods are difficult to implement because 
different people have different reactions when faced with uncertainty and choices, especially 
when these are theoretical. For example, in the standard gamble method, the patients are asked to 
find the probability “p” at which they would be unable to choose between remaining in their 
current state of health or dying immediately with a probability of p (and living healthy with a 
probability of 1-p). Given the difficulty in implementing such measures, several groups of 
researchers have developed multi-attribute classification systems implemented in the form of 
scale-based questionnaires. Each answer to the scaled questions contributes a certain weight 
towards calculating utility. The utility weights are determined during studies where both the 
questionnaire and one of the choice-based methods are used, and then assumed generalizable to 
other contexts. Multi-attribute questionnaires are more commonly used than choice-based 
measures in QALYs studies. One advantage of multi-attribute questionnaires is that they may not 
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only be used to estimate utility, but also to assess the perceptions of patients regarding different 
aspects of their health (i.e., mental, physical, social functioning).  
QALYs combine quantitative estimates of death and frequency and duration of disease 
with a qualitative assessment of how well (or not) patients can live with the disease. In other 
words, rather than just counting the number of people with the disease, QALYs try to “adjust” 
for how well people can live with the disease. Individuals experience different health states, 
where the health states are weighted according to their utility scores. Utilities are measured on a 
cardinal scale of 0-1. More preferable states receive more weight. A year of perfect health is 
worth 1 and a year of less than perfect health is worth less than 1. Death is considered to be 
equivalent to 0.  However, some health states may be considered worse than death and have 
negative values. Therefore, QALYs are a product of life expectancy and a measure of the quality 
of remaining life years, with weights placed on time spent in different health states [29]. 
The multi-attribute measurement scales most commonly used in developing countries, 
where NCC is endemic, are the Euro-Qol (EQ-5D) and the Short Form-12 (SF-12) [15,30]. 
These tools provide patient-based determination of quality of life and can be used to compare 
perceptions of physical, mental, and social health among patients with different diseases (or lack 
of disease), different stages of the same disease, or before and after treatment of the disease. The 
latter approach is often used in clinical trials where a drug, while very effective in treating the 
disease, may be linked to numerous side effects, which could lead to worse quality of life than 
the disease itself.  
Although QALYs are commonly used metrics in health economics, they also present 
some limitations. For example, adaptation of patients to certain symptoms may mask the impact 
of chronic disability [31]. In addition, it is difficult to assign a single utility score to those 
 9 
 
 
diseases that cause a variety of clinical manifestations, such as NCC [32]. One important 
criticism of QALYs (which some view as an advantage), is that QALYs are based on poor 
measurement techniques. In particular, values are often developed with small, non-representative 
sample sizes [33]. Measures are subjective and not meant to be generalized to society as a whole. 
QALYs associated with a disease in one country (or region) could not be used to estimate the 
burden in another region (or country). For example, having epilepsy in the United States would 
have very different social and functioning values than in Sub-Saharan Africa. This difficulty in 
using QALYs for international comparison led a group of researchers to develop a completely 
different type of metric for measuring burden: the DALY. Lastly, there are several concerns 
regarding the validity and reliability of measurements focused on the utility value of health status 
[34]. Since measuring utility values is a challenging process, different QALY methods can 
produce different results [33]. Also, populations may explain their state of illnesses and wellness 
differently. For example, physicians might assign different utility values than the general 
population. This has been shown in a study examining depression where patients assigned a 
utility value of 0.31 and physician assigned a utility value of 0.42 [35].  
 
I.2.1.2 Disability Adjusted Life Years (DALYs) 
DALYs were first constructed for the Global Burden of Disease (GBD) Study in 1990 in 
order to provide a comparable measure of output for interventions, program and sector 
evaluations, and planning [36]. The GBD Study was conducted to evaluate the non-monetary 
burden of a variety of infectious and non-infectious conditions, as well as risk factors, on pre-
defined regions of the world. The latest comprehensive assessment of the burden of diseases was 
for the year 2016 [37]. The DALY is a summary measure of population health that assesses the 
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disability and early mortality associated with the condition of interest. DALYs measure the gap 
in years between age at death and standard life expectancy and combines it with time lived in 
states other than excellent health (disabled). They are obtained by summing years of life lost 
(YLL) from premature death and healthy years lost due to disability (YLD). The formulas used 
for the calculation of YLL and YLD are described below: 
 
YLL = N * L……………………….Eq. 1 
where N = number of deaths per age-sex group, L = remaining life expectancy at age of death 
 
YLD = I * DW * D………………….Eq. 2 
where I = age and sex specific estimates of incidence, DW = disability weight, D = average 
duration of disability.  
  
 The GBD Study 2010 and subsequent versions (GBD 2013, 2015 and 2016) based the 
YLD calculation on prevalence rather than incidence [37-39]:  
 
YLD = P * DW..............................Eq. 3 
where P = number of prevalent cases, DW= disability weight. 
 
 The incidence-based YLD approach has many disadvantages [40]. If only incidence is 
considered, the measure will not reflect the current prevalent burden of disabling sequelae for a 
condition for which incidence has been substantially reduced [39]. In addition, the incidence-
based YLD calculation requires estimates of both incidence and average duration of disease 
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sequelae, whereas for many health conditions such as NCC, primarily prevalence data are 
collected. Using an incidence-based approach, all YLDs for a condition are assigned to the age-
groups at which the condition is first diagnosed, whereas the policy-maker is often more 
interested in the ages at which loss of health is experienced [39]. Finally, incorporation of 
comorbidity is more straightforward in a prevalence approach than an incidence approach [40]. 
In the prevalence approach, all conditions present at a point in time are measured or estimated to 
adjust for comorbidity, whereas in the incidence approach, each age-sex-geography-time group 
is modeled from the incidence of all conditions and their associated excess mortalities. This task 
is information intensive and computationally challenging.[39] 
Disability weights represent the magnitude of health loss associated with the outcome. 
Disability is placed on a uni-dimensional scale between 0 (perfect health) and 1 (death). In 
theory, utility is equal to 1-disability weight. Disability weights of clinical manifestations 
(referred to as indicator states) were determined for the original GBD Study by the person trade-
off (PTO) method [41]. The PTO method is a way of estimating social preferences for different 
health states by asking experts or a specific group of individuals how many people affected by 
the health state of interest they would be willing to trade for extending the lives of 100 healthy 
people.  
The GBD 2010 Study undertook a comprehensive re-estimation of disability weights 
through surveying respondents in two ways: household surveys (face-to-face interviews in 
Bangladesh, Indonesia, Peru, Tanzania; telephone interviews in USA) and an open-access web-
based survey (included respondents from most countries of the world) [42]. Data were collected 
from 13,902 household surveys and 16,328 web-based surveys. The GBD 2010 Study estimated 
disability weights for 220 health states using a method involving discrete choice comparisons of 
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“health” for pairs of health states described using lay descriptions consisting of a brief summary 
of the health state of an average or modal case in 30 words or less [42].  
 The GBD 2013 Study evaluated data from new web-based surveys of participants aged 
18–65 years, completed in four European countries (Hungary, Italy, the Netherlands, and 
Sweden), combined with data previously collected in the GBD 2010 disability weights 
measurement study [43]. Similar to the GBD 2010 Study, the GBD 2013 study also used paired 
comparison questions for which respondents considered two hypothetical individuals with 
different health states and specified which person they deemed healthier. The GBD 2015 and 
2016 calculated DALYs using the 2013 disability weights [37,44]. Changes implemented since 
the GBD 2013 include incorporation of sources of new mortality and morbidity data, important 
model improvement for certain diseases such as HIV, malaria, tuberculosis, injuries, diabetes and 
cancers, and disaggregation of specific causes into subgroupings to provide additional detail.  
The original GBD Study calculations considered two additional parameters: 1) 
discounting future time and 2) age weighting [36]. Discounting future time is a common concept 
in economic and social policy. In burden of disease estimations, a discount rate is applied so that 
future healthy life has less value than the net value of life today [41]. In the context of DALYs, a 
disability occurring today is worth more than the same disability occurring in the future. The 
subject of discounting is complex and several papers have been published in favor and against its 
use in the context of DALYs and health outcomes [41,45-47]. By including age weighting, the 
original GBD Study incorporated social preferences for the value of life lived during adulthood 
over life lived during childhood or later years. However, subsequent GBD studies did not include 
age weighting in the DALYs calculations. Therefore, the influence of age weighting was 
eliminated [39]. 
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The original GBD Study had several limitations [45,47-50]. For example, the study 
calculated the years of life lost due to premature mortality by comparing study population life 
spans to the average life expectancies (life expectancy of 82.5 years at birth for women and a life 
expectancy of 80.0 years at birth for men) of the population of Japan. Therefore, DALYs 
understated the burden of disease of females relative to males since the standard expectation of 
life at birth in Japan is very similar in men and women [45]. The DALY also does not take into 
consideration cultural or socioeconomic differences in populations so that it underestimates the 
disease burden in developing countries [48]. In addition, the discounting and age weighting used 
in the original GBD Study have been widely criticized  [45,47].  
The GBD 2010 Study and onwards addressed some of these limitations by   developing 
new disability weights, removing influence of age weighting and discounting, and using more 
appropriate life tables. Although DALYs are commonly used to measure the burden of zoonotic 
diseases, they are not capable of capturing the burden of disease associated with animal 
infections. However, even with these shortcomings, the DALY is a useful metric to measure and 
compare the disease burdens. 
 
I.2.2 Measuring monetary burden  
Estimates of the monetary burden of zoonotic diseases that impact both human and 
livestock health should include assessment of both human health costs and animal health costs. 
The overall estimated cost can be calculated using the following equation: 
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This equation corresponds to the additive societal costs for all affected species (S) across all age 
groups (A). For the age-species-specific population of size (Na,s), with the age-species-specific 
annual incidence (ßa,s), there is an age-species proportion (x,a,s,) of infected individuals with 
symptoms X. The treatment and consequences of each of these symptoms have a monetary 
burden of Cx,a,s. Ideally, the whole spectrum of symptoms and losses in humans and animals is 
included in the estimate [51].  
 
I.2.2.1 Human health costs 
Human health costs are classified into direct and indirect costs [15,29,52]. Direct costs 
are costs associated with the diagnosis and treatment of patients whereas indirect costs are costs 
associated with loss of working days due to illness. Commonly used diagnostic tests for NCC 
incorporated into direct cost estimates include diagnostic imaging, sero-immunological and 
blood tests, and tests on cerebral spinal fluid (CSF). Diagnostic costs, for a neurological 
condition such as NCC, can be high since CT scans and MRI confirmatory tests are not readily 
available in developing countries and, if available, are often distantly located and expensive  
[53]. Cost of treatment typically includes the cost of medicines, medical consultations, surgical 
charges, and hospital charges. In contrast to direct costs, indirect costs include costs of working 
days lost due to clinical manifestations or visits to hospitals, losses in productivity, buying over-
the-counter drugs to relieve symptoms, costs of traditional treatment, cost of transportation to 
and from medical treatment, and family member costs during their roles as caregivers [15]. 
Human health costs can also be divided into 1) hospital costs, 2) community care costs, 
3) patient and family costs, and 4) costs related to other sectors [29]. Hospital costs include 
diagnostic testing, hospitalization, and outpatient visits. Community care costs include general 
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practitioner visits, nurse visits, and ambulance use. Patient and family costs include patients’ and 
relatives’ time lost while seeking and receiving care and out-of-pocket expenses for over the 
counter medicines. Costs related to other sectors include social worker and home help visits [29]. 
 
I.2.2.2 Animal health costs 
Costs associated with animal disease can also be divided into direct and indirect costs 
[52]. Direct costs can result from the condemnation of all or part of an infected carcass. For 
example, the partial or full condemnation of a pig carcass with a heavy cysticercosis infection. 
The value of live animals can also be reduced [15]. Indirect costs are costs related to other 
disease-related production losses [52]. 
 
I.2.3 Decision tree analysis 
Decision trees are helpful in organizing the information gathered on the distribution of 
manifestations and treatment-seeking pattern in the study population. They can also be used to 
incorporate the probability of receiving different types of diagnoses and treatments [54]. The tree 
usually starts with a “trunk” which is the population of interest. From this trunk, a probability 
(chance node) corresponding to the frequency of the disease (in the case of NCC, this can be 
epilepsy) is used to create the first two “branches” of the tree: the presence or absence of the 
disease in the study population. Additional branches are added each time a new probability is 
added. Each probability (node) may lead to more than two branches. The end of each branch 
corresponds to the patient’s probability of following a certain treatment/diagnosis path, including 
the path of not seeking any medical care. The probability of each branch of a path can be 
multiplied by the costs corresponding to the options in that branch.  As an example, the use of 
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decision tree analysis to estimate the non-monetary burden of NCC in urban Mexico is shown in 
Figure 2. In this example, for the branch of people with epilepsy who have NCC and seek 
medical attention, we would multiply 0.69% by 25% by 13% to obtain the frequency of having 
NCC and being treated (0.0224%, as shown in Figure 2) [55-58]. Such trees can be developed 
for very complex treatment paths and for the impact of animal disease. 
 
Figure 2: Decision tree analysis for estimating the non-monetary burden of NCC in Mexico. 
Circle is a chance node and triangle is an end node [23]. 
  
 
 
In some cases, the sum of all probabilities from one node may be more than one. This is 
common when we look at diagnosis or treatments of patients, where patients may receive 
different tests or drugs [58]. Figure 3 shows a decision tree where the sum of the probabilities 
from one node was more than one. 
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Figure 3: Decision tree analysis for estimating the monetary burden of NCC patients 
receiving antiepileptic treatment 
 
 
 
I.2.4 Uncertainty and sensitivity analysis 
Common sources of epidemiological and economic data used in the assessment of disease 
burden include government and agency reports and values reported in the scientific literature 
[15]. Values for neglected zoonotic diseases, such as T. solium cysticercosis, are often 
underreported or else the method of collection might be biased. In short, exact estimates of these 
parameters are difficult to identify. Therefore, in order to account for uncertainties or to 
minimize collection bias, the distribution of these parameters should be selected carefully. 
Therefore, instead of using an exact value for each probability and cost, a distribution of values 
is used to reflect uncertainty [58]. Monte Carlo or Latin Hypercube sampling methods are often 
applied to incorporate the various distributions into the final estimate, which will itself be a 
distribution reflecting the uncertainty of all included parameters [58].  
Uniform distributions can be applied to parameters for which we have very limited 
knowledge and state that the shape of the uncertainty is flat [16,58]. The sampling method would 
start by sampling one value (for example, 1%) from this distribution, and then save the estimate 
of the cost of NCC using this value. Next, another value would be sampled from the distribution 
resulting in another estimated cost, which will also be saved. This process is usually repeated up 
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to 10,000 times until a distribution of the overall costs is obtained. The Latin Hypercube and 
Monte Carlo methods are efficient tools allowing sampling of several uncertain parameters 
iteratively [59].  
The sampling method described above will generate a database of 10,000 observations 
each associated with different values for the uncertain parameters. We can then employ linear 
regression using the estimated costs as the outcome and all of the uncertain parameters as 
“independent” variables to assess which uncertain parameters have the largest impacts on the 
estimated costs. The uncertain parameters with the largest impacts should be those that need to 
be better studied in the future because they have a strong influence on how much a disease costs 
a society.  
 
I.3 The non-monetary and monetary burden of cysticercosis  
I.3.1 Non-monetary burden 
The GBD Studies 2010, 2013, 2015 and 2016 as well as the World Health Organization 
(WHO) (2010) have published non-monetary estimates for cysticercosis [37-39,44,60].  In 
addition, five independent studies have estimated the non-monetary burden of cysticercossi in 
Cameroon, Mexico, Tanzania, India and Nepal [17,18,20,58,61].  Table 1 compares T. solium 
cysticercosis disease burden estimates from the GBD 2010, 2013 and 2016 with individual 
investigator estimates.  
The goal of the 2010 WHO study was to provide estimates of the global burden of 
foodborne diseases according to age, sex, and region for a defined list of infectious and non-
infectious causes. This study only published data at a regional level. Therefore, it has been 
excluded from table 1 [60]. The WHO study utilized the number of prevalent cases of epilepsy 
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used in the GBD 2010 Study to estimate the number of prevalent cases of epilepsy-associated 
NCC. Population at risk was estimated by taking into consideration religion, sanitation and pig 
population. 
According to a recent meta-analysis, approximately 29.0% (95% UI 22.9%– 35.5%) of 
people with epilepsy in populations living in T. solium-endemic areas have brain lesions due to 
NCC [56]. Therefore, twenty-nine percent of the burden of epilepsy from the GBD 2010 Study 
was applied to the population at risk to estimate the burden of epilepsy attributable to NCC [39].  
The GBD 2010 Study has not published their modeling methodology for estimating the burden 
of cyscticercosis and, therefore, it remains unclear how they obtained their estimates. The GBD 
2013 Study used the proportion of epilepsy patients with NCC based on studies in endemic areas 
and applied this proportion to prevalent epilepsy cases [38], whereas the GBD 2015 and 2016 
studies used similar methodologies to the WHO study [37,44]. 
The estimated numbers of DALYs lost based on independent studies were higher than 
those from the GBD studies. Differences in methodology as well as model inputs likely 
contributed to estimate disparities. While the GBD studies calculated prevalence-based DALYs, 
the independent studies calculated incidence-based DALYs. Other methodological differences 
include how populations were stratified. For example, the Mexico and India studies stratified by 
urban/rural areas, age groups, and gender whereas the other studies did not use such 
stratifications [20,58]. All studies, excluding the Mexico study, based its cysticercosis estimates 
solely on epilepsy cases whereas, the 2012 Mexico study evaluated both epilepsy and severe 
chronic headaches cases [58]. In addition, three percent discounting and non-uniform age-
weighting were applied in the Mexico and Cameroon studies. Therefore, the number of DALYs 
lost would be even higher if the discounting and age-weighting effect were removed.  
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 These independent studies have some limitations. Incidence was obtained by dividing the 
prevalence by the duration of symptoms. In addition, the duration of epilepsy and severe chronic 
headaches was assumed the same among treated and untreated cases, which is unlikely to be 
true. Due to limited published peer-reviewed data, several input parameters for estimating 
DALYs were based on systematic reviews of the literature, dissertations and data from other 
countries, indicating the need for additional studies. 
 
Table 1: Comparison of the non-monetary burden of cysticercosis estimated by the GBD 
studies [37-39,44], and independent studies conducted in Mexico, Cameroon, Tanzania, 
India and Nepal [17,18,20,58,61] 
 
Country DALYs 
attributed to 
cysticercosis by 
the GBD Study 
2010  
DALYs 
attributed to 
cysticercosis 
by the GBD 
Study 2013 
DALYs 
attributed to 
cysticercosis 
by the GBD 
Study 2016 
DALYs attributed to 
cysticercosis by 
independent studies 
(Year of the study) 
Mexico 7,649; 95% 
CR:2,629 – 
20,559 
28,299; 95% 
CR:19,412 – 
39,365 
13,897; 95% 
CR: 9,256  - 
19,921   
25,341; 95% CR: 
12,569–46,640 
(2012)*  
Nepal 4,220; 95% 
CR:2,785 – 
6,022 
1,453; 95% 
CR: 600 – 
2,670 
2,656; 95% 
CR: 1,537 - 
4,444 
14,268; 95% CR: 
5,450–27,694  
10,924; 95% 
CR:4,270 – 21,301* 
(2014) 
Cameroon 
 
9,025;  
95% CR: 6,238 
– 12,519 
6,025;  
95% CR: 
2,613  - 13,046    
9,135;  
95% CR: 4,823 
- 15,026 
45,838;  
95% CR: 14,108 – 
103,469 (2009)* 
Tanzania 14,230  
95% CR: 9637–
20,047 
3,900;  
95% CR: 
1,800 - 6,400 
 
5,018;  
95% CR: 3,284 
- 7,202 
27,225;  
95% CR: 8129–
58,921 
(2012)* 
India Not available  68,700; 
 95% CR: 
34,900 - 
124,300 
127,744 95% 
CR: 81,039 - 
180,589  
1,279,490 95% CR: 
697,795–2,271,556 
(2011)* 
* based on three percent discounting and non-uniform age-weighting 
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I.3.2 Monetary burden 
 Very few studies have been conducted to evaluate the economic burden of cysticercosis. 
Table 2 compares monetary burden estimates for T. solium cysticercosis, in U.S. dollars, from 
three studies which estimated the country-level cost of cysticercosis, including both human and 
agricultural losses [16-18]. A study conducted in India was not included in this comparison due 
to methodology differences, including using annual incident cases as compared to prevalent 
cases to calculate the monetary burden and excluding pig losses [20]. A study conducted in Lao 
PDR was also not included in the comparison due to unclear methodology [19]. For example, in 
the Lao PDR study, it was not clearly mentioned how the authors estimated the number of NCC-
associated epilepsy cases [19].  
 
Table 2: Comparison of the monetary burden due to T. solium cysticercosis in Eastern 
Cape Province, South Africa, West Cameroon and Tanzania (in U.S. $) 
 
Estimate Eastern Cape 
Province, South 
Africa [16] 
West 
Cameroon [17] 
Tanzania [18] 
Study year 2004 2009 2012 
Country population 7,088,000 5,065,382 44,928,923 
Estimated number of NCC-
associated epilepsy cases 
34,662 50,326# 47,804 
Overall monetary burden, 
including NCC-associated 
epilepsy losses and pig losses  
% due to porcine 
cysticercosis 
18.6 - 34.2 
million** 
 
 
14.6 - 26.9% 
14.9 million* 
 
 
 
4.7% 
7.9 million 
 
 
 
35.4% 
Average cost per NCC-
associated epilepsy patient  
632 - 844 240 106 
Average cost per capita  2.6 - 4.2 2.9 0.176 
* based on a 2009 exchange rate of 1 U.S.$ = 0.69 Euro 
 
** The range is due to the application of different calculation methods for wage and productivity 
losses (mean wage approach, generalist replacement costs, and opportunity costs).  
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 In the Eastern Cape Province (ECP) of South Africa, the average cost per NCC-
associated epilepsy case per year was U.S.$ 632-844 while in Cameroon  and Tanzania, the 
average cost was estimated to be much lower at U.S.$ 240 and U.S.$ 106, respectively [16-18]. 
The large difference in cost per NCC-associated epilepsy case may be due to lower salaries and 
treatment costs in Cameroon and Tanzania compared to the ECP. In all three studies, a large 
proportion of the total costs were related to indirect costs. In the ECP and Cameroon, agricultural 
losses contributed less to the total costs than in Tanzania. Compared to Tanzania, the pig 
population was also about four to five times lower in the ECP and Cameroon. In addition, the 
proportion of infected pigs as well as reduction in the price of infected pigs were lower in the 
ECP and Cameroon compared to Tanzania. All three studies only evaluated NCC cases 
presenting with epilepsy. Therefore, the total estimated costs were likely underestimated.  
 Few studies have been performed to evaluate the economic burden for patients with 
NCC. A study conducted in India, in 1997, estimated the cost of treating seizure disorders 
associated with solitary cysticercus lesions at U.S.$ 174.66 per patient [62].  Indian patients, in 
this study, were spending a considerable proportion (50.9%) of their per capita gross national 
product on treatment-related expenses. This study was conducted in a reference center and only 
represented a fraction of the total regional population with NCC, with an over-representation of 
more severe cases. Therefore, the overall cost per NCC case was not generalizable to all NCC 
cases. In addition, this study only estimated the cost of epilepsy due to a solitary cysticercus 
granuloma. These granulomas not only cause seizures, but also cause other clinical 
manifestations including severe chronic headaches, hydrocephalus, stroke, and dementia. The 
cost of treating these other clinical manifestations would increase the reported estimates. NCC is 
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also not only caused by solitary cysticercus granulomas and this study did not include clinical 
manifestations associate with multiple cystiscercus lesions and calcified cysts. 
 Another study conducted in a reference center for neurological disorders in Peru from 
1999 - 2002 estimated a mean cost of U.S.$ 966 per NCC patient, including treatment costs and 
wage/productivity losses due to NCC over a two-year treatment period [63]. Patients enrolled in 
the study reported seizures (21%), headaches (55%), unusual behavior changes (51%) and 
memory loss (57%). Treatment costs and wage/productivity losses were equivalent to 54% of an 
annual minimum wage salary during the first year of treatment and 16% of an annual minimum 
wage salary during the second year of treatment [63]. Similar to the Indian study, this study was 
also conducted in a reference center and only represented a fraction of the total regional 
population with NCC, with an over-representation of more severe cases. Therefore, the overall 
cost per NCC case was not generalizable to all NCC cases in Peru.  
A study conducted in a referral hospital in Santiago, Chile from 2006 – 2010 reported 
that the median cost of treating NCC was U.S.$ 1293. However, the number of patients was very 
small (six) and of the clinical manifestations presented by patients were not mentioned [64]. Two 
studies have been carried out in the U.S. The first study estimated an average hospitalization 
charge per NCC patient over the duration of treatment of U.S.$  37,600 based on 1991-2008 
California hospital discharge data [65]. The second study estimated that there were 28,565 
cysticercosis-related hospitalizations during 1998 – 2009 based on a nationwide inpatient sample 
of annual hospital discharge records, representing a hospitalization rate of 8.16 persons per 
million population [66]. There were an estimated 364 NCC-associated deaths in the U.S. during 
1998 - 2009, representing an overall case-fatality rate of 1.28% and a nationwide in-hospital 
mortality rate of 0.1 deaths per million population. National estimates of charges for 
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cysticercosis-related hospitalizations amounted to approximately U.S.$ 996 million for the 
twelve-year study period. The average annual charge per hospitalization discharge record was 
estimated at U.S.$ 37,140 [66]. Costs associated with healthcare provider visits and certain 
diagnostic techniques used before and after hospitalization were not included in either U.S.-
based estimate, likely resulting in an underestimate of actual treatment costs. 
 The findings from above studies suggest that T. solium can result in considerable 
monetary losses. These results can be used to show the importance of introducing control efforts 
to reduce or eliminate this disease in endemic areas. Since this infection is preventable, these 
results can be used to assist stakeholders in allocating scarce health and agricultural resources in 
endemic countries. 
 
I.4 Cysticercosis in Mexico 
Mexico is the third largest country in Latin America, with a 2017 population of almost 
124 million and an annual population growth rate of 1.2%. Seventy-eight percent of the 
population lives in urban areas.  The official literacy rate is 93.5% [67]. Traditional pig rearing 
practices (free roaming) in T. solium endemic areas allow pigs to have access to human feces in 
open fields, facilitating the completion of the parasite’s  life cycle [68,69]. Confined pigs in 
yards next to dwellings may also have direct access to poorly maintained and sealed outdoor 
latrines [70].  
There is currently a debate regarding the epidemiological status of cysticercosis in 
Mexico [71,72] and hence, it is important to find out to what extent it is still a significant burden 
to the society.  According to Fleury et al., 2010, NCC is still a public health problem in Mexico. 
This article showed that NCC frequency had not significantly changed between 1994 and 2009 
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among patients attending a tertiary care hospital in Mexico City [71]. However, the study was 
conducted in a single reference hospital and the results might not be applicable to the entire 
country. On the other hand, according to Flisser and Correa 2010, improving socioeconomic 
conditions have resulted in a decrease in the number of cysticercosis cases  in Mexico from 1995 
(reported cases: 1,608) to 2009 (reported cases: 231) [72].  
Studies are needed to estimate the current burden of cysticercosis in endemic countries, 
such as Mexico, to facilitate international comparison of disease burdens and identify priorities 
for control. To assess the current socioeconomic impact of cysticercosis in Mexico, it is 
important to estimate the costs incurred by NCC patients and society as a whole. The objectives 
of the research presented here are: 
I. To estimate the direct and indirect per-patient annual costs associated with the treatment 
of NCC outpatients receiving care between July 2007 and August 2008 in two tertiary 
care hospitals in Mexico City, Mexico  
II. To estimate the direct costs associated with pre-hospitalization, hospitalization, and post-
hospitalization for NCC patients seeking care at a referral hospital in Mexico City, 
Mexico 
III. To estimate the monetary burden of cysticercosis in Mexico, incorporating two common 
clinical manifestations of patients with NCC, epilepsy and severe chronic headaches, as 
well as pig infection-associated losses.  
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CHAPTER II 
COST OF NEUROCYSTICERCOSIS PATIENTS TREATED IN TWO REFERRAL 
HOSPITALS IN MEXICO CITY, MEXICO** 
 
II.1 Introduction 
Neurocysticercosis (NCC) is a parasitic disease, which most often manifests as epilepsy, 
hydrocephalus, severe chronic headaches, increased intracranial pressure, dementia, vasculitis, or 
stroke [8]. NCC occurs when a human ingests parasite eggs shed in the feces of a person infected 
with the intestinal form of Taenia solium, with the eggs developing into larvae in the central 
nervous system.  The epidemiological status of NCC in Mexico is being debated [71,72]; hence, 
it is important to determine to what extent this disease is still a burden to society.  The burden of 
a disease can be assessed qualitatively through the description of how it affects patients’ quality 
of life or quantitatively through the estimation of its morbidity, mortality or costs to the patients 
and the society where they live [15].   
 In Mexico, NCC-associated severe chronic headaches and epilepsy were recently 
reported to reduce the quality of life of NCC patients under care [9] and incur a life of NCC 
patients has also been reported in Brazil and Peru [13,73] and substantial numbers of NCC-
associated DALYS have been reported from Nepal and Cameroon [17,61].The monetary impact 
of NCC has been reported as the average treatment cost per patient under care for patients in  
____________________________ 
**Reprinted with permission from "Cost of neurocysticercosis patients treated in two referral hospitals in Mexico City, Mexico" 
by Bhattarai R, Carabin H, Proano JV, Flores-Rivera J, Corona T, et al. (2015) Trop Med Int Health 20: 1108-1119, Copyright 
[2015] by Wiley. 
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considerable number of disability adjuste life years (DALYs) [58]. Reduction in the quality of 
India and Peru [62,63]. Direct costs associated with treatment of NCC have also been assessed in 
California, U.S.A. [65].  In addition to focusing on NCC in humans, three studies have evaluated 
NCC-associated monetary losses to both the human health and agricultural sectors in South 
Africa, Lao PDR and Cameroon [16,17,19]. The objective of this study was to estimate the direct 
and indirect per-patient annual costs associated with the treatment of 224 NCC patients receiving 
care between July 2007 and August 2008 in two tertiary care hospitals in Mexico City, Mexico.   
 
II.2 Materials and methods 
II.2.1 Study location 
This study was conducted in the two main referral hospitals for adult neurological cases 
in Mexico City, Mexico: the Instituto Nacional de Neurologia y Neurocirugia (INNN) and the 
Hospital de Especialidades of the Instituto Mexicano del Seguro Social (HE-IMSS). The INNN 
is a referral institution that accepts patients who do not have medical coverage through their 
employment. The HE-IMSS is a referral institution that provides medical services to patients 
with social security coverage.   
 
II.2.2 Definition and study populations 
 NCC was defined based on the presence of compatible cerebral lesions on a computed 
tomography (CT) scan, by magnetic resonance imaging (MRI), or both [23]. Outpatients 
diagnosed with NCC and with a clinical appointment between July 17 and December 7, 2007 at 
the INNN and between June 2 and August 12, 2008 at the HE-IMSS were eligible to participate 
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in the study. Eligible patients were identified using outpatient appointment books, which allowed 
the research assistant to explain the study and ask for patient consent at the time of the 
appointment. At least 100 NCC outpatients were enrolled from each participating hospital.  For 
data analysis purposes, the study population was broken down into those patients that had been 
previously hospitalized and/or undergone a surgical procedure for the diagnosis or treatment of 
NCC (referred to as patients with a history of hospitalization) and those patients without a 
history of hospitalization or surgery (referred to as patients without a history of hospitalization). 
The study population was further stratified based on presenting clinical manifestations. 
 
II.2.3 Data collection  
 After obtaining informed consent, patients were interviewed by a trained member of the 
research team (e.g., a Mexican medical student, intern, or resident) at the time of their 
appointment. Questions focused on socio-demographic factors, knowledge of T. solium 
transmission, and time and monetary losses due to the inability to work or conduct their usual 
activities due to NCC. The questionnaire was originally written in English, translated into 
Spanish, back-translated into English by two independent persons, and pilot tested locally prior 
to use (Appendix A and B).  
The medical charts of all participating NCC patients were reviewed between July 17 and 
December 7, 2007 at the INNN and between June 2 and August 12, 2008 at the HE-IMSS. Intake 
forms were used to record information on the clinical manifestation(s) of NCC that caused the 
patient to be referred to the hospital. Diagnostic and treatment forms were used to record 
information on techniques used for the confirmation of NCC and the drugs and procedures used 
for its treatment. Inpatient and outpatient forms were used to record information on the number 
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of times patients were hospitalized or had an outpatient appointment for the treatment and 
management of NCC (Appendix C, D, E and F). 
 
II.2.4 Frequency of use of healthcare resources 
 The frequency of appointments with various healthcare providers (neurologists, 
neurosurgeons, psychiatrists, neurotologists and general practitioners), prescription medication 
use, hospitalizations, surgical interventions, and diagnostic testing (computed tomography (CT) 
scans, magnetic resonance imaging (MRI), cerebral spinal fluid (CSF) testing, enzyme-linked 
immunosorbent assays (ELISA), electroencephalograms (EEG), enzyme-linked 
immunoelectrotransfer blot (EITB), biopsies and neurological examinations) was estimated using 
the forms described above. The average number of times per year that study participants 
consulted with a healthcare provider or utilized a service was calculated by taking the total 
number of times each patient consulted each service and dividing this value by the number of 
years of follow-up. 
 
II.2.5 Estimation of direct costs 
Patients seen at the INNN pay medical fees according to their household income. There 
are seven levels of payment. Patients with a very low household income (level 0) do not pay 
anything out of pocket and all costs associated with treatment are paid for by the government 
(from here on referred to as health care provider (HCP) costs). Levels 1-6 pay increasingly more 
for services. When information on the payment level was not available, the median level of other 
patients was used (level 2). Patients treated at the HE-IMSS do not pay anything out-of-pocket 
and all medical costs, including prescription medication costs, are charged to the social security 
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administration at level 6 prices.  Since it  is believed that level 5 costs best represent the actual 
costs of products and services, this level was used as the base HCP costs (Flisser, personal 
communication, 2014). 
Direct costs associated with hospitalization, diagnostic testing, surgery, and doctor visits 
were based on the year 2006 tariffs for healthcare services at the INNN, which were presumed to 
be the same as the tariffs for the HE-IMSS [74]. Table 3 contains the costs for NCC-related 
services and procedures, by level, in 2006 U.S. dollars. Direct costs associated with prescribed 
medications were based on actual prices obtained from several pharmacies in Mexico City, 
Mexico. All patients seen at the INNN pay for prescription medications out-of-pocket. A 2006 
exchange rate of 10.80 Mexican pesos for 1 U.S. dollar was used [75].
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Table 3: Level 0-6 patient cost per service/procedure (in U.S. dollars) 
 
Parameter Level 0 Level 1 Level 2 Level 3 Level 4 Level 5* Level 6 
Cost for a visit to a neurologist 0 0.55 1.47 4.32 11.04 19.78 29.07 
Cost for a visit to a neurosurgeon 0 0.55 1.47 4.32 11.04 19.78 29.07 
Cost for a visit to a general practitioner 0 0.55 1.47 4.32 11.04 19.78 29.07 
Cost for a visit to a psychiatry 0 0.55 1.47 4.32 11.04 19.78 29.07 
Cost for a visit to a neurotologist 0 0.55 1.47 4.32 11.04 19.78 29.07 
Cost of  a CT scan 0 5.98 15.08 45.17 114.35 204.60 300.93 
Cost of an MRI 0 6.16 15.36 46.18 117.02 209.48 308.02 
Cost of an ELISA 0 0.92 2.30 6.90 17.48 31.19 45.91 
Cost of an EEG 0 3.04 7.54 22.54 57.13 102.30 150.42 
Cost of an EITB 0 3.04 7.63 22.91 58.05 103.77 152.63 
Cost of CSF examination 0 0.55 1.49 4.26 10.30 18.40 27.14 
Cost of a biopsy 0 15.55 38.27 114.72 290.35 519.06 763.32 
Cost of a neurological exam 0 0.55 1.47 4.32 11.04 19.78 29.07 
Cost of a one day stay in a hospital’s 
general ward 
0 2.02 4.97 14.99 37.99 68.08 100.01 
Cost of a one day stay in a hospital’s 
private ward  
0 2.39 5.98 17.94 45.54 81.42 119.78 
*Actual unit cost 
 
Note: CT = Computed Tomography, MRI = Magnetic Resonance Imaging, ELISA = Enzyme-linked immunosorbent assay, EEG = 
Electroencephalography, EITB = Enzyme-linked immunoelectro transfer blot test, CSF = Cerebrospinal Fluid. 
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II.2.6 Estimation of indirect costs 
Indirect costs included the loss of working days due to treatment seeking behavior and 
symptoms in addition to transportation costs to and from the hospital and doctor visits. Due to 
lack of available data, losses due to the purchase of over-the-counter medications, use of 
traditional healers, and time lost by the patients’ families were not included in indirect cost 
estimates. Patient information on occupation, monthly salary, numbers of sick days not involving 
a hospital or clinic visit, and means of transportation to and from treatment were collected from 
the questionnaire.  
Although 99% of the patients reported their occupation, 50% did not report their monthly 
salary. For missing data on monthly salary, the median salary provided by other patients, with 
the same occupation, was used when there were at least three other patients with available salary 
information. Missing wages for less common (<3 patients) occupations were based on the lowest 
estimated salaries provided by three sources: the international average salary income database, 
Mexico’s Department of Labor and the reported salaries of IMSS employees, for the year 2006 
[76-78].   
With the exception of retirees, unemployed citizens in Mexico do not receive government 
benefits. Retirees did not report their monthly salary or previous occupation. Therefore, it was 
assumed that retirees received 80% of the minimum wage as their pension [79]. Three 
approaches were used to capture productivity losses for housewives and the non-retired 
unemployed. The first method used traditional “opportunity costs” where work time was only 
lost for those who are currently employed outside of the home. The second method used the 
minimum wage approach where time lost was estimated at an 8-hour work day paid at Mexico’s 
2006 minimum wage of U.S.$ 4.34 per day [80]. For the third method, time lost was estimated at 
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an 8-hour work day paid at the 2006 mean salary estimate of U.S.$ 5.48 per day for a house 
cleaner in Mexico [80]. 
Treatment-related productivity losses were measured in units of time and monetized for 
wage earners by occupation. These productivity losses were based on the number of hours NCC 
patients lost due to hospitalization and treatment seeking behavior. It was assumed that patients 
who had to travel more than 2 hours for treatment lost an entire day of work whereas patients 
that traveled less than 2 hours for treatment lost half a day of work.  
Symptom-related productivity losses were those losses which occurred due to the 
inability to work due to illness, but did not involve a visit to the hospital or other healthcare 
provider. The questionnaire included a question on the number of working days lost due to 
illness in the past year and the past month. When available, lost working days over the past year 
were included in indirect cost estimates. When only lost working days in the past month were 
provided, this number was multiplied by the ratio of lost working days in the past year to lost 
working days in the past month obtained from patients reporting both values and then multiplied 
by 12. 
Transportation costs were estimated based on the mode of transportation and the distance 
travelled. Cost of transportation was estimated using the year 2014 cost of U.S.$ 9.60 per 10 km 
for transportation by taxi, U.S.$ 1.00 per liter of gasoline for transportation by personal vehicle, 
and U.S.$ 4.50 per hour for transportation by bus [81]. Cost of transportation, for those patients 
who travelled less than 1 hour by bus, was estimated using a fixed rate (U.S.$ 0.92) for local bus 
service in Mexico City in 2014 [81]. These 2014 values were converted to their 2006 values 
according to the Consumer Price Index for Mexico [82]. 
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II.2.7 Statistical analysis 
The average annual actual direct cost per NCC patient was calculated by adding the level 
5 costs per patient and dividing this total cost by the number of years of follow-up. The average 
annual indirect cost per NCC patient was estimated by adding the productivity losses and 
transportation costs per patient and dividing this total cost by the number of years of follow up. 
The average annual per patient out-of-pocket expense for INNN patients and the average annual 
per patient cost charged to the social security administration for IMSS patients were also 
calculated using this method. The average annual actual cost per NCC patient was calculated for 
all study patients and then stratified by hospitalization history and presenting clinical 
manifestation(s).  Since the number of observations was small after stratifying the patients based 
on clinical manifestations, the variance of the cost estimates was calculated using bootstrap 
techniques.  The average annual costs along with their 95% confidence intervals (CIs) were 
estimated using Stata® (StataCorp. 2011. Stata® Statistical Software: Release 11.2. College 
Station, TX: StataCorp LP).  
 
II.2.8 Ethical approval  
This study received IRB approval from Texas A&M University (2006-0606 and 2014-
0702), the INNN, and the HE-IMSS.  
 
II.3 Results 
II.3.1 Patient demographics 
 Chart reviews were conducted for 123 patients from the INNN and 101 patients from the 
HE-IMSS. The majority of the patients (82%) interviewed at the HE-IMSS were from Mexico 
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City. Patients interviewed at the INNN were primarily from the State of Mexico (41%) and 
Mexico City (25%). Among the 224 outpatients, 65% had a history of hospitalization.  Table 4 
shows the patient demographics.  
 
Table 4: Demographics of patients seeking treatment at the INNN and HE-IMSS 
 
Category Number of patients 
 HE-IMSS INNN Total 
 Number Proportion Number  Proportion  
Total number of 
patients 
101 0.45 123 0.55 224 
Sex      
Male 50 0.22 55 0.25 105 
Female 51 0.23 68 0.30 119 
Age      
< 45 years 35 0.16 66 0.29 101 
>46 years 66 0.29 57 0.26 123 
Number of 
patients who were 
hospitalized 
54 0.24 68 0.30 122 
 
 
 
II.3.2 Clinical manifestations  
 The most common presenting symptoms of participating NCC patients were 
hydrocephalus (48%), severe chronic headaches (47%), and epilepsy (31%) (Table 5).  
 
 
 
 
 
 
 
 
 
 
 
 36 
 
 
Table 5: NCC-related clinical manifestations of patients seeking treatment at the INNN and 
HE-IMSS 
 
Symptoms  Number of patients Percentage Final analysis group 
 HE-
IMSS 
INNN Total   
Epilepsy and seizures 22 42 64 28.57  
Hydrocephalus 26 15 41 18.30  
Severe chronic headaches and 
hydrocephalus 
16 21 37 16.52  
Severe chronic headaches 17 12 29 12.95  
Seizures/ epilepsy and severe 
chronic headaches 
7 7 14 6.25  
Severe chronic headaches, 
increased intracranial pressure, 
and hydrocephalus 
0 9 9 4.02 Included in the  severe 
chronic headaches and 
hydrocephalus group  
Severe chronic headaches and 
increased intracranial pressure 
1 4 5 2.23 Included in the severe 
chronic headaches group 
Seizures/epilepsy, severe 
chronic headaches, and 
hydrocephalus 
6 1 7 3.13  
Seizures/epilepsy and 
hydrocephalus 
5 3 8 3.57  
Stroke 0 2 2 0.89  
Dementia 0 1 1 0.45  
Seizures/epilepsy, increased 
intracranial pressure, and 
severe chronic headaches 
0 1 1 0.45 Included in the seizures/ 
epilepsy and severe 
chronic headaches group 
Increased intracranial pressure 
and seizures/epilepsy 
0 1 1 0.45 Included in the 
seizures/epilepsy group 
Increased intracranial pressure 
and vasculitis 
0 1 1 0.45 Included in the 
hydrocephalus only group 
Hydrocephalus, vasculitis, and 
severe chronic headaches 
0 1 1 0.45 Included in the 
hydrocephalus and severe 
chronic headaches group 
Seizures/epilepsy, 
hydrocephalus, vasculitis, and 
severe chronic headaches 
0 1 1 0.45 Included in the 
seizures/epilepsy, 
hydrocephalus, and severe 
chronic headaches group 
Seizures/epilepsy, 
hydrocephalus, and increased 
intracranial pressure 
1 0 1 0.45 Included in the 
seizures/epilepsy and 
hydrocephalus group 
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Table 5: Continued 
Symptoms  Number of patients Percentage Final analysis group 
 HE-
IMSS 
INNN Total   
Seizures/epilepsy, severe 
chronic headaches, 
hydrocephalus, and increased 
intracranial pressure 
0 1 1 0.45 Included in the seizures/ 
epilepsy, severe chronic 
headaches, and 
hydrocephalus group 
Total 101 123 224 100.00  
 
 
 
II.3.3 Frequency of use of healthcare resources 
 
Tables 6 and 7 show the average number of times per year that patients without a history 
of hospitalization (Table 6) and with a history of hospitalization (Table 7) consulted with each 
type of healthcare provider and had each type of diagnostic tests performed stratified by the 
presenting symptom.
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Table 6: Average number of times patients at the INNN and HE-IMSS without a history of hospitalization for NCC used healthcare resources per year  
 
 Hydroceph
alus only 
Severe 
chronic 
headaches 
only 
Epilepsy/sei
zures only 
Stroke Dementia Epilepsy/seizu
res and 
hydrocephalus 
Severe 
chronic 
headaches 
and 
hydrocephalu
s 
Epilepsy/seizures
,  severe chronic 
headaches, and 
hydrocephalus 
Epilepsy/seizure and 
severe chronic 
headaches 
 HE-
IMS
S 
INNN HE-
IMS
S 
INNN HE-
IMSS 
INNN HE-
IMS
S 
INNN HE-
IMS
S 
INNN HE-
IMSS 
INNN HE-
IMSS 
INNN HE-IMSS INNN HE-IMSS INNN 
Number of 
patients 
5 7 14 3 16 34 0 1 0 1 0 0 2 7 2 0 6 5 
Consultation 
with specialist 
                  
Neurologist 2.50 2.30 1.96 1.17 3.41 2.10 - 1 - 2 - - 1.30 2.12 1.55 - 2.46 2.15 
Neurosurgeon 0 0.04 0.05 0 0.05 0.02 - 0 - 0 - - 0 0.17 0 - 0.03 0 
General 
practitioner 
0 0 0 0 0 0.04 - 0 - 0 - - 0 0.06 0 - 0 0.07 
Psychiatrist 0 0 0 0 0.02 0.09  - 0 - 0 - - 0 0 0 - 0.13 0 
Neurotologist 0 0 0 0 0 0.02  0  0 - - 0 0 0 - 0 0 
Diagnostic tests                   
CT scan 0.70 0.30 0.30 0.10 0.70 0.93 - 1 - 0.36 - - 0.16 0.36 0.31 - 0.67 0.12 
MRI 0.30 0.80 0.20 0.10 0.50 0.60 - 0 - 0 - - 0 0 0.07 - 0.43 0.45 
EEG 0 0 0.10 0 0.40 0.20 - 0 - 0 - - 0 0.14 0.08 - 0 0.42 
CSF 0 0.45 0.03 0.32 0.05 0.31 - 0 - 0.2 - - 0 0.69 0 - 0.27 0.04 
ELISA 0 0.30 0 0.31 0.01 0.33 - 0 - 0.2 - - 0.08 0.65 0 - 0 0 
EITB 0 0 0.01 0 0.23 0 - 0 - 0 - - 0 0 0 - 0.06 0 
Biopsy 0 0 0 0 0 0 - 0 - 0 - - 0 0 0 - 0 0 
Neurological 
exam 
1.91 
 
0.32 
 
1.30 
 
0.31 
 
1.94 
  
0.61  
 
- 1 - 0 - - 1.30 
 
0.45 
 
0.92 
 
- 1.25 
 
0.28 
 
 
Note: CT = Computed Tomography, MRI = Magnetic Imaging Resonance, EEG = Electroencephalography, ELISA = Enzyme-linked immunosorbent assay, EITB = Enzyme-linked immunoelectro transfer blot test, 
CSF = Cerebrospinal Fluid 
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Table 7: Average number of times patients at the INNN and HE-IMSS with a history of hospitalization for NCC used healthcare resources per year  
 
 Hydrocephal
us only 
Severe 
chronic 
headaches 
only 
Epilepsy/se
izures only 
Stroke Dementia Epilepsy/seizures 
and 
hydrocephalus 
Severe chronic 
headaches and 
hydrocephalus 
Epilepsy/seizures,  
severe chronic 
headaches, and 
hydrocephalus 
Epilepsy/seizures and 
severe chronic headaches 
 HE-
IMSS 
INN
N 
HE-
IMS
S 
INN
N 
HE-
IMSS 
INN
N 
HE-
IMS
S 
INN
N 
HE-
IMS
S 
INN
N 
HE-
IMSS 
INNN HE-
IMSS 
INNN HE-IMSS INNN HE-IMSS INNN 
Number of 
patients 
19 11 4 13 6 9 0 1 0 0 6 3 14 24 4 3 1 4 
Consultation 
with 
specialist 
                  
Neurologist 2.29 1.58 2.31 1.90 2.02 1.84 - 2.48 - - 2.11 1.61 1.91 2.75 2.38 1.01 2.68 3.03 
Neurosurge
on 
0.36 0.81 0.55 0.23 0.14 0.13 - 0 - - 0 0 0.34 0.18 0.06 0 0 0.07 
General 
practitioner 
0 0.25 0 0.28 0 0 - 0 - - 0 0 0 0.05 0 0 0 0 
Psychiatrist 0.03 0 0 0.31 0 0.1 - 0 - - 0 0 0 0.08 0 0 0 0 
Neurotolog
ist 
0 0 0 0 0 0 - 0 - - 0 0 0 0.27 0 0 0 0.37 
Diagnostic 
tests 
                  
CT scan 0.32 0.44 1.11 0.37 0.37 0.50 - 0.74 - - 0.58 1.65 0.91 0.67 0.21  0.92 0.67 1.12 
MRI 0.57 0.85 1.16 1.05 0.2  1 - 1.24 - - 0.55 0.81 0.35 1.00 0.35 0.53 0.17 0.42 
EEG 0.01 0.17 0.35 0.27 0.07 0.20 - 0.24 - - 0.03 0.39 0.01 0.05 0.12 0.41 0.16 0.17 
CSF 0.18 0.62 0.13 0.57 0.06 0.50 - 2.47 - - 0.07 1.08 0.13 1.06 0 0.85 0 1.16 
ELISA 0 0.59 0 0.69 0 0.60 - 0 - - 0 0.62 0 0.78 0 0.41 0 1.31 
EITB 0.04 0 0 0 0.03 0 - 0 - - 0 0 0 0 0.06 0 0 0 
Biopsy 0 0 0 0.21 0 0 - 0 - - 0 0.09 0 0.01 0 0 0 0.07 
Neurologic
al exam 
1.40 0.74 3.06 0.72 1.5 1.04 - 0.24 - - 1.32 1.71 1.64 1.15 1.69 1.75 1.85 0.76 
Number of 
surgeries 
0.51 0.66 0.45 0.14 0.24 0.35 - 2.00 - - 0.46 1.11 0.74 0.63 0.21 0.58 0 0.44 
Number of 
days 
hospitalized 
5.44 10.87 5.97 5.84 2.24 7.25 - 13.86 - - 2.22 12.03 5.58 5.24 2.57 9.19 1.67 11.32 
 
Note: CT = Computed Tomography, MRI = Magnetic Imaging Resonance, EEG = Electroencephalography, ELISA = Enzyme-linked immunosorbent assay, EITB = Enzyme-linked immunoelectro transfer blot test, 
CSF = Cerebrospinal Fluid  
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II.3.4 Direct costs 
The majority of outpatients treated at the INNN paid for their treatment. However, out-
of-pocket expenses were usually less than the actual cost, with 0.6 % paying nothing (level 0), 
30.5% paying at level 1, 49.1% paying at level 2, 10.2% paying at level 3, 1.1% paying at level 
4, 3.4% paying at level 5, and 2.8% paying at level 6. The payment levels of four INNN 
outpatients were missing and imputed as being level 2.   
The annual average actual (level 5) direct costs were U.S.$ 503 (95% CI: 414 – 592) and 
U.S.$ 438 (95% CI: 322 – 571) for patients without a history of hospitalization seen at the INNN 
and at the HE-IMSS, respectively (Table 8). In contrast, the annual average actual (level 5) direct 
costs were U.S.$ 2,506 (95% CI: 1,797 – 3,215) and U.S.$ 2,170 (95% CI: 1,303 – 3,037) for 
patients with a history of hospitalization seen at the INNN and at the HE-IMSS, respectively 
(Table 9).  The average out-of-pocket expense was U.S.$ 242 (95% CI: 182 – 303) and U.S.$ 
301 (95% CI: 228 – 375) for INNN patients without and with a history of hospitalization, 
respectively. The annual per patient cost charged to the social security administration was U.S.$ 
571 and U.S.$ 3,109 for IMSS patients without and with a history of hospitalization, 
respectively. The total annual actual (level 5) direct cost for the 224 patients treating at INNN 
and HE-IMSS was U.S.$ 335,901. Figures 4 and 5 show the total per patient annual direct cost of 
treatment, by cost component and payer, for individuals enrolled with and without a history of 
hospitalization at the INNN and HE-IMSS respectively.  
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Table 8: Annual average actual (level 5) per patient direct costs for INNN and HE-IMSS patients with no history of 
hospitalization NCC in U.S. dollars (Values in brackets represent 95% CIs) 
 
 Number of 
patients 
Diagnostic tests Consultations Drugs Total 
 HE-
IMSS 
INN
N 
HE-IMSS INNN HE-IMSS INNN HE-IMSS INNN HE-IMSS INNN 
Epilepsy/seizur
e 
16 34 356 
(208 – 
508) 
248 
(169 -329)  
68 
(54 – 82) 
45 
(38 – 
53) 
199 
(109 – 
290) 
250 
(170 – 
332)  
624 
(426 – 
822) 
545 
(440 – 650)  
Hydrocephalus 5 7 124 
(11 – 237) 
254 
(83 – 425) 
49 
(35 – 63) 
46 
(35 – 
59) 
56 
(0 – 145) 
151 
(12 – 291) 
230 
(83 – 376) 
452 
(175 – 730) 
Severe chronic 
headaches 
14 3 153 
(79 – 228) 
71 
(10 – 132) 
39 
(34 – 46) 
23 
(17 – 
30) 
170 
(0 – 402) 
28 
(0 – 62) 
363 
(134 – 
593) 
122 
(10 – 235) 
Stroke 0 1 - 224 - 19 - 0 - 244 
Dementia 0 1 - 83 - 78 - 195 - 357 
Severe chronic 
headaches and 
hydrocephalus 
2 7 61 
(59 – 62) 
330 
(138 – 
523) 
26 
(21 – 32) 
46 
(28 – 
65) 
0 135 
(0 – 296) 
87 
(80 – 94) 
512 
(291 – 735) 
Epilepsy/seizur
e and severe 
chronic 
headaches 
6 5 291 
(33 – 500) 
172 
(77 – 268) 
53 
(35 – 69) 
43 
(32 – 
56) 
188 
(53 – 372) 
224 
(70 – 378) 
532 
(237 – 
827) 
441 
(198 – 684) 
Epilepsy/seizur
e, severe 
chronic 
headaches and 
hydrocephalus 
2 0 106 
(74 – 137) 
- 15 
(13 – 18) 
- 132 
(73 – 193) 
- 254 
(228 – 
280) 
- 
 42 
 
 
Table 9:  Annual average actual (level 5) per patient direct costs for INNN and HE-IMSS patients with a history of hospitalization for NCC in U.S. dollars (Values in brackets represent 95% CIs) 
 
  Number of 
patients 
Diagnostic tests Consultations Hospitalization Surgery Drugs Total 
 HE-
IMSS 
INNN HE-IMSS INNN HE-IMSS INNN HE-IMSS INNN HE-IMSS INNN HE-IMSS INNN HE-IMSS INNN 
Epilepsy/ 
seizure 
6 9 147 
(77 – 217) 
414 
(255 – 573)  
42 
(37 – 48) 
41 
(24 – 58) 
182 
(81 – 283) 
493 
(0 -  1,060) 
501 
(38 – 965) 
567 
(26 – 1,109) 
193 
(103 – 284) 
240 
(146 – 335) 
1,067 
(440 – 1,694) 
1,758 
(616 – 2,900) 
Hydrocephalus 19 11 222 
(154 – 291) 
330 
(222 – 438) 
53 
(42 – 64) 
52 
(42 – 62) 
442 
(106 – 780) 
740 
(58 – 1,422) 
778 
(461 – 1,094) 
689 
(361 – 1,017) 
93 
(0 – 193) 
60 
(13 – 108) 
1,590 
(990 – 2,191) 
1,872 
(938 – 2,806) 
Severe chronic 
headaches 
4 13 571 
(364 – 778) 
478 
(323 – 633) 
56 
(21 – 92) 
53 
(40 – 67) 
486 
(155 – 817) 
397 
(246 – 549) 
695 
(159 – 1,232) 
234 
(0 – 481) 
129 
(121 – 139) 
187 
(101 – 273) 
1,939 
(885 – 2,993) 
1,351 
(875 – 1,827) 
Stroke 0 1 - 507 - 49 - 943 - 1,266 - 412 - 3,178 
Severe chronic 
headache and 
hydrocephalus 
14 24 297 
(195 – 400) 
428 
(313 – 544) 
44 
(36 – 53) 
66 
(50 – 82) 
454 
(237 – 672) 
361 
(217 – 504) 
1081 
(342 – 1,820) 
695 
(370 – 1,021)  
145 
(34 – 255) 
97 
(54 – 141) 
2,022 
(1,141 – 2,904) 
1,648 
(1,117- 2,179) 
Epilepsy/seizur
e and 
hydrocephalus 
6 3 266 
(127 – 405) 
670 
(186 – 1153) 
20 
(12 – 29) 
63 
(49 – 79) 
180 
(63 – 298) 
890 
(20 – 1,761) 
675 
(228 – 1,122) 
1813 
(65 – 3,563) 
678 
(0 – 1,558) 
405 
74 – 737) 
1,821 
(664 – 2,979) 
3,844 
(432 – 7,256) 
Epilepsy/seizur
e and severe 
chronic 
headaches 
1 4 226 660 
(354 – 966) 
53 
 
66 
(49 – 84) 
136 
 
790 
(122 -1,459) 
0 1120 
(287 – 1,953) 
168 162 
(41 – 284) 
585 2,504 
(909 – 4,099) 
Epilepsy/seizur
e, severe 
chronic 
headaches and 
hydrocephalus 
4 3 168 
(106 – 232) 
402 
(195 – 609) 
24 
(14 – 35) 
40 
(0 – 85) 
222 
(150 – 294) 
658 
(0 – 1,393) 
263 
(70 – 456) 
965 
(491 – 1,439) 
96 
(11 – 181) 
272 
(187 – 357) 
775 
(599 – 952) 
2,338 
(1,059 – 3,618) 
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a)  
b)  
 
Figure 4: Average annual cost of treatment at the INNN per patient a) for 55 patients with 
no history of hospitalization NCC and b) for 68 patients with a history of hospitalization 
for NCC  
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a)  
b) 
 
Figure 5: Average annual cost of treatment at the HE-IMMS per patient a) for 47 patients 
with no history of hospitalization NCC and b) for 54 patients with a history of 
hospitalization for NCC  
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II.3.5 Indirect costs 
 Forty percent of study patients were housewives and 16% were unemployed. Table 10 
shows the average number of working days lost annually by enrolled NCC patients. Table 11 
shows the total per patient annual cost of NCC-associated productivity losses and transportation 
costs using the opportunity cost method, the minimum wage approach, and the house cleaning 
wage approach for patients not officially employed outside of the home. The total annual indirect 
cost for the 224 patients treated at the INNN and HE-IMSS was U.S.$ 17,172 based on the 
opportunity cost method, U.S.$ 41,841 based on the minimum wage approach, and U.S.$ 44,406 
based on the house cleaning approach. 
 46 
 
 
Table 10: Average number of working days lost annually by NCC patients who were receiving treatment at the INNN and HE-IMSS  
 
  Number of patients Loss of working days due to the 
inability to work due to illness 
Loss of working days due to visits to a health 
care provider 
Without a 
history of 
hospitalization 
and/or surgery 
With a history of 
hospitalization 
and/or surgery 
Without a 
history of 
hospitalization 
and/or surgery 
With a history of 
hospitalization 
and/or surgery 
Without a history of 
hospitalization and/or 
surgery 
With a history of 
hospitalization and/or 
surgery 
 HE-IMSS INNN HE-IMSS INNN HE-IMSS INNN HE-IMSS INNN HE-IMSS INNN HE-IMSS INNN 
Hydrocephalus 5 7 19 11 0 0 8.85 17.71 2.62 2.63 8.89 15.01 
Severe chronic 
headaches 
14 3 4 13 0 16 0 3.28 2.39 1.03 13.12 9.28 
Epilepsy/seizures 16 34 6 9 0.27 6.21 0 55 3.89 2.51 4.65 12.56 
Stroke 0 1 0 1 - 0 - 0 - 1.50 - 18.57 
Dementia 0 1 0 0 - 0 - - - 1.27 - - 
Seizures and 
hydrocephalus 
0 0 6 3 - - 0 0 - - 5.00 16.87 
Severe chronic 
headaches and 
hydrocephalus 
2 7 14 24 0 35.83 0 16.25 1.53 2.81 9.06 10.10 
Seizures, severe 
chronic headache 
and 
hydrocephalus 
2 0 4 3 0 - 0 0 1.72 - 5.35 13.71 
Seizures and 
severe chronic 
headaches 
6 5 1 4 20 0 0 10 3.09 2.02 5.95 11.44 
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Table 11: Average annual indirect costs of NCC for INNN and HE-IMSS patients due to productivity losses and 
transportation costs to and from the hospital and doctor visits in U.S. dollars (Values in brackets represent 95% CIs) 
 
Cost component Per patient 
Opportunity cost 
approach 
House cleaning approach Minimum wage approach 
HE-IMSS INNN HE-IMSS INNN HE-IMSS INNN 
Transportation 7 
(6 – 9) 
7 
(6 – 9) 
7 
(6 – 9) 
7 
(6 – 9) 
7 
(6 – 9) 
7 
( 6 – 9) 
Productivity losses 
due to treatment 
seeking behavior 
42 
(25 – 60) 
27 
(18 – 35) 
56 
(39 – 72) 
50 
(40 – 60) 
57 
(40 – 74) 
48 
(37 – 59) 
Productivity losses 
due to symptoms 
without treatment 
seeking 
22 
(0 – 46) 
42 
(8 – 77) 
50 
(0 – 108) 
214 
(125 – 302) 
50 
(0 – 113) 
190 
(115 – 265) 
Total 72 
(41 – 103) 
78 
(41 – 112) 
113 
(51 – 175) 
271 
(184 – 349) 
114 
(51 – 178) 
245 
(165 – 324) 
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II.3.6 Total costs 
 The total annual actual cost for the 224 patients treated at the INNN and the HE-IMSS 
was U.S.$ 352,961 based on the opportunity cost method, U.S.$ 377,742 based on the minimum 
wage approach, and U.S.$ 380,307 based on the house cleaning approach. The total annual 
average actual costs per patient were U.S.$ 581 (95% CI: 455 – 704) and U.S.$ 510 (95% CI: 
363 – 674) based on the opportunity cost method, U.S.$ 748 (95% CI: 579 – 916) and U.S.$ 552 
(95% CI: 373 – 749) based on the minimum wage approach, and U.S.$ 774 (95% CI: 598 – 941) 
and U.S.$ 551 (95% CI: 373 – 746) based on the house cleaning approach for patients without a 
history of hospitalization seen at the INNN and at the HE-IMSS, respectively. This amount 
increased to U.S.$ 2,584 (95% CI: 1,838 – 3,327) and U.S.$ 2,242 (95% CI: 1,344 – 3,140) 
based on the opportunity cost method, U.S.$ 2,751 (95% CI: 1,962 – 3,460) and U.S.$ 2,284 
(95% CI: 1,354 – 3,215) based on the minimum wage approach, and U.S.$ 2,777 (95% CI: 1,981 
– 3,564) and U.S.$ 2,283 (95% CI: 1,354 – 3,212) based on the house cleaning approach for 
those with a history of hospitalization seen at the INNN and at the HE-IMSS, respectively. 
 
II.4 Discussion 
 This is the first patient-based study to quantify the monetary losses of NCC-affected 
individuals in Mexico. In a study conducted in a reference center for neurological disorders in 
Peru from 1999 – 2002, a mean cost of U.S.$ 966 per NCC patient, including treatment costs and 
wage/productivity losses due to NCC over a two year treatment period, was estimated. In that 
study, treatment costs and wage/productivity losses were equivalent to 54% and 16% of an 
annual minimum wage salary during the first year and second year of treatment, respectively 
[63]. In the current study, the average annual treatment costs and wage/productivity losses for 
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patients with and without a history of hospitalization receiving care at tertiary referral hospitals 
were equivalent to 212% and 41% of an annual minimum wage salary, respectively. One 
difference between the Peruvian and Mexican studies is that the annual cost per NCC patient in 
the Mexican study was the average annual cost per patient over the documented course of 
treatment, whereas in the Peruvian study costs were stratified by year of initial diagnosis and the 
subsequent year of follow-up. Since most of the diagnostic tests are performed in the first year of 
treatment, the cost of treatment is likely to be higher in the first year compared to following 
years. When treatment costs for Mexican NCC patients were stratified by year, the first year 
costs for patients with and without a history of hospitalization were equivalent to 255% and 56% 
of an annual minimum wage salary, respectively, which is consistent with the Peruvian 
estimates.  
A study conducted in India in 1997 estimated the cost of treating seizure disorders 
associated with solitary cysticercus lesions from the time of seizure onset until resolution of the 
lesion confirmed by CT scan was U.S.$ 174 per patient [62]. Although the actual estimated 
direct costs due to NCC-associated seizures was low in Indian patients compared to the Mexican 
patients with NCC-associated epilepsy (U.S.$ 1,482 and U.S.$ 570 for patients with and without 
hospitalization), the Indian patients were also spending a considerable proportion (50.9%) of 
their per capita gross national product on their disease to a level similar to that of the Mexican 
patients.  
 In the current study, among patients without a history of hospitalization, the annual direct 
costs for patients with epilepsy as the only clinical manifestation were higher than the costs for 
patients with any other clinical manifestation (single or combined). This difference was primarily 
due to the high cost of epilepsy drugs. In contrast, among patients with a history of 
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hospitalization, the annual direct costs were highest for patients with severe chronic headaches or 
hydrocephalus, primarily due to the high cost of surgery to treat hydrocephalus. 
 Three methods were used to value productivity losses of individuals considered not 
economically active or employed. Since more than 50% of the patients were housewives or 
unemployed, the estimated indirect costs ignoring losses for this group lead to the smallest 
estimates. This method clearly undervalues the time of homemakers. Therefore, the total costs 
estimated from the minimum wage approach or the house cleaning approach likely better 
represent actual productivity losses.   
 This study has some limitations. The study was conducted in two neurology reference 
hospitals in Mexico City and only represents a fraction of the total regional population with 
NCC, with an over-representation of more severe cases. Therefore, the overall cost per NCC case 
is not generalizable to all NCC cases in Mexico. However, the annual costs for such severe NCC 
patients were likely underestimated since opportunity costs of family members who accompany 
patients to treatment, the cost of over-the-counter medication, and the cost of treatment by 
traditional healers were not included. Since patients were selected at the time of an outpatient 
visit, estimates excluded patients who never returned to one of the hospitals for follow-up care 
and any patients who may have died due to NCC. 
 In conclusion, individuals with NCC treated at tertiary hospitals in Mexico City, Mexico 
had a significant economic loss due to NCC-associated clinical manifestations. Additional 
studies are needed to determine the treatment gap of NCC, losses associated with individuals 
with untreated NCC, and losses associated with patients treated at lower level care facilities in 
Mexico.  This information can then be used to better define and estimate the total economic 
losses due to NCC for the entire country. 
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CHAPTER III 
PRE-HOSPITALIZATION, HOSPITALIZATION, AND POST-
HOSPITALIZATION COSTS OF NEUROCYSTICERCOSIS PATIENTS 
TREATED AT THE INSTITUTO NACIONAL DE NEUROLOGIA Y 
NEUROCIRUGIA (INNN) IN MEXICO CITY, MEXICO 
 
III.1 Introduction 
 Neurocysticercosis (NCC) is caused by the larval stage of Taenia solium. The disease 
occurs when a human inadvertently ingests parasite eggs that have been shed in the feces of a 
person infected with taeniosis, with the eggs developing into larvae in the central nervous 
system. NCC is predominantly found and considered endemic in Latin American, Asian, and 
African countries where pigs are raised using traditional methods, veterinary meat inspection is 
insufficient, and sanitation is poor [1-3]. It has also been increasingly diagnosed in higher 
income areas such as the United States, Western Europe, and Canada due to immigrants from 
endemic areas who may have taeniosis or cysticercosis [6,7,66]. In Mexico and other Latin 
American countries, NCC is considered one of the leading causes of epilepsy [58,83]. 
In humans, NCC is associated with numerous clinical manifestations, including epilepsy, 
hydrocephalus, focal deficits, severe chronic headaches, increased intracranial pressure, 
dementia, vasculitis, and stroke [8]. These NCC-associated clinical manifestations have been 
shown to affect patients’ quality of life leading to poorer physical and mental health and 
important economic consequences [13,16,17,84]. Studies conducted in India, Peru, and Mexico 
have estimated the average direct and indirect costs per NCC patient under care [62,63,84], while 
two studies from the United States and one from Chile evaluated hospital-associated charges for 
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NCC patients [64,65,85]. However, the per-patient costs associated with pre-hospitalization, 
hospitalization, and post-hospitalization for NCC have not been evaluated. 
Period-specific cost estimates will be crucial for policy makers to comprehensively 
understand the true economic impact of the disease in order to prioritize and allocate resources. 
Therefore, this study was conducted to better define direct costs associated with pre-
hospitalization, hospitalization, and post-hospitalization from a societal perspective for NCC 
patients seeking care at a referral hospital in Mexico City, Mexico. 
 
III.2 Materials and methods 
III.2.1 Study location 
 This study was conducted in a referral hospital for adult neurological cases in Mexico 
City, Mexico: the Instituto Nacional de Neurologia y Neurocirugia (INNN). The INNN only 
accepts patients who do not have medical insurance coverage through their employment. NCC 
patients with employer-provided medical insurance are seen at a different referral hospital in 
Mexico City and are, therefore, not represented in the current study. 
 
III.2.2 Definition and study populations 
 NCC was defined based on the presence of compatible cerebral lesions on a computed 
tomography (CT) scan, magnetic resonance imaging (MRI), or both [23]. Outpatients diagnosed 
with NCC and with a clinical appointment at the INNN between July 17 and December 7, 2007 
were eligible to participate.  Eligible patients were identified using outpatient appointment 
books, which allowed a research assistant to explain the study and ask for patient consent at the 
time of the appointment. NCC outpatients were sequentially invited to participate until at least 
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100 patients were enrolled. The medical charts of consenting patients were reviewed by a trained 
member of the research team (i.e., a Mexican intern, resident, or social worker). Only patients 
alive at the time of recruitment and who were hospitalized for the treatment of NCC between 
January 2002 and August 2007 were included in this study.  
 
III.2.3 Data collection 
Four forms were used to gather information on presenting clinical manifestations, 
diagnostic tests performed, number of days hospitalized, surgical procedures, and treatments 
received by the patients, including prescription medications (Appendix C, D, E and F). An intake 
form was used to record information on the NCC-associated clinical manifestation(s) that 
resulted in the patient being referred to the hospital. A diagnostic and treatment form was used to 
record information on techniques employed for the confirmation of NCC and the medications 
and procedures used for its treatment. Inpatient and outpatient forms were used to record 
information on the number of times patients were hospitalized or had an outpatient appointment 
for the treatment and management of NCC. 
 
III.2.4 Direct costs associated with pre-hospitalization, hospitalization, and post-
hospitalization of NCC patients 
 Diagnosis and treatment-related costs were calculated for the pre-hospitalization, 
hospitalization, and post-hospitalization periods, beginning with the first NCC-associated visit to 
the INNN. The frequency of appointments with various healthcare providers (neurologists, 
neurosurgeons, psychiatrists, neurootologists, and general practitioners), prescription medication 
use, hospitalizations, surgical interventions, and diagnostic testing (CT scans, MRI, 
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cerebrospinal fluid (CSF) testing, enzyme-linked immunosorbent assays (ELISA), enzyme-
linked immunoelectrotransfer blot (EITB), biopsies, electroencephalograms (EEG), and 
neurological examinations) performed before, during, and after hospitalization were obtained 
using the forms described above. Initial visits to the INNN prior to the first NCC-associated 
hospitalization were included in the pre-hospitalization cost estimation. Healthcare services 
received at the INNN between two hospitalizations contributed to post-hospitalization costs for 
patients hospitalized more than once.  
 The cost of physician office visits, diagnostic tests, a one-day stay in the hospital, and 
surgery were obtained from the year 2006 price list for healthcare services at the INNN [74]. 
Year 2006 tariffs were used due to their availability to study personnel and to be in line with 
previous studies looking at NCC-related costs in Mexico [84]. Services for all patients included 
in the study were costed in 2006 U.S. dollars (U.S.$) regardless of the date of hospitalization. 
The prices used in this study, are considered applicable to other healthcare facilities in Mexico. 
There are seven levels of payments at the INNN, where patients pay  medical fees according to 
their household income. Patients with a very low household income (level 0) do not pay anything 
out-of-pocket, with all costs associated with treatment paid for by the healthcare provider (HCP). 
Level 1-6 patients pay increasing amounts for procedures and services. Based on discussions 
with hospital personnel, level 5 best represents the true cost to the healthcare system.  
 In order to estimate costs associated with prescribed medications, a list of drugs along 
with their dosages were extracted from the medical records. Brand name drugs were noted if 
specifically stated in the medical record. Otherwise, the active ingredient was recorded.  
Medication costs were obtained from pharmacies in Mexico City, Mexico. When only the active 
ingredient was available, pharmacy costs could represent either a brand name or generic drug. In 
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situations where more than one dosage was available, the dosage that best matched the dosage 
and formulation presented in the medical record was used.  Table 12 shows a list of the drugs’ 
active ingredients, dosages, and year 2006 pharmacy prices. Some of these combinations are 
known to represent specific brands, while others may represent generic drugs. Table 13 shows a 
list of surgical procedures performed for NCC patients. All patients seen at the INNN pay for 
prescription medications out-of-pocket. An exchange rate for the year 2006 of 10.80 Mexican 
pesos to 1 U.S. dollar was used [75].  
 
Table 12: List of drugs prescribed for NCC patients treated at INNN between 2002 and 
2006  
 
 
 
Dosage Pharmacy price per dose in 
U.S.$ 
Acetaminophen 500 mg 0.08 
Acetylsalicylic acid 100 mg 0.07 
Albendazole 200 mg 0.69 
Captopril 25 mg 0.02 
Carbamazepine 200 mg 0.08 
Cinnarizine 75 mg 0.83 
Ciprofloxacin 500 mg 0.35 
Clobazam 10 mg 0.46 
Clonazepam 2.5 mg 0.04 
Clonixin lysine-
cyclobenzapine 
100 mg/2 ml 0.5 
Dexamethasone  8 mg/2 ml 0.27 
Enalapril 10 mg 0.23 
Fluoxetine 20 mg 2.4 
Galantamine 4 mg 1.27 
Ibuprofen 400 mg 0.75 
Ketorolac 10/30 mg 0.12 
Lamotrigine 100 mg 1.41 
Metoclopramide 10 mg 0.03 
Metronidazole 500 mg 0.19 
Nimodipine 30 mg 0.96 
Omeprazole 20/40 mg 0.04/3.50 
Phenytoin 100/250 mg 0.16/1.40 
Praziquantel 600 mg 5.86 
Prednisone 5mg/50 mg 0.02/0.10 
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Table 12: Continued 
 
 Dosage Pharmacy price per dose in 
U.S.$ 
Primidone 250 mg 0.16 
Propanolol 40 mg 0.13 
Quetiapine 25 mg 0.77 
Ranitidine 150/300 mg 0.10/0.15 
Topiramate 100 mg 1.93 
Valproic acid 200 mg 0.11 
Vigabatrin 300 mg 0.53 
 
 
 
Table 13: List of surgical procedures performed for NCC patients treated at the INNN 
between 2002 and 2006  
 
Type of Surgery Level 5 Cost in U.S.$ 
Close up ventriculostomy 71 
Craniotomy 2,389 
Cysticercosis removal/resection 1,535 
Endoscopic exploration 307 
Laminectomy 2,507 
Replacement/removal of vericulo-peritoneal 
shunt 
1,023 
Valve replacement 1,023 
Valvular dysfunction 1,023 
Ventriculoperitoneal shunt placement 1,535 
Ventriculostomy 511 
 
 
 
III.2.5 Statistical analysis 
Pre-hospitalization, hospitalization, and post-hospitalization costs were determined for 
each patient, with the average cost per period calculated for all patients. Pre-hospitalization costs 
were obtained by adding the actual (level 5) costs associated with physician office visits, 
diagnostic testing, and pharmacy costs for prescription medications prior to the first 
hospitalization. Similarly, hospitalization costs were obtained by adding actual (level 5) costs 
associated with diagnostic testing performed during hospitalization, a hospital stay in a private or 
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general ward, surgery, and pharmacy costs for prescription medications received during 
hospitalization. An individual patient’s per day hospitalization cost was obtained by dividing the 
patient’s total hospitalization cost by the number of days hospitalized. These costs were then 
averaged over the entire study population to obtain a mean per day hospitalization cost. Post-
hospitalization costs were calculated by adding the actual (level 5) costs associated with 
physician office visits, diagnostic testing, and pharmacy costs for prescription medications 
received after the first hospitalization for NCC at the INNN. 
Enrolled patients began receiving treatment for NCC at the INNN on various dates 
between 2002 and 2007. Therefore, at study commencement, patients had been followed for 
differing lengths of time. Annual costs were assessed for up to five years post-hospitalization 
based on the date of treatment initiation at the INNN. Only patients followed for at least 12 
months after hospitalization were included in any post-hospitalization costs estimates. For 
patients with more than one recorded hospitalization, post-hospitalization out-patient costs were 
assessed from the date of first hospitalization for NCC until the date of data collection. 
Average per-patient level 5 costs were calculated for the entire study population as well 
as stratified by presenting clinical manifestation(s). The average costs that patients paid out-of-
pocket during the pre-hospitalization, hospitalization, and post-hospitalization periods were also 
obtained using patient payment levels and prescription medication costs. The average per-patient 
cost for each clinical manifestation grouping was then compared across the pre-hospitalization, 
hospitalization, and post-hospitalization periods using a repeated measures ANOVA, with post 
hoc pairwise comparisons made using Tukey's method. The above comparisons were made for 
all patients followed at least one year post-hospitalization. For patients followed at least 3 years 
post-hospitalization, the average treatment costs for the first, second, and third years post-
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hospitalization were compared using a repeated measures ANOVA, with post hoc pairwise 
comparisons conducted using the Tukey method. A t-test was used to compare the average per-
patient hospitalization cost for patients who had a history of surgery with those who did not 
receive surgery. As the number of observations was small after stratifying the patients based on 
clinical manifestation(s), the variances of the cost estimates were calculated using bootstrap 
techniques. The obtained variances were then used to calculate the 95% confidence intervals 
(95% CIs) for the average annual costs. All calculations were performed using Stata (Stata 
Statistical Software: Release 11.2. College Station, TX: StataCorp LP). A p-value <0.05 was 
considered statistically significant.  
 
III.2.6 Ethical approval 
 This study received IRB approval from Texas A&M University (2006-0606 and 2014-
0702) and the INNN. 
 
III.3 Results 
III.3.1 Patient demographics 
 Among the 123 outpatients recruited, 108 had been hospitalized between 2002 and 2007 
and 18 of these patients were hospitalized more than once.  Patients were primarily from the 
State of Mexico (41%) and Mexico City (25%). The demographic characteristics of the 
hospitalized patients are shown in Table 14. The median age at the time of first hospitalization 
for NCC at the INNN was 42 years old and ranged from 19 to 84 years old. Almost half of the 
hospitalized patients were males (48%). The number of hospitalized days ranged from 2 to 56 
per patient. The lengths of time patients were treated at the INNN pre-hospitalization and post-
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hospitalization ranged from 0 days to 5 years and 1 month to 5 years, respectively. Fifty percent 
of patients paid at level 2, with no patients assigned to level 0 (Table 14). 
 
 
Table 14: Demographic features of 108 NCC patients hospitalized at the INNN from 2002 
to 2007 
 
 
 
Level 
1 
(n=37) 
Level 
2 
(n=54) 
Level 
3 
(n=9) 
Level 
4 
(n=1) 
Level 
5 
(n=3) 
Level 
6 
(n=4) 
Total 
(n=108) 
Number of patients who were 
hospitalized more than once 
9  8 0 0 0 1 18 
Number of patients who did not 
receive pre-hospitalization 
treatment at the INNN 
16 11 4 0 1 1 33 
Number of patients who received 
1 to 30 days of pre-hospitalization 
treatment at the INNN 
10 22 2 0 1 1 36 
Number of patients who received 
31 to 180 day of pre-
hospitalization treatment at the 
INNN 
5 7 2 1 0 0 15 
Number of patients who received 
181 to 365 days of pre-
hospitalization treatment at the 
INNN 
2 2 0 0 1 0 5 
Number of patients who received 
1 to 2 years of pre-hospitalization 
treatment at the INNN 
1 3 1 0 0 1 6 
Number of patients who received 
more than 2 years, but less than 3 
years of pre-hospitalization 
treatment the INNN 
1 3 0 0 0 1 5 
Number of patients who received 
more than 3 years, but less than 4 
years of pre-hospitalization 
treatment at the INNN 
1 2 0 0 0 0 3 
Number of patients who received 
more than 4 years, but less than 5 
years of pre-hospitalization 
treatment at the INNN 
1 4 0 0 0 0 5 
Number of patients with records 
available for at least 1 year post-
hospitalization 
31 43 7 1 2 2 86 
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Table 14: Continued 
 
 
 
Level 
1 
(n=37) 
Level 
2 
(n=54) 
Level 
3 
(n=9) 
Level 
4 
(n=1) 
Level 
5 
(n=3) 
Level 
6 
(n=4) 
Total 
(n=108) 
Number of patients with records 
available for at least 2 years post-
hospitalization 
19 25 7 1 2 1 55 
Number of patients with records 
available for at least 3 years post-
hospitalization 
14 17 7 0 2 1 41 
Number of patients with records 
available for at least 4 years post-
hospitalization 
8 12 5 0 1 0 26 
Number of patients with records 
available for 5 years post-
hospitalization 
4 7 4 0 0 0 15 
 
 
III.3.2 Clinical manifestations 
The most common clinical manifestations reported were severe chronic headaches (21%), 
hydrocephalus (19%), and the combination of hydrocephalus and severe chronic headaches 
(29%) (Figure 6).  
 
Figure 6: NCC-related clinical manifestations of study patients 
 
E/S = Epilepsy/seizures, H = Hydrocephalus, SCH= Severe chronic headaches, ST= Stroke, D = 
Dementia 
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III.3.3 Estimation of pre-hospitalization, hospitalization, and post-hospitalization costs 
Hospitalization costs were significantly higher compared to the costs incurred during the 
pre-hospitalization or complete post-hospitalization periods for all clinical manifestations except 
for epilepsy and stroke (Table 15). 
 
Table 15: Comparison of average pre-hospitalization, hospitalization and total post-
hospitalization costs for NCC patients treated at the INNN between 2002 and 2006 (2006 
U.S.$) by clinical manifestation(s) 
 
Clinical 
Manifestation(s) 
Pre-
hospitalization 
Hospitalization Post-
hospitalization 
P-value Overall 
p value 
Epilepsy/seizures 
(n=11) 
191 1,397  0.00 0.00 
191  1,258 0.00 
 1.397 1,258 0.88 
Hydrocephalus 
(n=16) 
155 1,983  0.00 0.00 
155  663 0.06 
 1,983 663 0.00 
Severe chronic 
headache 
(n=21) 
306 2,089  0.00 0.00 
306  806 0.18 
 2,089 806 0.00 
Stroke (n=2) 269 4,007  0.38 0.36 
269  1,054 0.94 
 4,007 1,054 0.51 
Epilepsy/seizures 
and severe 
chronic 
headaches (n=6) 
448 3,050  0.00 0.02 
448  872 0.7 
 3,050 872 0.01 
Epilepsy/seizures 
and 
hydrocephalus 
(n=4) 
119 4,544  0.00 0.04 
119  711 0.85 
 4,544 711 0.01 
Severe chronic 
headaches and 
hydrocephalus 
(n=22) 
290 3,022  0.00 0.00 
290  769 0.28 
 3,022 769 0.00 
Epilepsy/seizures, 
severe chronic 
headaches, and 
hydrocephalus 
(n=4) 
213 3,488  0.00 0.03 
213  539 0.94 
 3,488 539 0.00 
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Pre-hospitalization costs 
 The average actual (level 5) per-patient pre-hospitalization cost was U.S.$ 257 (95% CI: 
185 – 329). Diagnostic testing made up 81% of this cost, followed by physician office visits 
(10%) and prescription medications (9%). The average out-of-pocket pre-hospitalization cost 
was U.S.$ 62 (95% CI: 32 – 92). Table 16 shows the average per-patient pre-hospitalization 
costs by presenting clinical manifestation(s). No significant difference was found in the per-
patient pre-hospitalization costs for the various presenting clinical manifestation(s) (p=0.75). 
Overall, thirty-one percent of patients did not receive pre-hospitalization treatment. Since few 
patients received pre-hospitalization treatment for more than 30 days, stratification by the 
duration of pre-hospitalization care was not conducted. 
 
Table 16: Average actual (level 5) per-patient pre-hospitalization costs (2006 U.S.$) for 
NCC patients treated at the INNN between 2002 and 2006 by clinical manifestation(s) 
(values in brackets represent 95% CI) 
 
  Per-patient pre-hospitalization costs (95% CI) 
Clinical 
manifestation(s) 
Number of 
patients 
Diagnostic tests  Physician 
office visits 
 
Prescription 
medications  
Total  
 
Epilepsy/seizures 13 156 (10 - 303) 12 (0 - 32) 28 (4 - 52) 196 (8 – 402) 
Hydrocephalus 21 134 (44 -226)  10 (1 – 19) 7 (2 – 12) 152 (58 – 246) 
Severe chronic 
headaches 
23 239 (75 - 403) 24 (4 – 44) 24 (0 – 64) 287 (106 – 470) 
Stroke 2 269 (181 – 356) 0 0 269 (181 – 356) 
Dementia 1 0 60 0 60 
Severe chronic 
headaches and 
hydrocephalus 
31 270 (143 – 397) 49 (13 – 84) 12 (0 – 26) 331 (166 –495) 
Epilepsy/seizures and 
hydrocephalus 
4 108 (10 – 207) 5 (0 – 10) 6 (0 – 13) 119 (15 – 223) 
Epilepsy/seizures and 
severe chronic 
headaches 
6 263 (0 – 528) 46 (0 – 112) 139 (0 – 334) 448 (0 – 938) 
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Table 16: Continued 
  Per-patient pre-hospitalization costs (95% CI) 
Clinical 
manifestation(s) 
Number of 
patients 
Diagnostic tests  Physician 
office visits 
 
Prescription 
medications  
Total  
 
Epilepsy/seizures, severe 
chronic headaches, and 
hydrocephalus 
7 183 (51 – 316) 17 (0 – 42) 0 200 (43 – 355) 
Overall 108 210 (152 – 270) 26 (15 – 39) 21 (3 – 40) 257 (185 –  329) 
 
 
 
Hospitalization costs 
The average actual (level 5) per-patient hospitalization cost was U.S.$ 2,576 (95% CI: 
2,244 – 2,908), with an average per-patient per-day hospitalization cost of U.S.$ 269 (95% CI: 
218 – 320). The average total out-of-pocket hospitalization cost was U.S.$ 424 (95% CI: 247 – 
602), with an average daily cost of U.S.$ 67 (95% CI: 6 – 128) (Table 17). Figure 7 shows the 
average per-patient per-day hospitalization cost by presenting clinical manifestation(s). No 
significant difference was found in the per-patient hospitalization costs for the various presenting 
clinical manifestation(s) (p=0.13). However, the cost of hospitalization was significantly higher 
in patients who had surgery (n=66) (U.S.$ 3,487) compared to those who did not have surgery 
(n=42) (U.S.$ 1,166) (p<0.001). While 67% of NCC patients with clinical manifestations other 
than epilepsy underwent surgical procedures during hospitalization, only 23% of epilepsy 
patients had surgery. 
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Table 17: Average actual (level 5) per-patient hospitalization costs (2006 U.S.$) for NCC 
patients treated at the INNN between 2002 and 2006 by clinical manifestation(s) (values in 
brackets represent 95% CI) 
 
Clinical 
manifestation(s) 
Number of 
patients 
(Number of 
hospitalizations) 
Per-patient hospitalization costs (95% CI) 
Diagnostic 
tests  
Hospital 
stay  
Surgery  Prescription 
medications 
Total 
hospitalization  
Epilepsy/ 
seizures 
13(13) 177 (100 - 
253) 
1,026 
(655 – 
1,397)  
429 (5 - 
853) 
107 (0 – 220) 1,739 (926 – 
2,552) 
Hydrocephalus 21 (24) 186 (99 – 
273) 
803 (570 
– 1,037) 
1561 (947 
– 2,176) 
13 (2 –24) 2,565 (1,787 – 
3,342) 
Severe chronic 
headaches 
23 (25) 297 (198 – 
396) 
758 (585 
– 930) 
882 (382 – 
1,382) 
24 (7 – 42) 1,961 (1,427 – 
2,496) 
Stroke 2 (2) 229 (31 – 
427) 
2,416 
(441 – 
4,393) 
1,278 (90 
– 2,468) 
82 (11 – 154) 4,007 (467 – 
7,548) 
Dementia 1 (1) 469 748 0 99 1,316 
Severe chronic 
headaches and 
hydrocephalus 
31(44) 197 (115 – 
280) 
874 (664 
–1,084) 
1,782 
(1,245 – 
2,318) 
28 (10 – 47) 2,882 (2,265 – 
3,499) 
Epilepsy/seizures 
and 
hydrocephalus 
4 (9) 481 (154 – 
809) 
1,276 
(680 – 
1,872) 
2,771 
(1,289 – 
4,253) 
14 (0 -33) 4,544 (2,241 – 
6,847 
Epilepsy/seizures 
and severe 
chronic 
headaches 
6 (10) 433 (115 – 
749) 
1,316 
(869 – 
1,763) 
1,279 (447 
– 2,110) 
22 (9 – 35) 3,050 (1,803 – 
4,296) 
Epilepsy/seizures
, severe chronic 
headaches, and 
hydrocephalus 
7 (12) 472 (310 – 
634) 
904 (531 
– 1,277) 
1,819 (451 
– 3,187) 
38 (24 – 52) 3,223 (1,866 – 
4,579) 
Overall 108 (140) 254 (206 – 
302) 
922 (689 
– 1,155) 
1,365 (797 
– 1,933) 
35 (19 – 51) 2,576 (2,244 – 
2,908) 
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Figure 7: Average actual (level 5) per-patient per day hospitalization costs (U.S.$) for NCC 
patients treated at the INNN by clinical manifestation(s) (The plot whiskers extend to the 
upper and lower 95% confidence intervals) 
 
E/S = Epilepsy/ seizures, H = Hydrocephalus, SCH= Severe chronic headaches, ST= Stroke, D = 
Dementia 
 
 
 
Post-hospitalization costs 
 
The average actual (level 5) per-patient costs for one to five years post-hospitalization 
were U.S.$ 475 (95% CI: 423 – 527), U.S.$ 228 (95% CI: 167 – 288), U.S.$ 157 (95% CI: 111 – 
202), U.S.$ 150 (95% CI: 106 – 204), and U.S.$ 91 (95% CI: 27 – 154), respectively (Table 18 
and Figure 8).  For patients followed for at least 3 years post-hospitalization (n=41), the average 
cost for the first post-hospitalization treatment year (U.S.$ 445) was significantly higher than 
that for the second year post-hospitalization (U.S.$ 316) (p=0.05), which in turn was not 
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significantly higher than that of the third year post-hospitalization (U.S.$ 239) (p=0.35). No 
significant difference was found in the per-patient costs for the various presenting clinical 
manifestation(s) for the post-hospitalization period (p=0.37) (Table 18). Figure 8 shows the 
average post-hospitalization costs broken down by the cost components of diagnostic testing, 
visits to a healthcare provider, and prescription medications. The out-of-pocket costs for one to 
five years post-hospitalization were U.S.$ 114 (95% CI: 88 – 141), U.S.$ 56 (95% CI: 32 – 80), 
U.S.$ 47 (95% CI: 25 – 69), U.S.$ 45 (95% CI: 17 – 74), and U.S.$ 32 (95% CI: 0 – 66), 
respectively. Most of the out-of-pocket costs were due to prescription medications (Figure 9).  
 
 
Table 18: Average actual (level 5) per-patient post-hospitalization costs (2006 U.S.$) for 
NCC patients treated at the INNN between 2002 and 2006 by clinical manifestation(s) 
(values in brackets represent 95% CI) 
 
Clinical 
manifestation
s 
Per-patient post-hospitalization costs (95% CI), 
(number of patients) 
1
st
 year  2
nd
 year 3
rd
 year 4
th
 year 5
th
 year 
Epilepsy/ 
seizures 
648 (421 - 874) 
(n=11) 
319 (66 – 574) 
(n=9) 
220 (65 – 376) 
(n=6) 
207 (44 – 398) 
(n=4) 
197 
 (n=1) 
Hydrocephalu
s 
480 (369 – 591) 
(n=16) 
115 (51 – 180) 
(n=9) 
187(54 – 320) 
(n=4) 
159 (23 – 295) 
(n=3) 
127 (5 – 245) 
(n=2) 
Severe chronic 
headaches 
474 (357 – 592) 
(n=21) 
302 (173 – 432) 
(n=11) 
176 (78 – 275) 
(n=8) 
226 (99 – 353) 
(n=5) 
151 (1 – 301) 
(n=4) 
Stroke 506 (255 – 665) 
(n=2) 
105 (0 – 218) 
(n=2) 
238 
(n=1) 
304 
(n=1) 
209 
(n=1) 
Dementia* - - - - - 
Severe chronic 
headaches and 
hydrocephalus 
461 (379 – 542) 
(n=22) 
244 (136 – 352) 
(n=15) 
145 (84 – 206) 
(n=13) 
67 (16 – 118) 
(n=10) 
20 (1 – 38) 
(n=6) 
Epilepsy/seizu
res and 
hydrocephalus 
450 (328 – 571) 
(n=4) 
167 (46 – 291) 
(n=3) 
134 (0 – 291) 
(n=2) 
124 (0 – 275) 
(n=2) 
20 
 (n=1) 
Epilepsy/seizu
res and severe 
chronic 
headaches 
376 (221 – 531) 
(n=6) 
266 (46 – 487) 
(n=4) 
114 (0 – 246) 
(n=4) 
215 
(n=1) 
- 
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Table 18: Continued 
 
Clinical 
manifestation
s 
Per-patient post-hospitalization costs (95% CI), 
(number of patients) 
1
st
 year  2
nd
 year 3
rd
 year 4
th
 year 5
th
 year 
Epilepsy/seizu
res, severe 
chronic 
headaches, 
and 
hydrocephalus 
373 (161 – 585) 
(n=4) 
122 (31 – 213) 
(n=2) 
- - - 
Overall 475 (423 – 527) 
(n=86) 
228 (167 – 288) 
(n=55) 
157 (111 – 202) 
(n=41) 
150 (106 – 
204) 
(n=26) 
91 (27 – 154) 
(n=15) 
 
* The dementia patient was followed for less than 12 months and was, therefore, not included in 
the estimation of post-hospitalization costs 
 
 
 
 
Figure 8: Average costs broken down by cost component and year of treatment post-
hospitalization for NCC patients treated at the INNN 
 
Note: There were 86, 55, 41, 26, and 15 patients who received treatment one, two, three, four, 
and five years post-hospitalization, respectively. 
 
 68 
 
 
 
Figure 9: Average out-of-pocket costs breakdown by cost component and year of treatment 
post-hospitalization for NCC patients treated at the INNN  
 
Note: There were 86, 55, 41, 26, and 15 patients who received treatment one, two, three, four, 
and five years post-hospitalization, respectively. 
 
  
III.4 Discussion 
 This is the first patient-based study estimating the direct monetary losses associated with 
NCC-affected individuals in Mexico during the pre-hospitalization, hospitalization, and post-
hospitalization periods. Overall, substantial costs were associated with patients requiring 
hospitalization for NCC, with this burden continuing years post-hospitalization. When all 
patients, regardless of having received pre-hospitalization care at the INNN, were included in the 
analysis, the direct economic losses pre-hospitalization, during hospitalization, and during the 
first year post-hospitalization were equivalent to 22%, 224%, and 42% of an annual minimum 
wage salary in Mexico (U.S.$ 1,145), respectively [80]. Overall, pre-hospitalization represented 
the least expensive cost period for patients. However, pre-hospitalization costs increased from 
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22% to 32% of an annual minimum wage salary when only those patients with pre-
hospitalization treatment were included [80]. 
Very few studies have been conducted to estimate the cost associated with NCC patients. 
In the current study, patients incurred expenses equivalent to 64% of an annual minimum wage 
salary during the pre-hospitalization period plus one year post-hospitalization. In comparison, 
non-hospitalized Indian patients with NCC-associated epilepsy were shown to spend 51% of 
their per capita gross national product (GNP) on direct and indirect costs associated with their 
disease during their treatment period, which ranged from 1 to 14 months[62]. Unfortunately, 
direct comparison between these two studies is difficult. Not only did the Indian study use per 
capita GNP versus wage data, this study also restricted study participants to only those NCC 
patients with epilepsy. Since the cost of prescription medications tends to be higher for epileptic 
patients with NCC compared to non-epileptic NCC patients, it would be expected that epileptics 
would incur higher costs. In our study, epileptic patients were spending twice as much out-of-
pocket for their prescription medications compared to non-epileptic patients. If we consider only 
the epileptic patients in our study, economic losses were equivalent to 72% of an annual 
minimum wage salary during pre-hospitalization plus the first year post-hospitalization. Another 
reason why these two studies are difficult to compare is that the Indian study also included 
indirect losses whereas the current Mexican study did not. Productivity losses accounted for 17% 
of total costs associated with the Indian patients.   
In another study conducted in a reference hospital in Peru, NCC patients were spending 
54% and 16% of an annual minimum wage salary on direct and indirect costs associated with 
their disease during their first year and second year of treatment, respectively [63]. This study 
included patients with and without epilepsy as well as hospitalized and non-hospitalized patients 
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whereas the current study only included hospitalized patients. Overall, 78% of the patients in the 
Peruvian study were hospitalized. The Peruvian patients spent a smaller proportion of a 
minimum wage salary on treatment costs compared to the Mexican patients. One possible reason 
for this difference is that 61% of the patients in the current study underwent surgery whereas 
none of the Peruvian patients underwent surgery. The pre-hospitalization, hospitalization, and 
post-hospitalization costs for the Mexican patients who did not have surgery were 16%, 100% 
and 66% of an annual minimum wage salary, respectively. Hospitalization and post-
hospitalization values were, therefore, about 50% less than for the entire studied population. It 
should be noted that the Peruvian study also included productivity losses, which were not 
assessed in the current Mexican study. Productivity losses accounted for 10% of total costs in the 
Peruvian study.   
 In the current study, the hospitalization period incurred higher per-patient costs for all 
clinical manifestations when compared to the pre-hospitalization or entire post-hospitalization 
period. However, this cost was not significantly higher for patients with epilepsy or stroke as the 
sole presenting clinical manifestation. In comparison to patients with other clinical 
manifestations, fewer epilepsy cases had surgery and the number of patients with stroke was very 
small, explaining the lack of significant differences for these two groups. The post-
hospitalization costs were highest in the first year post-hospitalization, which was likely due to 
the greater number of diagnostic tests performed in this year as compared to subsequent years. 
The average number of hospitalized days for patients whose records were evaluated after they 
had received only one year of treatment post-hospitalization (11 days) was similar to patients 
whose records were evaluated after they had received more than one year of treatment post-
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hospitalization (13 days). Therefore, patient clinical severity at the time of hospitalization most 
likely did not greatly influence these values.  
Although our results suggest that the actual cost to treat NCC is high compared to an 
annual minimum wage salary in Mexico, most of the patients in this study paid a reduced amount 
based on their income. The exception was for prescription medications. The vast majority (83%) 
of patients paid at level 2 or under, which is well below the actual costs to the healthcare system, 
indicating that they fell into a lower income bracket. Although they paid a reduced amount 
compared to the actual price of services, they were still spending a considerable proportion of an 
annual minimum wage salary out-of-pocket during the pre-hospitalization and hospitalization 
periods combined (43%), and during the first year post-hospitalization (10%). It should be noted 
that costs associated with treatment that were not paid by patients were absorbed by the hospital 
system and, therefore, society as a whole. 
This study has some limitations. Data were collected from medical chart reviews, which 
limited assessed variables to those recorded as part of the standard medical charting process and 
those anticipated to be of value prior to commencement of this study. Therefore, type of NCC 
(intraparenchymal versus extraparenchymal), cyst viability, and actual wage data were not 
available for analysis. Our estimates are also an underestimate of the total costs associated with 
NCC among patients hospitalized at the INNN since indirect costs such as loss of working days 
due to visits to a healthcare provider or during hospitalization, cost of over-the-counter 
medication, cost of traditional medicine/treatment, reduction in productivity level, costs 
associated with transportation to and from medical treatment, and time lost by the patient’s 
family to take care of them or to accompany them to treatment were not available for 
consideration[86].  In addition, this analysis excludes any costs incurred while receiving 
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treatment in a healthcare facility other than the INNN, which could especially affect the 
estimated pre- and post-hospitalization costs. Finally, this study was conducted in a neurology 
reference hospital, which likely sees many of the more severe cases. Therefore, the determined 
costs cannot be extrapolated to all NCC cases in Mexico.  
While the actual costs associated with healthcare services may change over time, the 
relative proportion of costs associated with the pre-hospitalization, hospitalization, and post-
hospitalization periods will likely remain more stable. Therefore, values presented in this study 
can be used by Mexico to better define the direct costs associated with NCC patients who are 
hospitalized at tertiary care hospitals, with the ultimate goal of better conveying the true 
economic impact of NCC to policy makers.  
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CHAPTER IV 
THE MONETARY BURDEN OF CYSTICERCOSIS IN MEXICO 
 
IV.1 Introduction 
Cysticercosis is a public health and agricultural problem caused by the larvae of the 
zoonotic cestode Taenia solium. Humans are the definitive hosts of T. solium, with adult 
tapeworms found in the intestines after ingestion of undercooked pork containing cysticerci. 
Infection with the adult stage of the parasite is known as taeniasis. Pigs acquire cysticercosis 
when ingesting eggs shed in the feces of humans with taeniasis. Porcine cysticercosis results in 
the development of cysts in the muscles, including the tongue, and less commonly in the heart, 
diaphragm, brain, and other organ systems. When humans accidentally ingest eggs shed in the 
feces of an infected human, they develop larval cysts (cysticercosis) similar to infected pigs. 
Neurocysticercosis (NCC) occurs when T. solium cysticerci infect the central nervous system, 
which can result in symptoms such as epilepsy, severe chronic headaches, hydrocephalus, stroke, 
and dementia [8].  
Porcine cysticercosis and NCC have important economic consequences. NCC incurs 
direct and indirect costs. Direct costs include fees associated with medical services, diagnostic 
procedures, surgical interventions, prescribed chemotherapeutic treatment, hospitalization, and 
traditional therapies. Indirect costs are associated with loss of working days due to visits to a 
healthcare provider or hospitalization, over-the-counter medication, loss of  income due to 
reduced productivity, transportation to and from medical treatment, and time lost by the patient’s 
family to take care of them or to accompany them to receive medical care [86]. In pigs, 
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cysticercosis can lead to partial or full condemnation of the carcass and economic losses in areas 
where meat is inspected [2].  
NCC has been shown to result in a significant economic burden to people in Mexico 
requiring hospitalization [84]. However, no previous study has evaluated the burden of 
cysticercosis in Mexico incorporating both human and pig losses. NCC-associated monetary 
losses to both the human health and agricultural sectors have been evaluated in South Africa, Lao 
People's Democratic Republic, Cameroon, Tanzania, and India [16-20]. Studies are needed to 
estimate the burden of cysticercosis in endemic countries to facilitate comparisons with other 
locally important health conditions and to better prioritize disease control initiatives. The 
research presented here provides the first estimate of the monetary burden of human NCC-
associated epilepsy and severe chronic headaches and porcine cysticercosis for the country of 
Mexico. 
 
IV.2 Materials and Methods 
IV.2.1 Study area 
Mexico is the third largest country in Latin America, with a 2012 population of almost 
114 million and an annual population growth rate of 1.2% [67]. It is the eleventh most populous 
country in the world, with 23% of the population living in rural areas [67]. Traditional pig 
rearing practices in T. solium-endemic areas allow pigs to have access to human feces in open 
fields facilitating the completion of the T. solium life cycle [68,69]. Confined pigs in yards next 
to dwellings may also have direct access to poorly maintained outdoor latrines [70].  
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IV.2.2. Estimation of the number of NCC cases with epilepsy and severe chronic headaches 
in Mexico 
 The exact number of NCC cases in Mexico is not known. The proportion of people with 
NCC who develop epilepsy, severe chronic headaches or other clinical manifestations is also 
unknown. Therefore, the numbers of cases of NCC-associated epilepsy and NCC-associated 
severe chronic headaches, in urban and rural areas of Mexico, were estimated based on the 
model used by Bhattarai el 2012 [58]. The number of epilepsy cases in Mexico was estimated by 
multiplying the age and rural/urban stratified population size from the 2010 Mexico census by 
the epilepsy prevalence estimates for Mexico [55]. The number of NCC-associated epilepsy 
cases was obtained by multiplying the estimated numbers of people with epilepsy in rural and 
urban areas by the respective proportion of people with epilepsy with NCC lesions based on a 
meta-analysis of NCC-frequency data from Latin America [83]. The results from this meta-
analysis were also used to estimate the number of NCC-associated epilepsy cases receiving 
modern medical treatment in urban and rural areas. This was achieved by multiplying the 
numbers of NCC-associated epilepsy cases in rural and urban areas by the respective percentages 
seeking  treatment [83].  
 The proportion of NCC cases with severe chronic headaches in Mexico was estimated 
using a multistep process. First, the total number of NCC cases presenting to a healthcare facility 
for any NCC-associated symptom (epilepsy, severe chronic headaches, focal deficits, stroke, 
dementia, etc.) was calculated. This was done by dividing the estimated number of NCC-
associated epilepsy cases seeking treatment (see above) by the proportion of all symptomatic 
individuals with NCC who present to neurological clinics with epilepsy reported in a meta-
analysis of clinical manifestations associated with NCC [8]. The number of people with NCC-
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associated severe chronic headaches seeking care at a healthcare facility of any level was then 
estimated. The proportion of people with symptomatic NCC that have epilepsy or severe chronic 
headaches was assumed to be the same regardless of whether they were seen at a primary, 
secondary, or tertiary care facility, due to the lack of data for individuals treated at different 
levels in Mexico. The number of people with NCC-associated severe chronic headaches was 
obtained by multiplying the total number of NCC cases presenting to a healthcare facility for any 
NCC-associated symptom (stratified by urban/rural origin), by the proportion of NCC cases who 
seek care at a neurology referral hospital due to headaches based on the same systematic review 
[8].  The total number of people with NCC-associated severe chronic headaches, in urban and 
rural areas, was then calculated by dividing the total number of NCC-associated severe chronic 
headaches cases seen in healthcare facilities by the proportion of NCC cases with severe chronic 
headaches who received treatment in a neurology clinic based on Carabin et al. 2011 [8]. It 
should be noted that some individuals with NCC have both epilepsy and severe chronic 
headaches and these people contribute to the estimates for both NCC-associated epilepsy and 
NCC-associated severe chronic headaches. Table 19 shows the epidemiological parameters used 
to calculate the number of NCC-associated epilepsy and severe headache cases. 
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Table 19: Epidemiological parameters used to calculate the number of NCC-associated 
epilepsy and severe chronic headache cases 
 
Parameter Value or range of 
values 
Distribution References 
2010 Population of Mexico ('000)    
Total 112,336,538 Fixed [87] 
Urban areas 86,287,410 Fixed [87] 
Rural areas 26,049,128 Fixed [87] 
Prevalence of epilepsy in 0-14-year-old 
males in Mexico (per 1,000) 
Min:1.4 
Max:12.5 
Uniform 
(1.4 - 12.5) 
[55] 
Prevalence of epilepsy in 0-14-year-old 
females in Mexico (per 1,000) 
Min: 0.8 
Max: 10.0 
Uniform 
(0.8 - 10.0) 
[55] 
Prevalence of epilepsy in 15-44-year-old 
males in Mexico (per 1,000) 
Min: 1.4 
Max: 17.2 
Uniform 
(1.4 - 17.2) 
[55] 
Prevalence of epilepsy in 15-44-year-old 
females in Mexico (per 1,000) 
Min: 1.4 
Max: 11.7 
Uniform 
(1.4 - 11.7) 
[55] 
Prevalence of epilepsy in 45-59-year-old 
males and females in Mexico (per 1,000) 
Min: 0.1 
Max: 13.2 
Uniform 
(0.1 - 13.2) 
[55] 
Prevalence of epilepsy in males and 
females older than 60 years of age in 
Mexico (per 1,000) 
Min: 0.3 
Max: 30.8 
Uniform 
(0.3 - 30.8) 
[55] 
Proportion of epilepsy cases associated 
with NCC in urban area of Mexico 
Min: 0.21 
Max: 0.37 
Uniform 
(0.21 - 0.37) 
[83] 
Proportion of epilepsy cases associated 
with NCC in rural areas of Mexico 
Min: 0.26 
Max: 0.49 
Uniform 
(0.26 - 0.49) 
[83] 
Proportion of NCC patients 0-14 years of 
age with epilepsy 
Min: 0.70 
Max: 0.86 
Uniform 
(0.70 - 0.86) 
[8] 
Proportion of NCC cases older than 15 
years of age with epilepsy  
Min: 0.52 
Max: 0.74 
Uniform 
(0.52 - 0.74) 
[8] 
Proportion of people with epilepsy not 
receiving modern medical treatment in 
urban areas 
Min: 0.10 
Max: 0.46 
Uniform 
(0.10 - 0.46) 
[83] 
Proportion of people with epilepsy not 
receiving modern medical treatment in 
rural areas 
Min: 0.67 
Max: 0.87 
Uniform 
(0.67 - 0.87) 
[83] 
Proportion of people 0-14 years of age 
with severe chronic headaches presenting 
with NCC 
Min: 0.21 
Max: 0.35 
Uniform 
(0.21 - 0.35) 
[8] 
Proportion of individuals older than 15 
years of age with severe chronic 
headaches presenting with NCC 
Min: 0.11 
Max: 0.45 
Uniform 
(0.11 - 0.45) 
[8] 
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IV.2.3 Treatment seeking behavior of people with NCC in Mexico 
People with NCC-associated epilepsy and severe chronic headaches were divided into 
two categories; 1) those who do not seek modern medical treatment, and 2) those who seek 
modern medical treatment. Modern medical treatment is defined as western medicine/allopathic 
medicine. These categories were further divided into sub-categories as explained in the next 
sections. A flowchart showing treatment end-points for Mexicans with NCC-associated epilepsy 
and severe chronic headaches is found in Figure 10.  
Literature-based information on healthcare seeking behavior and treatment gaps was used 
to estimate the number of people with NCC in each of the above groups. A setting-specific 
questionnaire was developed in Spanish to obtain information not found in the published 
literature (Appendix G). 
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Figure 10: Flowchart showing categories of treatment-seeking behavior of people with NCC-associated epilepsy and NCC-
associated severe chronic headaches in Mexico 
Note: Please refer to table 19 for information concerning the uncertainty distributions associated with the specific parameters. All data were stratified by 
rural/urban residence. Localities of 2,500 or more inhabitants were considered urban (UN 2010).
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IV.2.4 People with NCC-associated epilepsy or severe chronic headaches not seeking 
modern medical treatment 
 A recent systematic review of epilepsy and NCC in Latin America was used to estimate 
the number of NCC-associated epilepsy cases receiving modern medical treatment in urban and 
rural areas of Mexico [83]. Due to limited data on the treatment gap for severe chronic 
headaches, the treatment gap was assumed to be 10% more than that of epilepsy due to the 
generally greater clinical severity of epilepsy. This estimate is consistent with treatment gaps 
reported in other countries. For example, studies conducted in the United Kingdom (U.K.) 
reported that the epilepsy treatment gap was 2%, whereas the migraine treatment gap was 
14% [88,89] (Table 20). 
It was assumed that some individuals with epilepsy or severe chronic headaches seek 
treatment exclusively from traditional healers. Questionnaire findings from employees at the 
Michoacán Office of the Ministry of Health estimated that an average of 23% (min: 0%, mode: 
0%, max: 70%) and 26% (min: 0%, mode: 0%, max: 80%) of people with epilepsy and severe 
headaches from rural areas, respectively, seek medical attention exclusively from traditional 
healers. Questionnaire findings are in line with a study conducted in rural Mexico where 33% of 
people with epilepsy sought treatment from traditional healers after their first seizure [90]. There 
was no literature to support the proportion of people with severe chronic headaches seeking 
treatment from traditional healers in Mexico. However, questionnaire findings are similar to 
those of a study conducted in rural and urban Taiwan where 24.2% of people with migraines 
sought treatment from practitioners of traditional Chinese medicine [91]. Triangular distributions 
using the minimum, mode, and maximum values from the questionnaires were used to estimate 
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the number of NCC-associated epilepsy and severe chronic headache cases seeking treatment 
solely from traditional healers in rural areas of Mexico.   
According to Hoeven et al. 2012, individuals residing in rural areas of South Africa were 
twice as likely to prefer treatment from a traditional healer compared to individuals residing in 
urban areas [92]. Since such data are not available from Mexico, the proportions of individuals 
with epilepsy and severe chronic headaches who seek medical attention exclusively from a 
traditional healer in rural areas of Mexico were multiplied by 0.5 to obtain the proportions of 
individuals who seek medical attention exclusively from a traditional healer in urban areas of 
Mexico. The numbers of NCC-associated epilepsy and severe chronic headaches cases seeking 
treatment solely from traditional healers were estimated by multiplying the number of NCC-
associated epilepsy and NCC-associated severe chronic headaches cases in rural and urban areas 
by the proportion of people seeking treatment from traditional healers (Table 20). 
The proportion of people with NCC-associated epilepsy or severe chronic headaches who 
do not receive any treatment was estimated by subtracting the proportion of people who only 
receive treatment from traditional healers from the proportion of people who do not seek modern 
medical treatment. These proportions were multiplied by the numbers of people with NCC-
associated epilepsy and severe chronic headaches in rural and urban areas to obtain the 
respective numbers of people with NCC not receiving any form of treatment. 
 
IV.2.5 People with NCC-associated epilepsy or severe chronic headaches seeking modern 
medical treatment 
People with NCC receiving modern medical treatment were further broken down into six 
sub-categories representing the highest level of care obtained; i) those who receive medical 
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attention from a primary care provider, ii) those who receive medical attention from both a 
primary care provider and a traditional healer, iii) those who receive medical attention from a 
secondary care provider and are not hospitalized, iv) those who receive medical attention from a 
secondary care provider and are hospitalized, v) those who receive medical attention at a tertiary 
care hospital and are not hospitalized, and vi) those who receive medical attention at a tertiary 
care hospital and are hospitalized.  
In Mexico, people with epilepsy or severe chronic headaches generally initially seek 
treatment at a primary care clinic. From there, a proportion of them are referred for further 
treatment at a secondary or tertiary care facility. Due to a lack of published data on the 
proportion of people with epilepsy, in urban areas, who are referred for upper level care in 
Mexico, data from a 2007 study conducted in Brazil and a 2010 study conducted in the U.K. 
were used. The Brazilian and U.K. studies reported that 59% and 23% of people with epilepsy 
who came to primary care clinics in urban areas were referred to upper level care, respectively 
[93,94]. The estimate was modeled as a uniform distribution between the U.K. study (23%) and 
the Brazilian study (59%). Similarly, the proportion of people with severe chronic headaches 
referred to upper level care in urban areas was assumed to follow a uniform distribution between 
an estimate from a study of people with migraine conducted in Latin America in 2005 (8%) and 
a study conducted in the United States (U.S.) in 1993 (30%) [95,96].  
Since referral data based on a rural versus urban setting are not available from Mexico, it 
was assumed that the proportion of cases of epilepsy and severe chronic headaches referred in 
rural areas would be half that seen in urban areas. This estimate was based on a U.S. study 
showing that urban physicians are twice as likely to refer people for upper level care on the 
suspicion of hereditary breast cancer compared to rural physicians [97]. The proportion of 
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patients referred to a secondary care clinic directly from a primary care clinic was based on 
questionnaire responses provided by physicians working in a primary care clinic in Michoacán.  
The proportion of patients referred to a tertiary care hospital directly from a primary clinic was 
based on questionnaire responses provided by neurologists working in a secondary care clinic in 
Michoacán. The estimate was modeled as a triangular distribution using the provided values for 
minimum, mode, and maximum. Based on the assumption that the referral rate is double in urban 
areas, the values provided by the physicians were multiplied by two to estimate the proportions 
referred from primary to tertiary care in urban areas. The proportions of people with epilepsy or 
severe chronic headaches referred from a primary care provider to a secondary care provider 
were estimated by subtracting the proportion of people referred to a tertiary care hospital from all 
referred patients with epilepsy and severe chronic headache for both rural and urban locations. It 
was assumed that secondary care providers and tertiary hospitals are primarily located in urban 
areas; therefore, the proportions of patients that were referred to tertiary hospitals from 
secondary care clinics would be the same for both urban and rural areas. 
Some people with epilepsy and severe chronic headaches seek medical attention from 
both a modern doctor and a traditional healer. This proportion (35% for epilepsy and 31% for 
severe chronic headaches) was based on questionnaire responses provided by employees of the 
Michoacán branch of Mexico’s Ministry of Health (Appendix G). The estimate provided is 
consistent with findings from a study conducted in the Rio Grande Valley of Texas where 44% 
of Mexican Americans were found to use alternative medicine in addition to modern medicine 
[98]. Based on the assumption that individuals residing in rural areas are twice as likely to prefer 
treatment from a traditional healer compared to individuals residing in urban areas, the above 
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values were multiplied by 0.5 to estimate the proportion of people who seek medical attention 
from both a modern doctor and a traditional healer in urban areas. 
 
Table 20: Human epidemiologic parameters used to estimate the monetary burden of 
cysticercosis in Mexico 
 
Parameter Value Distribution Reference 
Proportion of people with epilepsy not receiving modern 
medical treatment in urban areas 
Min: 0.10 
Max: 0.46 
Uniform 
 
[83] 
Proportion of people with epilepsy not receiving modern 
medical treatment in rural areas 
Min: 0.67 
Max: 0.87 
Uniform 
 
[83] 
Proportion of people with severe chronic headaches not 
receiving modern medical treatment in urban areas 
Min: 0.21 
Max: 0.56 
Uniform 
 
[see text] 
Proportion of people with severe chronic headaches 
people not receiving modern treatment in rural areas 
Min: 0.78 
Max: 0.97 
Uniform 
 
[see text] 
Proportion of people with epilepsy who seek treatment 
exclusively from a traditional healer in urban areas 
Min: 0 
Mode: 0 
Max: 0.35 
Triangular 
 
Appendix 
G 
Proportion of people with epilepsy who seek treatment 
exclusively from a traditional healer in rural areas 
Min: 0 
Mode: 0 
Max: 0.7 
Triangular 
 
Appendix 
G 
Proportion of people with severe chronic headaches who 
seek treatment exclusively from a traditional healer in 
urban areas 
Min: 0 
Mode: 0 
Max: 0.4 
Triangular 
 
Appendix 
G 
Proportion of people with severe chronic headaches who 
seek treatment exclusively from a traditional healer in 
rural areas 
Min: 0 
Mode: 0 
Max: 0.8 
Triangular 
 
Appendix 
G 
Proportion of people with epilepsy in urban areas who 
seek medical attention at a primary care clinic and are 
referred to upper level care 
Min: 0.21 
Max: 0.59 
Uniform 
 
[93,94] 
Proportion of people with epilepsy in rural areas who 
seek medical attention at a primary care clinic and are 
referred to upper level care 
Min: 0.10 
Max: 0.30 
Uniform 
 
[see text] 
Proportion of people with severe chronic headaches in 
urban areas who seek medical attention at a primary care 
clinic and are referred to upper level care 
Min: 0.08 
Max: 0.30 
Uniform 
 
[95,96] 
Proportion of people with severe chronic headaches in 
urban areas who seek medical attention at a primary care 
clinic and are referred to upper level care 
Min: 0.04 
Max: 0.15 
Uniform 
 
[see text] 
Proportion of urban people with epilepsy referred to a 
tertiary hospital from a primary care clinic  
Min: 0 
Mode: 0 
Max: 0.8 
Triangular 
 
Appendix 
G 
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Table 20: Continued 
 
Parameter Value Distribution Reference 
Proportion of rural people with epilepsy referred to a 
tertiary hospital from a primary care clinic  
Min: 0 
Mode: 0 
Max: 0.4 
Triangular 
 
Appendix 
G 
Proportion of urban people with severe chronic 
headaches referred to a tertiary hospital from a primary 
care clinic  
Min: 0 
Mode: 0 
Max: 0.2 
Triangular 
 
Appendix 
G 
Proportion of rural people with severe chronic 
headaches referred to a tertiary hospital from a primary 
care clinic  
Min: 0 
Mode: 0 
Max: 0.1 
Triangular 
 
Appendix 
G 
Proportion of urban people with epilepsy referred to a 
tertiary care hospital from a secondary care clinic  
Min: 0 
Mode: 0 
Max: 0.5 
Triangular 
 
Appendix 
G 
Proportion of rural people with epilepsy referred to a 
tertiary care hospital from a secondary care clinic  
Min: 0 
Mode: 0 
Max: 0.5 
Triangular 
 
Appendix 
G 
Proportion of urban people with severe chronic 
headaches referred to a tertiary care hospital from a 
secondary care clinic  
Min: 0 
Mode: 0 
Max: 0.25 
Triangular 
 
Appendix 
G 
Proportion of rural people with severe chronic 
headaches referred to a tertiary care hospital from a 
secondary care clinic  
Min: 0 
Mode: 0 
Max: 0.25 
Triangular 
 
Appendix 
G 
Proportion of urban people with epilepsy who seek 
medical attention from a modern doctor and also receive 
treatment from a traditional healer  
Min: 
0.005 
Mode: 
0.025 
Max: 0.5 
Triangular 
 
[see text] 
Proportion of rural people with epilepsy who seek 
medical attention from a modern doctor and also receive 
treatment from a traditional healer  
Min: 0.01 
Mode: 
0.05 
Max: 1 
Triangular 
 
Appendix 
G 
Proportion of urban people with severe chronic 
headaches who seek medical attention from a modern 
doctor and also receive treatment from a traditional 
healer  
Min: 0 
Mode: 0 
Max: 
0.475 
Triangular 
 
[see text] 
Proportion of rural people with severe chronic 
headaches who seek medical attention from a modern 
doctor and also receive treatment from a traditional 
healer  
Min: 0 
Mode: 0 
Max: 0.95 
Triangular 
 
Appendix 
G 
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IV.2.6 Parameters associated with use of healthcare resources 
Parameters associated with the use of healthcare resources by people with NCC-
associated epilepsy and NCC-associated severe chronic headaches in Mexico are shown in 
Tables 21 and 22. Frequency of doctor visits and prescribed medications taken by individuals 
seeking medical attention at a primary care clinic were based on data provided by primary care 
physicians in Michoacán. Frequency of doctor visits, medications, diagnostic tests such as 
computed tomography (CT) scans and magnetic resonance imaging (MRI), and hospitalization 
for people seeking medical attention at a secondary care clinic were based on data provided by 
neurologists working at a secondary care clinic in Michoacán. Data on frequency of 
electroencephalogram (EEG) and cerebrospinal fluid (CSF) testing for people who received 
treatment at a secondary care clinic were not available from study questionnaires and were 
assumed the same as for people seen in tertiary care facilities. Frequency of doctor visits, 
medications, hospitalizations, surgical intervention, and diagnostic tests, including CT scans, 
MRIs, CSF testing, EEGs, EITBs, and ELISAs were based on the results of a recent study 
conducted in two tertiary care hospitals in Mexico City, Mexico [84]. It was assumed that all 
NCC-related surgical interventions were performed at a tertiary care facility. For people referred 
to a higher level of care, a single consultation with a healthcare provider was attributed to the 
referring lower level facility or facilities. Since diagnostic tests, including CT, MRI, and 
serology, are not typically available at primary care clinics, it was assumed that anthelminthic 
treatment is only prescribed in higher level clinics. 
Data on length of hospitalization in a secondary care facility were not available from the 
questionnaires and hospital stay length was assumed the same as that observed for non-surgical 
cases hospitalized at a tertiary care facility. Assuming that the same non-anthelminthic drugs are 
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available in both rural and urban areas, people with epilepsy and severe chronic headaches 
receiving care at primary and secondary care facilities were assumed to receive the same non-
NCC specific medical treatment protocols as people treated in tertiary care hospitals [84].  
It was assumed that people with epilepsy exclusively seeking traditional care visited a 
healer 4 to 6 times per year. Due to the lack of published data on this topic from Mexico, these 
values were chosen in light of cross-sectional data from India suggesting that individuals with 
epilepsy visited a traditional healer 1 to 8 times per year [99]. For severe chronic headaches, the 
number of visits was assumed to be only 2 to 3 times per year, due to lesser clinical severity. It 
was also assumed that the number of visits to a traditional healer would be less for those people 
who seek medical attention from both a modern doctor and a traditional healer (2 to 3 times and 
1 to 2 times per year for people with epilepsy and severe chronic headaches, respectively).  
 
Table 21. Parameters associated with the use of healthcare resources (per year) in people 
with NCC-associated epilepsy or severe chronic headaches in Mexico 
 
Parameter Value Distribution Reference 
Number of visits to a traditional healer by 
an epilepsy patient who also receives 
treatment from a modern doctor 
Min: 2 
Max: 3 
Uniform 
 
[see text] 
Number of visits to a traditional healer by a 
severe chronic headaches patient who also 
receives treatment from a modern doctor 
Min: 1 
Max: 2 
Uniform 
 
[see text] 
Number of visits to a traditional healer by 
an epilepsy patient who exclusively seeks 
treatment from a traditional healer 
Min: 4 
Max: 6 
Uniform 
 
[see text] 
Number of visits to a traditional healer by a 
severe chronic headaches patient who 
exclusively seeks treatment from a 
traditional healer 
Min: 2 
Max: 3 
Uniform 
 
[see text] 
Number of visits to a physician by an 
epilepsy patient who seeks treatment at a 
primary care clinic 
Min: 1 
Mode: 2 
Max: 12 
Triangular 
 
Appendix G 
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Table 21: Continued 
 
Parameter Value Distribution Reference 
Number of visits to a physician by a severe 
chronic headaches patient who seeks 
treatment at a primary care clinic 
Min: 1 
Mode: 1 
Max: 12 
Triangular 
 
Appendix G 
Number of visits to a neurologist by an 
epilepsy patient who seeks treatment at a 
secondary care clinic 
Min: 2 
Mode: 3 
Max: 20 
Triangular Appendix G 
Number of visits to a neurologist by a 
severe chronic headaches patient who seeks 
treatment at a secondary care clinic 
Min: 1 
Mode: 3 
Max: 8 
Triangular 
 
Appendix G 
Proportion of people with NCC-associated 
epilepsy treated at a tertiary care facility 
that receive a surgical intervention per year  
0.25 Fixed [84] 
Proportion of people with NCC-associated 
severe chronic headaches treated at a 
tertiary care facility that receive a surgical 
intervention per year  
0.57 Fixed [84] 
Proportion of people with epilepsy 
receiving treatment at a secondary care 
clinic who are hospitalized  
Min: 0.02 
Mode: 0.2 
Max: 1 
Triangular 
 
Appendix G 
Proportion of people with severe chronic 
headaches receiving treatment at a 
secondary care clinic who are hospitalized  
Min: 0.01 
Mode: 0.2 
Max: 0.5 
Triangular 
 
Appendix G 
Length of a hospital stay (in days) for 
people with epilepsy who are hospitalized 
at a secondary care clinic  
7 Fixed [see text] 
Length of a hospital stay (in days) for 
people with severe chronic headaches who 
are hospitalized at a secondary care clinic  
4 Fixed [see text] 
Length of a hospital stay (in days) for 
people with epilepsy who are hospitalized 
at a tertiary care facility 
10.96 Fixed [84] 
Length of a hospital stay (in days) for 
people with severe chronic headaches who 
are hospitalized at a tertiary care facility  
7.56 Fixed [84] 
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Table 22: Parameters associated with the use of diagnostic tests and prescription 
medications in people with NCC-associated epilepsy or severe chronic headaches in Mexico 
  
Parameter Value Distribution Reference 
Proportion of people with epilepsy who seek 
medical attention at a primary, secondary or tertiary 
care clinic and are prescribed the anti-epileptic drug 
phenytoin 
0.95 Fixed [84] 
Proportion of people with epilepsy who seek 
medical attention at a primary, secondary or tertiary 
care clinic and are prescribed the anti-epileptic drug 
carbamazepine 
0.33 Fixed [84] 
Proportion of people with epilepsy who seek 
medical attention at a primary, secondary or tertiary 
care clinic and are prescribed the anti-epileptic drug 
valproic acid 
0.20 Fixed [84] 
Proportion of people with severe chronic headaches 
who seek medical attention at a primary, secondary 
or tertiary care clinic and are prescribed the anti-
inflammatory drug ketorolac tromethamine 
0.37 Fixed [84] 
Proportion of people with severe chronic headaches 
who seek medical attention at a primary, secondary 
or tertiary care clinic and are prescribed the 
antipyretic drug acetaminophen 
0.26 Fixed [84] 
Proportion of people who are diagnosed with NCC 
and prescribed the anthelmintic drug albendazole at 
a secondary or tertiary care clinic 
0.36 Fixed [84] 
Proportion of people who are diagnosed with NCC 
and prescribed the anthelmintic drug praziquantel at 
a secondary or tertiary care clinic 
0.02 Fixed [84] 
Proportion of people who are diagnosed with NCC 
and receive a CT scan and/or MRI at a secondary 
care clinic 
0.18 Fixed Appendix 
G 
Proportion of people who are diagnosed with NCC-
associated epilepsy and receive a CT scan at a 
tertiary care clinic  
0.42 Fixed [84] 
Proportion of people who are diagnosed with NCC-
associated severe chronic headaches and receive a 
CT scan at a tertiary care clinic 
0.5 Fixed [84] 
Proportion of people who are diagnosed with NCC-
associated epilepsy and receive an MRI at a tertiary 
care clinic 
0.77 Fixed [84] 
Proportion of people who are diagnosed with NCC-
associated severe chronic headaches and receive an 
MRI at a tertiary care clinic 
0.76 Fixed [84] 
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Table 22: Continued 
Proportion of people who are diagnosed with NCC-
associated epilepsy and receive an EEG at a 
secondary or tertiary care clinic  
0.36 Fixed [84] 
Proportion of people who are diagnosed with NCC-
associated severe chronic headaches and receive an 
EEG at a secondary or tertiary care clinic 
0.09 Fixed [84] 
Proportion of people who are diagnosed with NCC-
associated epilepsy and receive EITB testing at a 
tertiary care clinic 
0.05 Fixed [84] 
Proportion of people who are diagnosed with NCC-
associated severe chronic headaches and receive 
EITB testing at a tertiary care clinic  
0.007 Fixed [84] 
Proportion of people who are diagnosed with NCC-
associated epilepsy and receive CSF testing at a 
secondary or tertiary care clinic  
0.33 Fixed [84] 
Proportion of people who are diagnosed with NCC-
associated severe chronic headaches and receive 
CSF testing at a secondary or tertiary care clinic 
0.45 Fixed [84] 
Proportion of people who are diagnosed with NCC-
associated epilepsy and receive ELISA testing at a 
tertiary care clinic 
0.33 Fixed [84] 
Proportion of people who are diagnosed with NCC-
associated severe chronic headaches and receive 
ELISA testing at a tertiary care clinic  
0.42 Fixed [84] 
Proportion of people who are diagnosed with NCC-
associated epilepsy and receive surgery at a tertiary 
care clinic 
0.25 Fixed [84] 
Proportion of people who are diagnosed with NCC-
associated severe chronic headaches and receive 
surgery at a tertiary care clinic 
0.57 Fixed [84] 
 
 
 
IV.2.7 Parameters associated with productivity losses in people with NCC   
 
Table 23 shows the parameters associated with productivity losses in people with NCC. 
Information on loss of working days due to people with NCC-associated epilepsy and severe 
chronic headaches seeking medical attention at a primary care clinic was based on minimum, 
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mode, and maximum values provided by physicians at a primary care clinic in Michoacán. 
Information on loss of working days due to NCC-associated epilepsy and severe chronic 
headaches for people seeking medical attention at tertiary care hospitals was based on a study 
conducted in Mexico [84]. In the absence of available data, people seeking care in secondary 
healthcare facilities were assumed to lose 25% fewer working days than those seeking care at 
tertiary care facilities.  Information on loss of working days due to NCC-associated epilepsy and 
severe chronic headaches for people not seeking modern medical treatment was based on values 
provided by employees of the Michoacán branch of Mexico’s Ministry of Health.  
 
Table 23: Parameters associated with productivity losses in people with NCC-associated 
epilepsy or severe chronic headaches in Mexico  
 
    
Number of working days lost per year by 
people with NCC-associated epilepsy who 
seek medical attention at a primary care 
clinic 
Min: 0 
Mode: 12 
Max: 36 
Triangular Appendix G 
Number of working days lost per year by 
people with NCC-associated severe chronic 
headaches who seek medical attention at a 
primary care clinic 
Min: 0 
Mode: 12 
Max: 24 
Triangular Appendix G 
Number of working days lost per year by 
people with NCC-associated epilepsy who 
seek medical attention at a secondary care 
clinic and are not hospitalized 
18.75 Fixed [see text] 
Number of working days lost per year by 
people with NCC-associated epilepsy who 
seek medical attention at a secondary care 
clinic and are hospitalized 
46.5 Fixed [see text] 
Number of working days lost per year by 
people with NCC-associated severe chronic 
headaches who seek medical attention at a 
secondary care clinic and are not 
hospitalized 
12 Fixed [see text] 
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Table 23: Continued 
 
Parameter Value/Range 
of values 
Distribution Reference 
Number of working days lost per year by 
people with NCC-associated severe chronic 
headaches who seek medical attention at a 
secondary care clinic and are hospitalized 
28.5 Fixed [see text] 
Number of working days lost per year by 
people with NCC-associated epilepsy who 
seek medical attention at a tertiary care 
hospital and are not hospitalized 
25 Fixed [84] 
Number of working days lost per year by 
people with NCC-associated epilepsy who 
seek medical attention at a tertiary care 
hospital and are hospitalized 
62 Fixed [84] 
Number of working days lost per year by 
people with NCC-associated severe chronic 
headaches who seek medical attention at a 
tertiary care hospital and are not 
hospitalized 
16 Fixed [84] 
Number of working days lost per year by 
people with NCC-associated severe chronic 
headaches who seek medical attention at a 
tertiary care hospital and are hospitalized 
38 Fixed [84] 
Number of working days lost per year by 
people with NCC-associated epilepsy who 
do not seek treatment from a modern doctor 
Min: 12 
Mode: 24 
Max: 120 
Triangular 
 
Appendix G 
Number of working days lost per year by 
people with NCC-associated severe chronic 
headaches who do not seek treatment from 
a modern doctor 
Min: 12 
Mode: 12 
Max: 60 
Triangular 
 
Appendix G 
Proportion of Mexican adults that are not 
considered economically active excluding 
retirees 
0.41 Fixed [100] 
 
 
 
IV.2.8 Epidemiologic parameters for porcine cysticercosis 
 
Epidemiologic parameters for porcine cysticercosis are presented in Table 24. The 
number of pigs slaughtered in Mexico was obtained from the United States Department of 
Agriculture (USDA) Foreign Agricultural Service for the year 2009 [101]. Year 2009 data were 
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used because this is the only year for which slaughter numbers were reported by facility type, 
namely federally inspected, municipal, and in-situ. In-situ facilities are those without inspection, 
including home slaughtering. The prevalence of porcine cysticercosis was assumed lower in 
federally inspected and municipal facilities because most pigs slaughtered there would come 
from industrialized establishments. The prevalence of porcine cysticercosis in pigs slaughtered at 
in-situ facilities was assumed to vary between 5% and 33% based on a study conducted in 13 
villages located in the Sierra de Huautla region of Morelos, Mexico [68]. Due to limited data on 
cysticercosis in pigs slaughtered in federally inspected and municipal facilities, the prevalence of 
porcine cysticercosis was assumed to be between 0 and 0.05%. This value seems reasonable 
when compared with a study conducted in Brazil from 2008 to 2013 where the prevalence of 
porcine cysticercosis in pigs reared under an intensive management system was 0.009% [102]. 
The average reduction in the price of a cysticercosis-infected pigs, regardless of slaughter 
location, was estimated at 20 – 30% of market value based on information from the only 
identified study of its kind, which was conducted in Africa [2]. 
 
Table 24: Epidemiologic parameters used to estimate the monetary burden of porcine 
cysticercosis in Mexico 
 
Parameter Value/Range of 
values 
Distribution Reference 
Number of pigs slaughtered at federally inspected 
facilities 
5,812,675 Fixed [101] 
Number of pigs slaughtered at municipal facilities 4,726,933 Fixed [101] 
Number of pigs slaughtered at in-situ facilities 3,460,153 Fixed [101] 
Prevalence of porcine cysticercosis in pigs 
slaughtered at in-situ facilities  
Min: 0.05 
Max: 0.33 
Uniform [68] 
Prevalence of porcine cysticercosis in pigs 
slaughtered at federally inspected and municipal 
facilities  
Min: 0 
Max: 0.0005 
Uniform [see text] 
Percent reduction in the price of a pig with 
cysticercosis 
Min: 20 
Max: 30 
Uniform [2] 
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IV.2.9 Human and pig economic parameters 
Table 25 contains the economic parameters used to estimate the monetary burden of 
cysticercosis in Mexico in 2012 U.S. dollars. The cost of doctor visits, diagnostic techniques and 
tests, a one-day stay in the hospital, and surgery were obtained from the 2006 standardized tariffs 
for healthcare services in Mexico [74]. Year 2006 tariffs were used due to their availability to 
study personnel and to be in line with previous studies looking at NCC-related costs in Mexico 
[84]. Although patients pay based on their income, the actual costs of products and services were 
used in order to estimate the societal costs incurred due to NCC. The costs of medications used 
by people with NCC were based on year 2006 prices obtained from several pharmacies in 
Mexico. All 2006 costs were converted to the 2012 value according to the Consumer Price Index 
for Mexico [82]. The cost for a visit to a traditional healer to treat epilepsy or severe chronic 
headaches was based on the minimum, mode, and maximum values provided by employees of 
the Michoacán branch of the Ministry of Health who completed the questionnaire. The 2015 
median wage and 2012 minimum wage were applied to lost working days for those who were 
officially employed and those not employed outside of the home, respectively [103,104]. Median 
wage data were only availabe for 2015, therefore, the 2015 median wage was converted to the 
2012 value according to the Consumer Price Index for Mexico [82]. To capture the productivity 
losses of the unemployed population, excluding retirees, the minimum wage approach was used 
where time lost was estimated at an 8-hour workday. The proportion of the population that was 
not economically active was obtained from Mexico's Instituto Nacional de Estadistica y 
Geografia [100].  It was assumed that losses for a child less than 15 years of age would be the 
same as for an adult since a parent would need to take time off work or would lose productivity 
while caring for the child.  
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The price of an average finished live pig (weighing 150 lb) in Mexico in 2012 was 
obtained from the Food and Animal Organization of the United Nations [105]. A 2012 exchange 
rate of 13.06 Mexican pesos for 1 U.S. dollar was used for all estimates [75]. 
 
Table 25: Economic parameters used to estimate the monetary burden of cysticercosis in 
Mexico (in 2012 U.S.$) 
 
Parameter Value/range 
of values 
Distribution Reference 
Cost of a visit to a general practitioner/ 
neurologist/neurosurgeon 
17 Fixed [74] 
Cost of a CT scan 173 Fixed [74] 
Cost of an MRI 178 Fixed [74] 
Cost of an EEG 87 Fixed [74] 
Cost of CSF testing 17 Fixed [74] 
Cost of an EITB test 88 Fixed [74] 
Cost of an ELISA 26 Fixed [74] 
Cost of a one-day stay in a hospital’s general 
ward 
58 Fixed [74] 
Cost of a one-day stay in a hospital’s private 
ward  
69 Fixed [74] 
Cost of surgery (ventriculoperitoneal shunt 
placement or cyst removal) 
 
1,301 Fixed [74] 
Cost of a visit to a traditional healer to treat 
epilepsy 
Min: 1 
Mode: 2 
Max: 8 
Triangular Appendix G 
Cost of a visit to a traditional healer to treat 
severe chronic headaches 
Min: 0.5 
Mode: 2 
Max: 8 
Triangular Appendix G 
Minimum wage (per day) 5 Fixed [104] 
Median wage (per day)  20.2 Fixed [103] 
Price of an adult pig  106 Fixed [105] 
 
 
IV.2.10 Analysis 
 Economic losses due to NCC-associated epilepsy and severe chronic headaches, with 
95% credible regions (95% CRs), were estimated using @Risk (Palisade Corporation, Ithaca, 
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NY, version 5.7). Latin Hypercube sampling was used for uncertain parameters. The model was 
run for 20,000 iterations to achieve convergence. Uncertain epidemiologic and economic 
parameters were modeled using normal, uniform, and triangular distributions. Regression 
sensitivity analysis was conducted in @Risk by varying the value of each parameter to estimate 
its correlation to the total cost estimate. The relative values of the regression coefficients indicate 
which parameters had the greatest impact on the total cost estimate.  
 
IV.2.11 Ethical approval  
This study received IRB approval from Texas A&M University (2006-0606 and 2014-
0702), the Instituto Nacional de Neurologia y Neurocirugia (INNN), and the Hospital de 
Especialidades of the Instituto Mexicano del Seguro Social (HE-IMSS).  
 
IV.3 Results 
IV.3.1 Estimated number of people with NCC-associated epilepsy and NCC-associated 
severe chronic headaches  
 The estimated number of people with NCC-associated epilepsy and severe chronic 
headaches in Mexico in 2012, along with their treatment patterns, are shown in Table 26.  
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Table 26: Estimated number of NCC-associated epilepsy and NCC-associated severe 
chronic headaches cases in 2012 along with their 95% CRs 
 
Estimate Number 95% CR 
Number of NCC-associated epilepsy and severe chronic 
headaches cases whose final level of care was received at a 
primary care clinic 
158,967 86,116 - 243,398 
Number of NCC-associated epilepsy and severe chronic 
headaches cases whose final level of care was received at a 
secondary care clinic 
Hospitalized  
Not hospitalized 
 
 
 
18,172 
31,359 
 
 
 
3,998 - 48,502 
2,448 - 67,907 
Number of NCC-associated epilepsy and severe chronic 
headaches cases whose final level of care was received at a 
tertiary care hospital 
Hospitalized 
Not hospitalized 
 
 
 
7,675 
16,765 
 
 
 
1,736 - 18,287 
3,186 - 41,354 
Number of NCC-associated epilepsy and severe chronic 
headaches cases that only received treatment from a 
traditional healer 
74,452 18,335 - 153,714 
Number of NCC-associated epilepsy and severe chronic 
headaches cases that received no treatment 
144,972 43,837 - 259,860 
*Total 452,362 274,158 - 628,833 
 
* Note: Of this total, 44,446 ( 95% CR: 12,173 – 94,209) people are estimated to have received 
care from both a modern medical facility and a traditional healer.   
 
 
 
IV.3.2 Monetary losses due to people with NCC-associated epilepsy and severe chronic 
headaches who received modern medical treatment 
 Tables 27 and 28 show the total direct and indirect losses and the cost-per-patient 
associated with individuals with NCC-associated epilepsy and severe chronic headaches who 
received modern medicine treatment.  
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Table 27: Total direct losses and the cost-per-patient for people with NCC-associated 
epilepsy and NCC-associated severe chronic headaches who received modern medical 
treatment in 2012 along with their 95% CRs (in 2012 U.S. $) 
 
Cost component Total direct loss Cost per patient 
Direct cost of people with NCC-
associated epilepsy who received 
treatment at a primary care clinic  
14,769,004 (6,005,470 - 
29,553,557) 
146 (88 - 236) 
 
Direct cost of people with NCC-
associated severe chronic headaches 
who received treatment at a primary care 
clinic 
4,592,473 (400,575 - 
13,627,948) 
79 (20 - 173) 
Direct cost of people with NCC-
associated epilepsy who received 
treatment at a secondary care clinic 
Hospitalized 
Not hospitalized 
 
 
11,066,273 (1,542,767  -  
33,230,824) 
7,065,744 (1,057,012 -  
19,263,910) 
 
 
717 (622 - 867) 
313 (245- 407) 
Direct cost of people with NCC-
associated severe chronic headaches 
who received treatment at a secondary 
care clinic 
Hospitalized 
Not hospitalized 
 
 
 
 
1,062,161 (65, 231 - 3,230,748) 
1,394,583 (122,135 - 3,633,475) 
 
 
 
 
389 (348 - 440) 
158 (105 - 199) 
Direct cost of people with NCC-
associated epilepsy who received 
treatment in a tertiary care hospital  
Hospitalized 
Not hospitalized 
 
 
10,645,300 (1,856,578 - 
26,599,973) 
8,076,970 (1,408,652 - 
20,182,344) 
 
 
1,511 (245 - 
3,046) 
491 (388 - 603) 
Direct cost of people with NCC-
associated severe chronic headaches 
who received treatment in a tertiary care 
hospital 
Hospitalized 
Not hospitalized 
 
 
 
1,059,954 (47,979 - 3,606,657) 
136,658 (6,186 - 465,001) 
 
 
 
1,628 (567 - 
2,873) 
408 (345 - 499) 
Cost of a traditional healer for people 
with NCC-associated epilepsy who 
received treatment from both a 
traditional healer and a modern doctor 
256,504 (27,620 - 858,696) 8 (2 - 18) 
Cost of a traditional healer for people 
with NCC-associated severe chronic 
headaches who received treatment from 
both a traditional healer and a modern 
doctor 
61,037 (1,203 – 242,689) 5 (1 - 11) 
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Table 28: Total indirect losses and the cost-per-patient for people with NCC-associated 
epilepsy and NCC-associated severe chronic headaches who received modern medical 
treatment in 2012 along with their 95% CRs (in 2012 U.S. $) 
 
Cost component Total loss Cost-per-patient 
Indirect cost of people with 
NCC-associated epilepsy who 
received treatment at a primary 
care clinic 
20,757,603 (3,737,745 – 48,884,756) 205 (42- 403) 
Indirect cost of people with 
NCC-associated severe chronic 
headaches who received 
treatment at a primary care 
clinic 
8,973,618 (728,951 – 22,762,576) 154 (34- 274) 
Indirect cost of people with 
NCC-associated epilepsy who 
received treatment at a 
secondary care clinic 
Hospitalized 
Not hospitalized 
 
 
 
 
9,226,230 (1,303,254 - 27,079,478) 
5,435,671 (900.855 - 13,984,043) 
 
 
 
 
598 (263 - 789) 
241 (145 - 346) 
Indirect cost of people with 
NCC-associated severe chronic 
headaches who received 
treatment at a secondary care 
clinic 
Hospitalized 
Not hospitalized 
 
 
 
 
 
1,002,332 (61,203 - 3,027,342) 
1,364,949 (124,713 - 3,407.690) 
 
 
 
 
 
367 (65 - 645) 
154 (43 -307) 
Indirect cost of people with 
NCC-associated epilepsy who 
received treatment in a tertiary 
care hospital 
Hospitalized 
Not hospitalized 
 
 
 
 
5,616,663 (979,566 - 14,034,657) 
5,284,495 (921,635 - 13,204,651) 
 
 
 
 
797 (635 - 903) 
322 (289 - 387) 
Indirect cost of people with 
NCC-associated severe chronic 
headaches who received 
treatment in a tertiary care 
hospital 
Hospitalized 
Not hospitalized 
 
 
 
 
 
318,141 (14,401 - 1,082,523) 
69,007 (3,124 - 234,806) 
 
 
 
 
 
489 (57 - 978) 
206 (177 - 253) 
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IV.3.3 Monetary losses and the cost-per-case associated with people with NCC-associated 
epilepsy and severe chronic headaches who did not receive modern medical treatment 
Table 29 shows the total monetary losses and the cost-per-case associated with people 
with NCC-associated epilepsy and NCC-associated severe chronic headaches who did not 
receive modern medical treatment in Mexico in 2012. 
 
Table 29: Indirect losses and the cost-per-case for people with NCC-associated epilepsy and 
NCC-associated severe chronic headaches who did not receive modern medical treatment 
in 2012 along with their 95% CRs (in U.S. $) 
 
Cost component Total loss 
(95% CR) 
Cost-per-case 
(95% CR) 
Indirect cost of people with NCC-associated 
epilepsy who received no treatment 
78,417,534 
(22,736, 939 - 180,245,832) 
669 (227 - 1,336) 
Indirect cost of people with NCC-associated 
severe chronic headaches who received no 
treatment 
36,800,776 
(23,546 - 100,506,588) 
360 (162 - 674) 
Cost of a traditional healer for people with 
NCC-associated epilepsy who exclusively 
received treatment from a traditional healer  
758,597 
(99,074 - 2,191,523) 
18 (8 - 35) 
Cost of a traditional healer for people with 
NCC-associated severe chronic headaches 
who exclusively received treatment from a 
traditional healer 
264,132 (32,453- 1,025,4844,) 8 (2 - 17) 
 
 
IV.3.4 Pig losses 
Monetary losses associated with porcine cysticercosis were estimated at U.S.$ 
16,473,528 (95% CR U.S.$ 4,906,568 - U.S.$ 30,464,504) in 2012. 
 
IV.3.5 Total economic losses 
The total 2012 monetary losses associated with people with NCC-associated epilepsy and 
NCC-associated severe chronic headaches, in Mexico, along with losses to the agriculture sector, 
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was estimated to be U.S.$ 250,219,772 (95% CR U.S.$ 145,560,590  U.S.$ 384,051,262), with 
U.S.$ 521 (95% CR: 344 - 760) lost per patient.  
 
IV.3.6 Sensitivity Analysis 
 Figure 11 shows how uncertain parameters influenced the total monetary burden 
estimate. Prevalence of epilepsy in 15-44 year-old males and females, number of working days 
lost due to untreated epilepsy and severe chronic headaches, and the proportion of individuals 
older than 15 years of age with severe chronic headaches presenting with NCC were the five 
parameters with the greatest effect on the total cost estimate. 
 
Figure 11: Sensitivity analysis for the estimated cost of cysticercosis in Mexico  
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IV.4 Discussion 
 This study is the first to estimate the monetary burden of cysticercosis due to people with 
NCC-associated epilepsy and severe chronic headaches, as well as pig-associated losses, in 
Mexico. Table 30 summarizes estimations of monetary losses due to T. solium cysticercosis in 
Mexico (the current study) and studies conducted in West Cameroon, the Eastern Cape Province 
(ECP) of South Africa, and Tanzania [16-18] .  
 The overall monetary burden reported in the current Mexican study was much higher 
than what was reported in the South African, West Cameroon, and Tanzanian studies. However, 
these studies only accounted for the disease burden due to human NCC-associated epilepsy and 
pig losses and not for severe chronic headaches. The estimated monetary burden of cysticercosis, 
in Mexico, when only NCC-associated epilepsy and pig losses are considered would be U.S.$ 
193.9 million. Although the monetary burden due to NCC-associated epilepsy (U.S.$ 176.6 
million) was higher in Mexico, the cost per epilepsy patient (U.S.$ 632) is similar to the estimate 
produced for South Africa and higher than the estimates for Cameroon and Tanzania. This may 
be due to lower salaries and treatment costs in Cameroon and Tanzania.  
In the current study, the median wage was used to value productivity losses of all 
economically active individuals, and Mexico’s minimum wage was used to value productivity 
losses of all economically inactive individuals. The minimum wage approach was used since 
these individuals do contribute to society even though they are not formally employed outside of 
the home and make-up about forty percent of the population. In contrast, the South African study 
used three approaches (the mean wage approach, opportunistic cost approach, and the generalist 
replacement costs approach) to calculate productivity losses whereas the Cameroon and 
Tanzanian studies used the minimum and maximum salary and applied either a uniform or 
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gamma distribution. In the Mexican study, a large proportion (65%) of the total costs was related 
to indirect costs, which is in line with the conclusions of the South African, Cameroon, and 
Tanzanian studies. Compared to Tanzania and West Cameron, the cost of a visit to the hospital, 
doctor or traditional healer was higher in Mexico. Traditional healer costs were not included in 
the South African study. 
 
 
Table 30: Comparison of disease burden estimates due to T. solium cystercosis in Mexico 
with other countries 
 
Estimate Mexico 
(This study) 
Eastern Cape 
Province, 
South Africa 
[16] 
West Cameroon 
[17] 
Tanzania 
[18] 
Study year 2012 2004 2009 2012 
Country population 112,336,538 7,088,000 5,065,382 44,928,923 
Estimated number 
of NCC-associated 
epilepsy cases 
201,897 34,662 50,326# 47,804 
Overall monetary 
burden, including 
NCC-associated 
epilepsy losses and 
pig losses (in US 
dollars) 
% due to 
porcine 
cysticercosis 
193.6 million 
 
 
 
 
 
6.8% 
18.6 - 34.2 
million** 
 
 
 
 
14.6 - 26.9% 
14.9 million* 
 
 
 
 
 
4.7% 
7.9 million 
 
 
 
 
 
35.4% 
Average cost per 
NCC-associated 
epilepsy patient 
(U.S. dollars) 
635 632 - 844 240 106 
Average cost per 
capita (U.S. dollars) 
1.7 2.6 - 4.2 2.9 0.176 
 
* based on a 2009 exchange rate of 1 U.S.$ = 0.69 Euro 
** The range is due to the application of different calculation methods for wage and productivity 
losses (mean wage approach, generalist replacement costs, and opportunity costs).  
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 The annual monetary loss per NCC–associated epilepsy patient was higher than the 
annual loss for an NCC-associated severe chronic headaches patient who received treatment at a 
primary or secondary care clinic in Mexico. This may be due to the higher costs associated with 
epilepsy drugs compared to drugs to treat severe chronic headaches. The annual monetary loss 
per hospitalized NCC–associated epilepsy patient was lower than the annual loss for a 
hospitalized NCC-associated severe chronic headaches patient who received treatment in a 
tertiary care facility. This was due to the lower number of patients with NCC-associated epilepsy 
who had surgery compared to the number with severe chronic headaches who had surgery. The 
annual monetary losses per untreated NCC–associated epilepsy or untreated severe chronic 
headaches case were higher than the annual losses for their counterparts who received treatment 
at a primary care clinic in Mexico. This was due to a greater number of lost working days for 
those people not receiving any form of treatment.    
Based on the regression sensitivity analysis, the most influential parameters were 
prevalence of epilepsy in 15-44 year-olds and the number of working days lost due to untreated 
epilepsy.  The epilepsy prevalence estimates were based on a single study that may not fully 
reflect the regional variation in epilepsy cases. Numbers of days lost due to untreated epilepsy 
were based on questionnaire responses obtained from people who worked in the Ministry of 
Health in Michoacán, with the obtained values having quite large ranges. Studies on the impact 
of NCC on productivity are needed for both treated and untreated individuals to obtain more 
accurate estimates of disease burden. 
Our study has some limitations. The model most likely overestimated the costs associated 
with people manifesting both epilepsy and severe chronic headaches since the model assumes 
that costs associated with these two conditions were additive, which is most likely not the case.  
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However, the total estimated cost was most likely underestimated since only the NCC-associated 
clinical manifestations of epilepsy and severe chronic headaches were included. Other 
neurological manifestations of NCC, such as stroke and dementia may also carry a significant 
burden, but were not included due to the absence of valid frequency data. Costs associated with 
family members who may accompany adults with NCC to clinics or hospitals were also not 
included due to the absence of reliable data. To estimate monetary losses due to epilepsy and 
severe chronic headaches, this study relied on responses provided by physicians working in 
primary care clinics, neurologist working in secondary and tertiary care clinics, and employees at 
the Office of the Ministry of Health in Michoacán.  Since these values come from a single 
endemic region, they may not be applicable to the entire country. The uncertainty placed around 
these parameters and the findings of the sensitivity analysis suggest that additional studies about 
healthcare seeking behavior and treatment gaps are needed. Due to the absence of data 
evaluating how infection affects the cost of pigs that are not slaughtered in formal settings, it was 
assumed that there would be a reduction across all settings. This was also the assumption for the 
South African and Cameroon study [6]. If only losses in inspected pigs were assumed, pig-
associated losses would decrease from U.S.$ 16,539,552 to U.S.$ 66,024. 
This preliminarily estimate suggests that T. solium cysticercosis results in considerable 
monetary losses in Mexico even when compared to other diseases. For example, a study showed 
that the monetary burden of dengue in Mexico was U.S.$ 170 million in 2010. Although the 
estimated number of people affected by dengue was three times lower than the estimated number 
with cysticercosis, the cost was similar because  surveillance and vector control accounted for 
48.9% of the total economic burden of dengue [106]. In conclusion, this is a first study to 
estimate the monetary burden of cysticercosis in Mexico. The methodology developed here can 
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be applied to estimate the monetary burden of cysticercosis in other regions in order to better 
prioritize disease control initiatives. 
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CHAPTER V 
SUMMARY AND CONCLUSIONS 
 
 Taenia solium cysticercosis is considered a public health and agricultural problem in 
many low and middle-income countries where health education, sanitation, pig management 
practices and meat inspection infrastructure are insufficient. Cysticercosis affects both human 
and animal health and has important economic consequences. Very few studies have been 
conducted to evaluate the monetary burden of cysticercosis. The monetary impact of NCC has 
been reported as the average treatment cost per patient under care for patients in India and Peru 
[62,63]. Direct costs associated with treatment of NCC have also been assessed in California 
[65]. NCC-associated monetary losses to both the human health and agricultural sectors have 
been evaluated in South Africa, Lao PDR, Cameroon, Tanzania and India [16-20]. While there 
are studies concerning the economic impact of cysticercosis in other countries, this dissertation 
evaluates the socioeconomic impact of cysticercosis in Mexico. 
 Mexico is the third largest country in Latin America where about twenty percent of the 
population lives in rural areas. Traditional pig rearing practices in rural T. solium-endemic areas 
allow pigs to have access to human feces in open fields, facilitating the completion of the 
parasite's life cycle [68,69]. The findings presented from our study will be crucial for policy 
makers to comprehensively understand the true economic impact of the disease in order to 
prioritize and allocate resources. 
 NCC produces a variety of clinical manifestations such as severe chronic headaches, 
epilepsy, hydrocephalus, stroke and other neurological symptoms [8]. Severe headaches, 
epilepsy and hydrocephalus were the most common clinical manifestations reported in this study. 
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The total annual cost for patients who had and had not been hospitalized and/or undergone a 
surgical procedure for the diagnosis or treatment of NCC in a tertiary care hospital corresponded 
to 212% and 41% of an annual minimum wage salary, respectively. Among patients without a 
history of hospitalization, the annual direct costs for patients with epilepsy as the only clinical 
manifestation were higher than the costs for patients with any other clinical manifestation (single 
or combined). In contrast, among patients with a history of hospitalization, the annual direct 
costs were highest for patients with severe chronic headaches or hydrocephalus, primarily due to 
the high cost of surgery to treat hydrocephalus. 
 We also attempted to estimate the direct monetary losses associated with NCC-affected 
individuals in Mexico during the pre-hospitalization, hospitalization, and post-hospitalization 
periods. Overall, substantial costs were associated with patients requiring hospitalization for 
NCC, with this burden continuing years post-hospitalization. When all patients, regardless of 
having received pre-hospitalization care at the reference hospital, were included in the analysis, 
the direct economic losses pre-hospitalization, during hospitalization, and during the first year 
post-hospitalization were equivalent to 22%, 224%, and 42% of an annual minimum wage salary 
in Mexico (U.S.$ 1145), respectively [80]. The hospitalization period incurred higher per-patient 
costs for all clinical manifestations when compared to the pre-hospitalization or entire post-
hospitalization period. However, this cost was not significantly higher for patients with epilepsy 
or stroke as the sole presenting clinical manifestation because, in comparison to patients with 
other clinical manifestations, fewer epilepsy cases had surgery and the number of patients with 
stroke was very small, explaining the lack of significant differences for these two groups. The 
post-hospitalization costs were highest in the first year post-hospitalization, which was likely due 
to the greater number of diagnostic tests performed in this year as compared to subsequent years. 
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The final part of this study evaluated the overall socioeconomic impact of Taenia solium 
cysticercosis in humans and pigs in Mexico. The estimated cost of human NCC took into 
consideration direct and indirect losses due to NCC-associated epilepsy and NCC-associated 
severe chronic headaches. The estimated cost of porcine cysticercosis took into consideration 
losses due to the reduction in the price of cysticercosis-infected animals. The total 2012 
monetary losses associated with people with NCC-associated epilepsy and NCC-associated 
severe chronic headaches, in Mexico, along with losses to the agriculture sector, was estimated 
to be U.S.$ 250,219,772 (95% CR U.S.$ 145,560,590 - U.S.$ 384,051,262), with U.S.$ 521 
(95% CR: U.S.$ 344 - U.S.$ 760) lost per patient. Monetary losses associated with porcine 
cysticercosis were estimated at U.S.$ 16,473,528 (95% CR U.S.$ 4,906,568 - U.S.$ 30,464,504). 
 The sensitivity analysis indicated that the input parameters with the most influential 
impact on the total estimated losses associated with T. solium cysticercosis were prevalence of 
epilepsy in 15-44 year-olds and the number of working days lost due to untreated epilepsy. The 
epilepsy prevalence estimates were based on a single study that may not fully reflect the regional 
variation in epilepsy cases. Numbers of days lost due to untreated epilepsy were based on 
questionnaire responses obtained from people who worked in the Ministry of Health in 
Michoacán, with the obtained values having quite large ranges. Studies on the impact of NCC on 
productivity are needed for both treated and untreated individuals to obtain more accurate 
estimates of disease burden. 
Our study has some limitations. Data were collected from medical chart reviews, which 
limited assessed variables to those recorded as part of the standard medical charting process and 
those anticipated to be of value prior to commencement of this study. Therefore, type of NCC 
(intraparenchymal versus extraparenchymal), cyst viability, and actual wage data were not 
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available for analysis. Our estimates are also an underestimate of the total costs associated with 
NCC patients hospitalized at the reference hospital since cost of over-the-counter medication, 
cost of traditional medicine/treatment, and time lost by the patient’s family to take care of them 
or to accompany them to treatment were not available for consideration [86].  In addition, this 
analysis excluded any costs incurred while receiving treatment in a healthcare facility other than 
the reference hospital, which could especially affect the estimated pre- and post-hospitalization 
costs.  
Similarly, the economic model most likely overestimated the costs associated with people 
manifesting both epilepsy and severe chronic headaches since the model assumes that costs 
associated with these two conditions were additive, which is most likely not the case.  However, 
the total estimated cost was likely underestimated since only the NCC-associated clinical 
manifestations of epilepsy and severe chronic headaches were included. Other neurological 
manifestations, such as stroke and dementia may also carry a significant burden, but were not 
included due to the absence of valid frequency data. Costs associated with family members who 
may accompany adults with NCC to clinics or hospitals were also not included due to the 
absence of reliable data. To estimate monetary losses due to epilepsy and severe chronic 
headaches, this study relied on responses provided by physicians working in primary care clinics, 
neurologist working in secondary and tertiary care clinics, and employees at the Office of the 
Ministry of Health in Michoacán.  Since these values come from a single endemic region, they 
may not be applicable to the entire country. The uncertainty placed around these parameters and 
the findings of the sensitivity analysis suggest that additional studies about healthcare seeking 
behavior and treatment gaps are needed.  
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In conclusion, this is the first attempt to obtain an estimate of the monetary burden of 
cysticercosis in Mexico. The disease tends to affect rural socioeconomically disadvantaged 
populations and creates health disparities and significant economic losses.  This parasitic disease 
should be prioritized for preventive measures because the disease is, in essence, 100% 
preventable. 
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APPENDIX A 
 
GENERAL QUESTIONNAIRE FOR PATIENTS AT THE INNN AND IMSS 
Patient study code__________________________________________ 
Last name : _______________________ First name : _________________________ 
      Questionnaire number  _______________ 
      District ____________________________ 
      Village _____________________________ 
      Hut (house) number __________________ 
      How long have you lived in this village? (yrs.) 
 
1 How old are you? _____________ (years) 
2 What is your date of birth?____ Day         _____  Month        _______  Year 
3 Sex   1 Male     2 Female   
4 What is the highest schooling grade you have completed?   
1 None    2 Primary school  
3 High School   4 College   
5 What further education have you completed?   
 1 None    2 Technical school  
3 University   4       Aprentice diploma 
6 What is your occupation?  
1 Self-employed (crafts)  2 Self-employed (farmer)  
3 Housewife    4 House maid 
5 Employed by someone else (specify occupation) _________________________ 
 6.1 What is your income (per month): _____________________________________ 
7 How many days of work have you missed in the past month because of illness? ____days 
 7.1 If you are not employed outside the home (i.e. house wife), how many days in the past 
month have you been unable to attend to your daily chores because of illness? _______ days 
8 How many days of work have you missed in the past year because of illness? ______ days 
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 8.1 If you are not employed outside the home, how many days in the past year have you been 
unable to attend to your daily chores because of illness? _____ days 
9 Where do you usually get your drinking water?     
1 River    2 Bore-hole 
3 Well    4 Other [Specify] _________________ 
10 How often do you boil your drinking water?      
1 Always   2 Almost always  
3 Sometimes  4 Never  
11 How often do you eat pork?        
1 At least once a month  2 Less than once a month but at least once a year 
3 Less than once a year  4 Never [Skip to Q13]  
12.1 How is the pork that you eat prepared? [Check all that apply.]  
1 Boiling          2 BBQ 
3 Fried          4Others[Specify]______________________________ 
12.2 Have you ever eaten [Read list and check all that apply.] 
1 Raw pork meat   2 Rare pork meat 
3 Medium cooked pork meat 4 Well done pork meat 
      5 Cannot remember, do not know 
13 Do you have a toilet at home? 
1 Yes    2 No [Skip to Q14] 
 13.1 How often do you use a toilet when you have to defecate? 
     1 Always  2 Sometimes   3 Never 
14 Do you keep pigs? 
 Yes [please fill in the pig questionnaire]   No  
15. Have you ever owned pigs? [If they answer “yes”, ask when they owned pigs]  
 Yes [please fill in the pig questionnaire]   No  
18  Have you ever heard of tapeworm infection in humans?  
      1 Yes       2 No [Skip to Q 19]    
 18.1 How did you learn about it? 
1 From a doctor   2 From a friend or family member 
3 From a traditional healer  4 From the radio / newspaper 
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5 Other [Specify] ________________________________________________ 
 18.2  How does a person know if they have a tapeworm?  
1 They can see it in their faeces 2 They have diarrhoea 
3 They have fever   4 Other [Specify] ___________________ 
5 I don’t know 
 18.3  Have you ever had a tapeworm or seen small parts (segments) of worms that look like 
rice grains in your faeces? (Show photographs of proglottids) 
1 Yes               2 No [Skip to Q 18.4] 
3 I don’t know/cannot remember [Skip to Q 18.4] 
18.3.1 When that happened, what did you do? [Read list and check all that apply] 
 1 Went to a primary health care provider (hospital, clinic, dispensary) 
 2 Went to the pharmacy to get a drug to treat it 
 3 Went to a traditional healer   
4 Did nothing 
 5 I cannot remember, I do not know 
 18.4 How does a person get tapeworm infection?  
1 They do not wash their hands          2 They eat undercooked pig meat 
3 They are in contact with an infected person      4 Other [Specify] ______ 
5 I don’t know 
19 Have you ever had skin nodules or hard lumps under the skin?  [Show photograph of person 
with subcutaneous cysticercosis nodules]             
1 Yes, currently has   2 Yes in the past year, but not currently 
3 Yes, one year or more ago, but not currently 4 No 
5 Cannot remember, do not know 
24 Have you ever hurt yourself when you lose consciousness or during a seizure? 
1 Yes    2 No 
3 I do not lose consciousness or have seizures [Skip to Q 25] 
4 Cannot remember [Skip to Q 25]  
 24.1 If yes, how did you hurt yourself? 
1 Fell in the fire  2 Fell in the water 
3 Fell off your bicycle 4 Fell while walking along the road 
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5 Cut yourself  6 Other [Specify] _______________________ 
25 Is there someone in your household with epilepsy or seizures?     
1 Yes, currently is  2 Yes in the past year, but not currently 
3 Yes, one year or more ago, but not currently   4 No   
25.1 (If yes) Who in your household has epilepsy or seizures? [check all that apply] 
 1 Mother     2 Father 
3 Brother/sister  4 Child (how many) __________ 
5 Other relative (how many) __________ 6 Other [specify] _____________ 
 
(Interviewer: Read the following statement) 
Now I want to ask you a few questions about your treatments for [insert name of symptom 
or condition they reported having in question 21.1-21.6] 
 
26 Before you came to this hospital, had you ever consulted a health provider because of this 
condition? 
2 No [Skip to Q 26.6]   3 Cannot remember [Skip to Q 26.6] 
1 Yes 
26.2 Before you first came to this hospital for treatment, when was the last time you had 
consulted a health provider for your condition? 
1 Within the previous month  2 Within the previous year 
3 From one (1) to five (5) years before 4 More than five (5) years before 
5 Cannot remember, not sure 
26.3 Before you first came to this hospital for treatment, what kind of health provider(s) had 
you consulted and how many times in the past 5 years [check any that apply]? 
1 A physician /_______ times (26311)    
2 A neurologist/___________times (26322) 
3 A nurse/_________ times (26331)     
4 A herbalist/_________ times (26341) 
5 A traditional healer /_____times (26351)    
6 A psychiatrist/psychologist/ __ times (26361) 
7 Other (specify _____________________________)/________ times (26371) 
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8 Cannot remember, not sure 
26.4 Before you first came to this hospital, how much did it cost each time you consulted 
with one health provider [specify the currency used]? 
1 A physician/ (26411)___________   
2 A neurologist/(26421)_________________ 
3 A nurse/ (26431) _______________ 
4 A herbalist ____________ 
5 A traditional healer/(26451) 
6 A psychiatrist / psychologist/(26461) _____________________   
7 Other (specify ___________________________)(26471) _______________ 
8 Cannot remember, not sure 
9 I never pay because the government covers my health expenses 
26.5 Before you came to this hospital, how far did you have to travel to go to the health 
provider from your house and how did you get there (1 foot, 2 bicycle, 3 bus, 4 train, 5 
taxi, 6 car, 7 other)? 
1 Physician at/ _____ km reached by___  
2 Neurologist at ____ km reached by___ 
3 Nurse at ____ km reached by____  
4 Herborist at ____ km reached by____ 
5 Traditional healer at _____ km reached by______ 
6 A psychiatrist / psychologist at _____ km reached by______ 
7 Other (specify ___________________) at _____ km reached by_________ 
  8 Cannot remember  
26.6 How far is this hospital from your house?  ___________________________km 
26.7 How do you usually come to this hospital? [Check all that applies] 
 and how do you get here (1 foot, 2 bicycle, 3 bus, 4 train, 5 taxi, 6 car, 7 other)? 
1 By foot    2 by bicycle 
3 By bus    4 By train 
5 By taxi     6 by car 
7 Other (specify ________________________)  
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 26.8 Are you currently being followed by a health provider outside of this hospital for this 
condition? 
2 No [Skip to Q 28]    3 Cannot remember [Skip to Q 28] 
1 Yes 
26.9 When was the last time you consulted with that health provider for your condition? 
1 Within the past month   2 Within the past year 
3 From one (1) to five (5) years ago  4 More than five (5) years ago 
5 Cannot remember, not sure 
26.10 What kind of health provider(s) is currently seeing you outside of this hospital and how 
many times have you seen him/her in the past 5 years [check several boxes if 
appropriate]? 
1 A physician /_______ times(26311)    
2 A  neurologist/___________times(26322) 
3 A nurse/___________ times(26331)       
4 A herbalist/_______times(26341) 
5  A traditional healer /_____times(26351)    
6 A psychiatrist/psychologist/ __ times(26361) 
7 Other (specify _____________________________)/________ times (26371) 
8 Cannot remember, not sure 
26.11 How much does it cost each time you consulted with that health provider (outside of 
the hospital) for this condition [specify the currency used]? 
1 A physician/ (26411)___________    
2 A neurologist/(26421)_________________ 
3 A nurse/ (26431) _______________ 
4 A herbalist ____________ 
5 A traditional healer/(26451) 
6 A psychiatrist / psychologist/(26461) _____________________   
7 Other (specify __________________________)(26471) ________________ 
8 Cannot remember, not sure 
9 I never pay because the government covers my health expenses 
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26.12 How far do you have to travel to go to the health provider from your house and how do 
you usually get there (1 foot, 2 bicycle, 3 bus, 4 train, 5 taxi, 6 car, 7 other)? 
1 Physician at/ _____ km reached by___  
2 Neurologist at ____ km reached by___ 
3 Nurse at ____ km reached by____  
4 Herborist at ____ km reached by____ 
5 Traditional healer at _____ km reached by______ 
6 A psychiatrist / psychologist at _____ km reached by______ 
7 Other (specify _____________________) at _____ km reached by_______ 
8 Can not remember  
29. Before you came to this hospital, were you ever treated with drugs for this condition? 
2 No (the interview is finished)  
3 Can’t remember, do not know (interview is finished) 
1 Yes 
29.4 What medication was it and how much did it cost (check several boxes if appropriate)?  
1 Carbamazepine/Tegretol______   2 Phenytoin/Dihydan_________  
3 Valproic acid/Dépakin________   4 Phenobarbital/Gardénal ______ 
5   Traditional medicine ________   6 Other (specify _____) _______  
7 Can not remember, not sure 
 
THIS IS THE END OF THE INTERVIEW 
THANK YOU VERY MUCH FOR YOUR COOPERATION 
 
INTERVIEWER: ______________________ 
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APPENDIX B  
 
ESTUDIO DE NEUROCISTICERCOSIS HUMANA (NCC)  
CUESTIONARIO GENERAL 
    Número de expediente  _______________________ 
    Municipio _________________________________ 
    Comunidad ________________________________ 
    Número de casa (lote, manzana, etc.) _____________ 
    ¿Cuántos años ha vivido en esta comunidad?________ 
¿Tiene seguro médico?    Si    No   No sabe 
Tipo de seguro médico     Popular       IMSS       ISSSTE     
Privado 
 
1 ¿Qué edad tiene? _____________ (años) 
2 ¿Cuál es su fecha de nacimiento?____ Día        _____  Mes        _______  Año 
3 Género  1 Hombre     2 Mujer   
4 ¿Cuál es el último grado de escolaridad que terminó?   
1 Ninguno    2 Primaria 
3 Secundaria     4  Preparatoria 
5 ¿Qué otro tipo de educación ha terminado? 
1 Escuela técnica   2 Licenciatura 
3 Posgrado     
6 ¿Cuál es su ocupación? _________________________________________ 
 6.1 Si trabaja, cual es su salario mensual? 
7 ¿Puede calcular cuántos días ha faltado a su trabajo por enfermedad en el último mes? 
_________       2 No puede calcular 
 7.1 Si no tiene un empleo oficial, ¿Puede calcular cuántos días no ha podido realizar sus 
tareas diarias en el último mes? _____   2 No puede calcular 
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8 ¿Puede calcular cuántos días ha faltado a su trabajo por enfermedad en el último año? ______    
     2 No puede calcular 
 8.1 Si no tiene un empleo oficial, ¿Puede calcular cuántos días no ha podido realizar sus 
tareas diarias en el último año? _____   2 No puede calcular 
9 ¿Por lo general de dónde obtiene su agua para beber?     
 1 Río  2 Pipa  3 Pozo  4 Embotellada 
5 Otro [Especifique] _________________ 
10 ¿Hierve su agua para beber?       
1 Siempre   2 Casi siempre  
3 A veces   4 Nunca  
11 ¿Con qué frecuencia come cerdo?        
1 Por lo menos una vez al mes 2 Menos de 1 vez al mes pero por lo menos 1 vez al año 
3 Menos de una vez al año 4 Nunca [Pase a la P13]  
12.1  ¿Cómo se prepara el cerdo que usted come? [Marque todas las que se apliquen.] 
1 Carnitas    2 Chorizo 
3 Embutidos   4 Otro 
[Especifique]______________________________ 
12.2  ¿Alguna vez ha comido [Marque todas las que se apliquen.] 
1 Carne de cerdo cruda   2 Carne de cerdo poco cocida 
3 Carne de cerdo medio cocida 4 Carne de cerdo bien cocida 
      5 No recuerdo, no sé 
13 ¿Tiene un baño o letrina en su casa? 
1 Sí    2 No [Pase a la P14] 
 13.1 ¿Con qué frecuencia usa un excusado cuando tiene que defecar? 
     1 Siempre   2 A veces   3 Nunca 
 13.2 ¿Con qué frecuencia defeca en el campo o en las milpas? 
     1 Siempre   2 A veces   3 Nunca 
14 ¿Cría cerdos? 
 Sí (por favor conteste el cuestionario de cerdos)   No  
15 ¿Alguna vez ha tenido cerdos? [Si la respuesta es “sí”, pregunte cuándo] 
1 Sí, el año pasado   2 Sí, hace de 1 a 5 años  
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3 Sí, hace más de 5 (cinco años 4 No [Pase a la P 17]   
 15.1 ¿Qué tipo de cerdos eran? 
1 Europeos (blancos)   2 Criollos (oscuros) 
3 Europeos y criollos   4 No recuerda, no sabe 
16  ¿Alguna vez le dijeron que sus cerdos tenían grano, granillo o tomate (cisticercosis)? 
      1 Sí    2 No [Pase a la P 17] 
16.1. ¿Cuándo le dijeron que sus cerdos tenían grano, granillo o tomate (cisticercosis)? 
1 El año pasado      2 Hace de 1 a 5 años   3 Hace más de 5 años 
4 Nunca me dijeron (Pase a la P 17) 5 No recuerdo, no sé (Pase a la P 17) 
16.1.1 ¿Pudo vender sus cerdos después de que le dijeron que tenían grano, granillo o 
tomate? 
1 Vendí todos 2 Vendí algunos  3 No pude venderlos [Pase a la P 17] 
5 No recuerdo, no sé [Pase a la P 17] 
16.1.2  Cuando sucedió eso, ¿a qué precio vendió sus cerdos adultos 
(Especifique la forma de pago, puede ser dinero o trueque)? ________________ 
16.1.3  Cuando sucedió eso, ¿a qué precio vendió sus cerditos de 4 meses de edad o 
menos (Especifique la forma de pago, puede ser dinero o trueque)? _____ 
17  ¿Alguna vez ha visto o escuchado grano, granillo o tomate en la canal de cerdo? 
 1 Sí    2 No [Pase a la P 18] 
 17.1  ¿Dónde se pueden encontrar grano, granillo o tomate en un cerdo vivo?  
1 No es posible encontrarlos en un cerdo vivo   
2 Debajo de la piel              3 Debajo de la lengua 
4 No sé               5 En algún otro lugar [Especifique] ____ 
 17.2  ¿Por qué sale grano, granillo o tomate a los cerdos? 
1 Por comer excremento humano 2 Por comer excremento de cerdo 
3 De otro cerdo infectado    4 Otro [Especifique] _______________ 
5 No sé 
 17.3 ¿Qué haría si descubriera que su cerdo tiene grano, granillo o tomate? 
1 Lo vendería   2 Lo trataría con hierbas 
3 Picar los granos   4 Otro [Especifique] ________________ 
5 No sé 
18  ¿Alguna vez ha escuchado de una infección por solitaria o tenia en humanos?  
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      1 Sí       2 No [Pase a la P 19]   
 18.1 ¿Cómo supo de ella? 
1 Por un doctor   2 Por un amigo o familiar 
3 Por un curandero   4 En la radio / periódico 
5 Otro [Especifique] _____________________________________________ 
 18.2  ¿Cómo sabe una persona si tienen una solitaria?  
1 Lo puede ver en su excremento 2 Tiene diarrea 
3 Tiene fiebre   4 Otro [Especifique] ________________ 
5 No sé 
 18.3  ¿Alguna vez ha tenido una solitaria o visto pequeñas partes (segmentos) de gusanos que 
parecen como tallarines planos en su excremento? (Muestre fotografías de proglótidos) 
1 Sí               2 No [Pase a la P 18.4] 
3 No sé / no recuerdo [Pase a la P 18.4] 
18.3.1 Cuando sucedió eso, ¿qué hizo? [Marque todas las que se apliquen] 
 1 Fui al centro de salud, hospital, clínica o dispensario   
 2 Fui a la farmacia para comprar la medicina y tratarlo 
 3 Fui con un curandero  4 No hice nada 
 5 No recuerdo, no sé 
 18.4  ¿Cómo se infecta una persona con solitaria?  
1 No se lava las manos  
       2 Come carne de cerdo que no está bien cocida 
3 Está en contacto con una persona que tiene solitaria      
4 Otro [Especifique] ________ 
5 No sé 
 18.5  ¿Sabe si algún familiar o persona que vive en su casa tiene o ha tenido una solitaria? 
1 Sí               2 No [Pase a la P 19] 
18.5.1 ¿Hace cuanto tiempo la tuvo? 
1 En los últimos 6 meses  2 Hace 1 a 2 años 
 3 Hace 3 a 5 años  4 Hace más de 5 años 
 5 No recuerdo, no sé 
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19 ¿Alguna vez ha tenido nódulos en la piel o bolitas duras debajo de la piel?  [Muestre la 
fotografía de la persona con nódulos subcutáneos por cisticercosis]          
1 Sí, actualmente los tengo  2 Sí, el año pasado pero ahora no 
3 Sí, hace como un año o más, pero no ahora 4 No 
5 No recuerdo, no sé 
20  ¿Alguna vez ha tenido dolores de cabeza graves que duran varios días?    
1 Sí, actualmente los tengo  2 Sí, el año pasado pero ahora no 
3 Sí, hace como un año o más, pero no ahora 4 No 
5 No recuerdo, no sé 
21 ¿Alguna vez ha tenido alguno de los siguientes casos? 
21.1 Pérdida repentina de la conciencia y episodios de incontinencia o espuma en la boca o 
morderse la lengua  
1 Sí, actualmente los tengo             2 Sí, el año pasado pero ahora no 
3 Sí, hace como un año o más, pero no ahora  
4 No [Pase a la P 21.2]             5 No recuerdo, no sé   
  21.1.1 (Si la respuesta es sí) ¿Cuántas veces le ha sucedido esto? 
1 Solamente una vez  2 Más de una vez 
  21.1.2 ¿Qué edad tenia cuando esto le sucedió por primera vez? [Indicar el edad si lo se]  
   1 Cuando era niño (menos de 15 anos) y tenia ________________años 
   2 Cuando era joven (15-19 anos) y tenia _____________________años 
   3 Desde que soy adulto (20 anos o mas) y tenia _______________años 
   4 No recuerdo, no se 
  21.1.3 Cuando le sucedió esto por primera vez? 
   1 Durante el año (12 meses) pasado  
   2 De 1 a 2 años 
   3 De 3 a 4 años 
   4 Al menos 5 años 
   5 No recuerdo, no se 
21.2 Un período breve de ausencia o pérdida de contacto con sus alrededores que empieza de 
repente  
1 Sí, actualmente lo tengo  2 Sí, el año pasado pero ahora no 
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3 Sí, hace como un año o más, pero no ahora  
4 No [Pase a la P 21.3]   5 No recuerdo, no se [Pase a la P 21.2.1] 
¿Cuántas veces le ha sucedido esto? 
1 Solamente una vez   2 Más de una vez 
  21.2.2 ¿Qué edad tenia cuando esto le sucedió por primera vez? [Indicar el edad si lo se]  
   1 Cuando era niño (menos de 15 años) y tenia ________________ años 
   2 Cuando era joven (15-19 años) y tenia ____________________ años 
   3 Desde que soy adulto (20 años o mas) y tenia _______________años 
   4 No recuerdo, no se 
  21.2.3 ¿Cuando le sucedió esto por primera vez? 
   1 Durante el año (12 meses) pasado  
   2 De 1 a 2 años 
   3 De 3 a 4 años 
   4 Al menos 5 años 
   5 No recuerdo, no se 
 21.3 Sacudidas o tirones (alferecias) o movimientos anormales incontrolables de una o más 
extremidades (convulsiones) que empiezan de repente y duran algunos minutos 
1 Sí, actualmente los tengo  2 Sí, el año pasado pero ahora no 
3 Sí, hace como un año o más, pero no ahora  
4 No [Pase a la P 21.4]  5 No recuerdo, no sé [Pase a la P 21.4] 
 21.3.1 ¿Cuántas veces le ha sucedido esto? 
1 Solamente una vez  2 Más de una vez 
  21.3.2 ¿Qué edad tenia cuando esto le sucedió por primera vez? [Indicar el edad si lo se]  
   1 Cuando era niño (menos de 15 años) y tenia ________________ años 
   2 Cuando era joven (15-19 años) y tenia ____________________ años 
   3 Desde que soy adulto (20 años o mas) y tenia _______________años 
   4 No recuerdo, no se 
  21.3.3 ¿Cuando le sucedió esto por primera vez? 
   1 Durante el año (12 meses) pasado  
   2 De 1 a 2 años 
   3 De 3 a 4 años 
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   4 Al menos 5 años 
   5 No recuerdo, no se 
21.4 Inicio repentino de un período corto de oír u oler o ver cosas que no existen o tener 
sensaciones raras en el cuerpo  
1 Sí, actualmente lo tengo  2 Sí, el año pasado pero ahora no 
3 Sí, hace como un año o más, pero no ahora  
4 No [Pase a la P 21.5]  5 No recuerdo, no sé [Pase a la P 21.5] 
21.4.1 ¿Cuántas veces le ha sucedido esto? 
1 Solamente una vez  2 Más de una vez 
  21.4.2 ¿Qué edad tenia cuando le sucedió esto por primera vez? [Indicar el edad si lo se]  
   1 Cuando era niño (menos de 15 años) y tenia ________________ años 
   2 Cuando era joven (15-19 años) y tenia ____________________ años 
   3 Desde que soy adulto (20 años o mas) y tenia _______________años 
   4 No recuerdo, no se 
  21.4.3 ¿Cuando le sucedió esto por primera vez? 
   1 Durante el año (12 meses) pasado  
   2 De 1 a 2 años 
   3 De 3 a 4 años 
   4 Al menos 5 años 
   5 No recuerdo, no se 
21.5 ¿Alguna vez le dijeron que tenía epilepsia o que había tenido una convulsión epiléptica? 
1 Sí, durante el mes pasado  2 Sí, durante el año pasado pero no el mes pasado 
3 Sí, hace como un año o más 4 No  
5 No recuerdo, no sé 
  21.5.2 ¿Qué edad tenia cuando le sucedió esto por primera vez? [Indicar el edad si lo se]  
   1 Cuando era niño (menos de 15 años) y tenia ________________ años 
   2 Cuando era joven (15-19 años) y tenia ____________________ años 
   3 Desde que soy adulto (20 años o mas) y tenia _______________años 
   4 No recuerdo, no se 
  21.5.3 ¿Cuando le sucedió esto por primera vez? 
   1 Durante el año (12 meses) pasado  
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   2 De 1 a 2 años 
   3 De 3 a 4 años 
   4 Al menos 5 años 
   5 No recuerdo, no se 
21.6  ¿Alguna vez ha tenido convulsiones o ataques?     
1 Sí, actualmente los tengo  2 Sí, el año pasado pero ahora no 
3 Sí, hace como un año o más, pero no ahora  
4 No [Pase a la P 22]  5 No recuerdo, no sé [Pase a la P 22] 
21.6.1 ¿Cuántas veces le ha sucedido esto? 
1 Solamente una vez  2 Más de una vez 
  21.6.2 ¿Qué edad tenia cuando le sucedió esto por primera vez? [Indicar el edad si lo se]  
   1 Cuando era niño (menos de 15 años) y tenia ________________ años 
   2 Cuando era joven (15-19 años) y tenia ____________________ años 
   3 Desde que soy adulto (20 años o mas) y tenia _______________años 
   4 No recuerdo, no se 
  21.6.3 ¿Cuando le sucedió esto por primera vez? 
   1 Durante el año (12 meses) pasado  
   2 De 1 a 2 años 
   3 De 3 a 4 años 
   4 Al menos 5 años 
   5 No recuerdo, no se 
 
[Si el entrevistado ha contestado “no” a las preguntas 21.1-21.6, la entrevista ha terminado. 
Vaya a la última página y conteste las preguntas 30 y 31 tomando como base sus 
observaciones] 
MUCHAS GRACIAS POR SU COOPERACIÓN 
[De lo contrario, por favor continúe con el cuestionario] 
 
[Entrevistador: Si contestaron “sí” a cualquiera de las preguntas 21.1-21.6, pregunte lo 
siguiente. De lo contrario, pase a la P. 25.] 
22 ¿Ha tenido alguno de los siguientes casos? 
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22.1  Lesión en la cabeza por la que perdio  la conciencia?  
    1Sí     2 No [Pase a la P 22.2] 
 22.1.1  Si la respuesta fue afirmativa, ¿cuándo empezaron sus síntomas de convulsiones? 
1 Antes de la lesión en la cabeza   
2 Pronto después de la lesión en la cabeza 
3 Mucho tiempo después de la lesión en la cabeza  
4 No recuerdo, no sé 
 22.2  ¿Meningitis (infección cerebral) durante la infancia?   
   1 Sí     2 No  
  22.2.1  Si la respuesta fue afirmativa, ¿cuándo empezaron sus síntomas de convulsiones?
 1 Antes de la meningitis    
   2 Pronto después de la meningitis 
 3 Mucho tiempo después de la meningitis    
 4 No recuerdo, no sé 
23 ¿Qué le pasa cuando tiene una convulsión o un ataque? ________________ 
24 ¿Alguna vez se ha lastimado cuando pierde la conciencia o durante una convulsión? 
1 Sí    2 No 
3 No pierdo la conciencia ni tengo convulsiones [Pase a la P 25] 
4 No recuerdo [Pase a la P 25]  
 24.1 Si la respuesta fue afirmativa, ¿cómo se lastimó? 
1 Caí en el fuego  2 Caí al agua 
3 Me caí de la bicicleta 4 Me caí mientras caminaba en la calle 
5 Me corté   6 Otro [Especifique] _____________________ 
25 ¿Hay alguien en su hogar que tenga epilepsia o convulsiones?     
1 Sí, actualmente  2 Sí, el año pasado pero ahora no 
3 Sí, hace como un año o más, pero no ahora   4 No   
25.1  (Si la respuesta fue sí) ¿Quién tiene epilepsia o convulsiones en su hogar? [Marque 
todas las que se apliquen] 
 1 Madre      2 Padre 
3 Hermano / hermana    4 Hijo (cuántos) ________ 
5 Otro pariente (cuántos) __________  6 Otro [Especifique] ____ 
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(Entrevistador: Lea la siguiente declaración) 
Ahora voy a hacerle unas preguntas sobre sus tratamientos para [diga el nombre del 
síntoma o condición que dijeron tener en la pregunta 21.1-21.6] 
 
26 ¿Alguna vez ha consultado a un proveedor de atención médica (médico, neurólogo, 
enfermera,  herbolario, curandero, psiquiatra o psicólogo) por esta condición? 
2 No [Pase a la P 27]    3 No recuerdo [Pase a la P 27] 
1 Sí 
26.2 ¿Cuándo fue la última vez que consultó a un proveedor de atención médica por su 
condición? 
1 El mes pasado   2 El año pasado 
3 Hace de 1 (uno) a 5 (cinco) años 4 Hace más de 5 (cinco) años 
5 No recuerdo, no estoy seguro 
26.3 ¿Qué tipo de proveedor o proveedores de atención médica consultó y cuántas veces en 
los últimos 5 años? [marque varias casillas, según sea el caso] 
1 Un médico /_____ veces (26311)    2 Un neurólogo /______ veces (26322) 
3 Una enfermera/____ veces (26331)      4 Un herbolario /___ veces (26341) 
5  Un curandero /_____ veces (26351)    
6 Un psiquiatra / psicólogo / __ veces (26361) 
7 Otro (Especifique __________________________)/________ veces (26371) 
8 No recuerdo, no estoy seguro 
26.4 ¿Cuánto le costó cada vez que consultó a un proveedor de atención médica [Especifique 
la forma de pago]? 
1 Un médico/ (26411)___________    2 Un neurólogo/(26421)________ 
3 Una enfermera / (26431) ____________4 Un herbolario ______________ 
5 Un curandero /(26451) 
6 Un psiquiatra / psicólogo /(26461) _____________________   
7 Otro (Especifique ________________)(26471) ______________________ 
8 No recuerdo, no estoy seguro 
8 Nunca pago porque el gobierno cubre mis gastos médicos 
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26.5 ¿A qué distancia está el proveedor de salud de su casa y cómo llegó allí? (anote si fue: a 
pie 1, en bicicleta 2, en autobús 3, por tren 4, en taxi 5, en coche 6, otro 7) 
1 Médico a / ___ km  y llegué ___  
2 Neurólogo a ____ km y llegué___ 
3 Enfermera a ____ km y llegué__  
4 Herbolario a ____ km y llegué____ 
5 Curandero a _____ km y llegué______ 
6 Psiquiatra / psicólogo _____ km y llegué______ 
7 Otro (Especifique ____________________) a _____ km y llegué_________ 
  8 No recuerdo  
27 ¿Alguna vez ha sido hospitalizado por esta condición? 
2 No [Pase a la P 28]  3 No recuerdo [Pase a la P 28] 1 Sí 
27.2  ¿Cuántas veces lo han hospitalizado en los últimos 5 años?   _________veces 
27.3 ¿Cuándo fue su última hospitalización? ________________(meses)    
27.3.1 ¿Cuántos días se quedó en el hospital? ____________________ (días) 
27.3.2 ¿Cuánto le costó (Especifique la unidad monetaria) __________________ 
27.3.3 ¿A qué distancia está el hospital de su casa? ____________________ km 
27.3.4 ¿Cómo llegó al hospital?  
1 A pie            2 En bicicleta       3 En autobús  4 En taxi 
5 En coche   6 Por tren           7 Otro [Especifique] _____________ 
28. ¿Alguna vez le han hecho exámenes médicos por esta condición? 
2 No [Pase a la P 29]  3 No recuerdo, no sé [Pase a la P 29] 1 Sí 
28.2 ¿Qué tipo de examen fue (marque todas las casillas que se apliquen)? 
1 Examen de sangre para cisticercosis 2 Tomografía del cerebro 
3 Rayos X del cerebro  4 Resonancia magnética del cerebro 
5 Electroencefalograma (EEG) 6 Otro [Especifique] ________________ 
7 No recuerdo, no estoy seguro 
28.3 ¿Cuándo se le hizo el último examen médico para esta condición? 
1 El mes pasado   2 El año pasado 
3 Hace de 1  a 5 años  4 Hace más de 5  años 
5 No recuerdo, no estoy seguro 
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28.4 ¿Cuánto le costó cada examen [Especifique la unidad monetaria]? 
1 Examen de sangre para cisticercosis_______    
2 Tomografía del cerebro __________ 
3 Rayos X del cráneo __________    
 4 Resonancia magnética del cerebro __________ 
5 Electroencefalograma ______________  
6 Otro [Especifique] _____________ 
7 No recuerdo, no estoy seguro 
28.5 ¿Qué distancia tuvo que recorrer desde su casa para hacerse este examen y cómo llegó 
allí? (anote 1 a pie, 2 en bicicleta, 3 en autobús, 4 por tren, 5 en taxi, 6 en coche, 7 otro)? 
1 Examen de sangre para cisticercosis a _____ km y llegué______  
2 Tomografía a _____ km y llegué______ 
3 Rayos X a _____ km y llegué________ 
4 Resonancia magnética a ______ km y llegué_______  
5 Electroencefalograma a _____ km y llegué________ 
6 Otro (Especifique ___________________) a _____ km y llegué_________ 
7 No recuerdo, no estoy seguro 
29. ¿Alguna vez lo han tratado por esta condición? 
2 No (se termina la entrevista)  
3 No recuerdo, no sé (se termina la entrevista) 
1 Sí 
29.2 ¿Cuándo fue la última vez que usó medicamentos para su condición? 
1 El mes pasado  2 El año pasado 
3 Hace de 1 a 5 años 4 Hace más de 5 años 
5 No recuerdo, no estoy seguro  
29.3 ¿Qué medicamento usó y cuántas veces ha usado algún medicamento en el último año 
(marque varias casillas, según sea el caso)?  
1 Carbamazepina/Tegretol____ veces  
2 Fenitoína/Dihydan______ veces 
3 Ácido valpróico/Dépakin________ veces  
4 Fenobarbital/Gardénal _______veces 
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5   Medicina tradicional ________ veces    
6 Otro (Especifique _________) ___veces 
7 No recuerdo, no estoy seguro 
29.4 ¿Cuánto pagó cada vez que compró este medicamento (Especifique la unidad monetaria 
usada)? 
1 Carbamazepina/Tegretol ______  2 Fenitoína/Dihydan __________ 
3 Ácido valpróico/Dépakin ________       4 Fenobarbital/Gardénal _______ 
5 Medicina tradicional ______________  
6 La recibí gratis del proveedor de atención médica (No la pagué yo) _____  
7 Otro (Especifique ___________________________________) _____  
8 No recuerdo, no estoy seguro 
 
ÉSTE ES EL FINAL DE LA ENTREVISTA 
MUCHAS GRACIAS POR SU COOPERACIÓN 
 
ENTREVISTADOR: _____________________ FECHA DE LA ENTREVISTA____________ 
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APPENDIX C 
 
Neurocysticercosis Health Study (intake form) 
 
Individual ID   
 
Abstractor ID   
 
Hospital/Clinic ID 
 
Today’s Date   
                        ( d    d    m   m   y    y ) 
 
Date of Birth  
                        ( d   d    m  m    y    y  ) 
 
Gender:          (male)            (female) 
 
State of Residence:       (Mexico City)               (Mexico State)                (Michoacan)                 
(Guerrero)  
                                      (Morelos)                     (Other_______________) 
 
Village of Residence __________________________   
 
Postal Code  
 
Highest Education Level Completed:    None       Elementary school 
      High school      Some college 
      Technical degree       Graduate degree   
      University degree    
 
Insurance Type:      (IMSS)       (SSA)       (no insurance)      ( ISTEE)      (Not reported/unknown) 
 
Payment Classification: (for SSA)                  (levels 0 - 6) 
 
NCC/seizure-associated reason(s) for today’s visit. Follow-up for: (check all that apply) 
1. Epilepsy (>1 afebrile seizure not associated with an acute CNS process)    
2. Acute symptomatic seizures                                                                       
3. Single seizure                                                                                     
4. Dementia                                                                                                        
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5. Hydrocephalus                                                  
6. Vasculitis/stroke          
7. Increased intracranial pressure       
8. Severe headaches lasting more than 3 days      
9. Other ___________________________       
        
Medical History: 
 
HIV Status:          Positive      Negative     Not reported / unknown 
 
AIDS Status:       Positive      Negative     Not reported / unknown  
 Has the patient ever been diagnosed with any of the following? (check all that apply)                                                                
                                                                                              
              If yes, date of 1
st
 diagnosis      Information 
Source 
 
        (d     d      m   m    y      y)    
                                                                                                                                
1. Epilepsy                                                                        History      File     
 Other record 
  
2. Acute symptomatic seizures                                             History      File     
 Other record 
 
3. Single seizure                                                              History      File     
 Other record 
 
4. Dementia                                                        History      File     
 Other record 
                                                                                                                                                                               
5. Hydrocephalus                                                                  History      File     
 Other record                                        
 
6. Vasculitis/stroke                                                                     History      File     
 Other record                                         
 
7. Increased intracranial pressure                                     History      File     
 Other record                            
 
8. Severe headaches (>3 days)                                                 History      File     
 Other record                                             
Seizure types: (check all that apply) 
1. Atonic            
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2. Absence           
3. Tonic/clonic         
4. Myoclonic         
5. Simple partial         
6. Complex partial         
7. Partial seizures with secondary generalization    
8. Other type_________________________     
9. Type not specified         
10. Never had seizures          
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APPENDIX D 
 
Neurocysticercosis Health Study (clinic visit/hospitalization form) 
 
 
Individual ID   
 
Abstractor ID   
 
Hospital/Clinic ID  
 
Today’s Date   
                        ( d    d    m   m   y    y ) 
 
 
Diagnostic testing record (2002-present): (list oldest to most recent) 
Test Date 
(dd/mm/yy) 
Findings 
(list for each test performed) 
Testing Location 
(name of hospital or 
clinic) 
EITB  (1=neg, 2=pos, 9=NR)  
1.    
2.    
3.    
    
Ag-ELISA  (1=neg, 2=trace, 3= +, 4= ++, 
9=NR) 
 
1.    
2.    
3.    
    
Ab-ELISA  (1=neg, 2=trace, 3= +, 4= ++, 
9=NR) 
 
1.    
2.    
3.    
    
CSF study  (1=normal, 2=T. solium cysticerci 
Ab pos, 3=other abnormal, 9=NR) 
 
1.    
2.    
3.    
    
EEG  (1=normal, 2=abnormal, 9=NR)  
1.    
2.    
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3.    
    
Skull x-rays  (1=normal, 2=calcifications, 
3=other abnormal, 9=NR) 
 
1.    
2.    
3.    
    
Neurological exam  (1=normal, 2=abnormal, 9=NR)  
1.    
2.    
3.    
4.    
5.    
    
Examination for 
subcutaneous nodules  
 (1=present, 2=absent, 9=NR)  
1.    
2.    
3.    
    
Subcutaneous nodule 
biopsy 
 (1=normal, 2=cysticerci,  
3=other abnormal, 9=NR) 
 
1.    
2.    
    
CT  (list primary findings)  
1.    
2.    
3.    
    
MRI  (list primary findings)  
1.    
2.    
3.    
    
Dementia evaluation 
(list testing method) 
 (1=normal, 2=abnormal, 9=NR)  
1.    
2.    
3.    
    
Other 
______________ 
 (1=normal, 2=abnormal, 9=NR)  
1.    
2.    
3.    
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Medications (2002-present) (re-list medication if dosage changes) 
Name of 
medication 
Dosage 
(units) 
Times/day Start date 
(dd/mm/yy) 
Stop date 
(dd/mm/yy) 
Reason for stop/change 
1.      
2.      
3.      
4.      
5.      
6.      
7.      
8.      
9.      
10.      
Continue list on extra medication form 
 
NCC-related surgery record (2002-present) (list oldest to most recent): 
Type of Surgery Surgery date 
(dd/mm/yy) 
Hospital where surgery was performed 
1.   
2.   
3.   
4.   
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Individual ID    
         Abstractor ID   
         Hospital ID   
 
INPATIENT ADMISSIONS RECORD (2002-present): (Use a separate sheet for each 
admission) 
 
Admission number (number sequentially from oldest to most recent) ______  
 
Admission Date                                                     Discharge Date       
                               ( d   d    m  m    y    y  )                                         ( d   d    m  m   y    y) 
                          
Type of room:          (private)       (2 beds)       (3 beds)        (other__________) 
 
 
Admitting hospital:        (INNN)        (IMSS)          (INNN pediatric)         (IMSS pediatric) 
                                               (SSA hospital-Uruapan)        (Other_________) 
 
Services consulted during this admission: (check all that apply) 
1. Neurology       
2. Cardiology     
3. Oncology     
4. Infectious disease    
5. Psychiatry     
6. General/Internal medicine   
7. Other_________    
 
Karnofsky score at admission    
(999 = not reported) 
 
 
Reason for this admission: (check all NCC/seizure-associated conditions that apply) 
10. Epilepsy (>1 afebrile seizure not associated with an acute CNS process)  
11. Acute symptomatic seizures        
12. Single seizure           
  
13. Dementia          
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14. Hydrocephalus           
15. Vasculitis/stroke          
16. Increased intracranial pressure       
17. Severe headaches lasting more than 3 days      
18. Other ___________________________       
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         Individual ID    
         Abstractor ID   
         Clinic ID   
OUTPATIENT RECORD (2002-present): (Use a separate sheet for each outpatient visit) 
 
Outpatient visit number (number sequentially from oldest to most recent) _____  
 
Date of outpatient visit   
                                        ( d   d    m  m    y    y  ) 
 
Hospital/clinic visited:      (INNN)          (IMSS)              (INNN pediatric)          (IMSS pediatric) 
 
                                                  (SSA hospital- Uruapan)              (Other_________) 
 
Services consulted: (check all that apply) 
1. Neurology      
2. Cardiology    
3. Oncology    
4. Infectious disease   
5. Psychiatry    
6. General/Internal medicine  
7. Other_________   
 
Reason for this visit: (check all NCC/seizure-related conditions that apply) 
 
1. Epilepsy (>1 afebrile seizure not associated with an acute CNS process)  
2. Acute symptomatic seizures        
3. Single seizure          
4. Dementia          
5. Hydrocephalus          
6. Vasculitis/stroke          
7. Increased intracranial pressure       
8. Severe headaches lasting more than 3 days      
9. Other ___________________________       
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APPENDIX E 
 
Estudio de neurocisticercosis (NCC) 
Formato para registro de la primera vez que se diagnosticó NCC 
 
No. Expediente 
 
Identificación del encuestador 
 
Hospital/Clínica:   (INNN)             (CMNSXXI)              (INPed)               (SSA Uruapan)  
                              (Otro)  (Nombre:_______________________________________________________) 
 
Fecha de hoy  
                        ( d    d    m   m   a    a ) 
 
Fecha de nacimiento  
                                    ( d   d    m   m    a    a  ) 
 
Género:          (hombre)            (mujer) 
 
Estado de residencia:       (México DF)               (Estado de México)                (Michoacán)                 
(Guerrero)  
                                         (Morelos)                   (Otro) (especifique_______________________) 
 
Comunidad o ciudad de residencia __________________________________________ 
 
Código Postal 
 
Nivel de estudios concluido      Ninguno       Primaria 
      Secundaria      Preparatoria 
      Escuela técnica      Licenciatura 
      Posgrado 
 
Tipo de seguro médico:      (Popular)       (IMSS)       (ISSSTE)      (no asegurado)      (no sabe) 
                                            (Privado)  (Nombre:______________________)      (Otro) 
(Nombre:__________________) 
 
Nivel de cuota de recuperación en la SSA: (0 a 6) 
 
Visita de hoy debida a NCC/convulsiones. Causa de seguimiento: (marcar las necesarias) 
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19. Epilepsia (>1 convulsión no febril y no asociada a un proceso agudo del SNC)  
20. Convulsiones agudas sintomáticas       
21. Convulsión única          
22. Demencia          
23. Hidrocefalia          
24. Vasculitis                                                                                                         
25. EVC          
26. Hipertensión intracraneana        
27. Cefalea grave con duración mayor a 3 días      
28. Otra causa, especifique_________________________________________  
 
Historia Médica: 
VIH:          Positivo      Negativo     No reportado / desconocido 
 
SIDA:        Positivo      Negativo     No reportado / desconocido 
 
El paciente ha sido diagnosticado alguna vez con: (marcar las necesarias) 
 
            En caso afirmativo, fecha del Dx           Fuente de 
información 
       (d     d      m   m    a      a)    
   
9. Epilepsia         Historia    
Archivo    Otra        
 especifique_________________ 
 
10. Convulsiones agudas sintomáticas      Historia    
Archivo    Otra        
 especifique_________________ 
 
11. Convulsión única          Historia    
Archivo    Otra        
 especifique_________________ 
 
12. Demencia         Historia    
Archivo    Otra        
 especifique_________________ 
 
13. Hidrocefalia         Historia    
Archivo    Otra        
 especifique_________________ 
 
14. Vasculitis                                                                                          Historia    
Archivo    Otra        
 especifique_________________ 
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15. EVC         Historia    
Archivo    Otra        
 especifique_________________ 
 
16. Hipertensión intracraneana       Historia    
Archivo    Otra        
 especifique_________________ 
 
17. Cefalea grave (>3 días)       Historia    
Archivo    Otra        
 especifique_________________ 
 
Tipo de convulsiones: (marcar las necesarias) 
11. Atónica       
12. Ausencias       
13. Tónico/clónica       
14. Mioclónica       
15. Parcial simple       
16. Parcial compleja       
17. Convulsión parcial con generalización secundaria  
18. Otro tipo, especifique______________________  
19. Tipo no especificado       
20. Nunca ha tenido convulsiones    
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APPENDIX F 
 
Estudio de neurocisticercosis (NCC) 
Formato para Dx y Tx en consulta externa o eu hositalización 
 
No. Expediente 
 
Identificación del encuestador 
 
Hospital/Clínica:  (INNN)             (CMNSXXI)              (INPed)               (SSA Uruapan)  
                             (Otro)  (Nombre:_______________________________________________________) 
 
Fecha de hoy 
                        ( d    d    m   m   a    a ) 
 
Registros de pruebas diagnósticas (del 2002 a la fecha de hoy): (enlistar de la más vieja a la 
más nueva, si requiere mas espacio utilice otra hoja) 
Prueba Fecha 
(dd/mm/aa) 
Hallazgos 
(enlistar para cada prueba 
realizada) 
Sitio en donde se 
realizó la prueba 
(nombre del hospital, 
clínica o laboratorio) 
Estudio del líquido 
cefalorraquídeo 
 (1=normal, 2= positivo a 
anticuerpos contra el cisticerco 
de T. solium, 3=otro dato 
anormal, 9=NR) 
 
1.    
2.    
3.    
Electroencefalograma  (1=normal, 2=anormal, 9=NR)  
1.    
2.    
3.    
Rayos X simples de 
cráneo 
 (1=normal, 2=calcificaciones, 
3=otro dato anormal, 9=NR) 
 
1.    
2.    
3.    
Examen neurológico  (1=normal, 2=anormal, 9=NR)  
1.    
2.    
3.    
4.    
5.    
Tomografía computada  (enliste hallazgos primarios)  
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1.    
2.    
3.    
Resonancia magnética  (enliste hallazgos primarios)  
1.    
2.    
3.    
Evaluación de demencia  
(enliste método de 
estudio) 
 (1=normal, 2=anormal, 9=NR)  
1.    
2.    
3.    
4.    
5.    
Otro ______________  (1=normal, 2=anormal, 9=NR)  
1.    
2.    
3.    
EITB o Western Blot 
para cisticercosis  
 (1=neg, 2=pos, 9=NR)  
1.    
2.    
3.    
ELISA para anticuerpos  (1=neg, 2=dudoso, 3= +, 4= ++, 
9=NR) 
 
1.    
2.    
3.    
Búsqueda de nódulos 
subcutáneos  
 (1=presentes, 2=ausentes, 9=NR)  
1.    
2.    
3.    
Biopsia de nódulos 
subcutáneos  
 (1=normal, 2=con cisticercos,  
3=otro dato anormal, 9=NR) 
 
1.    
2.    
3.    
 
Medicinas tomadas (del 2002 a la fecha de hoy): (enlistar de la más vieja a la más nueva, si 
requiere mas espacio utilice otra hoja y vuelva a anotar si cambió la dosis de la medicina) 
Nombre de la 
medicina 
Dosis (en 
unidades) 
Veces/día Fecha de 
inicio 
(dd/mm/aa) 
Fecha de 
conclusión 
(dd/mm/aa) 
Razón por la que se 
concluyó o cambio el 
medicamento 
1.      
2.      
3.      
4.      
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5.      
6.      
7.      
8.      
9.      
10.      
11.      
12.      
 
Registro de neurocirugías para NCC  (del 2002 a la fecha de hoy): (enlistar de la más vieja a 
la más nueva, si requiere mas espacio utilice otra hoja) 
Tipo de cirugía Fecha de la 
cirugía 
(dd/mm/aa) 
Hospital en donde se realizó la cirugía 
1.   
2.   
3.   
4.   
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Estudio de neurocisticercosis (NCC) 
Formato para costeo de hospitalización 
 
No. Expediente 
 
Identificación del encuestador 
 
Hospital/Clínica   (INNN)             (CMNSXXI)              (INPed)               (SSA Uruapan)  
                             (Otro)   (Nombre:_________________________________________________________) 
 
Fecha de hoy 
                        ( d    d    m   m   a    a ) 
 
REGISTRO DE HOSPITALIZACIONES (del 2002 a la fecha de hoy): (Use una hoja 
separada para cada admisión) 
 
Número de la admisión (número secuencial de la admisión más vieja a la más nueva) _________ 
 
Fecha de ingreso                                                         Fecha de alta 
                               ( d   d   m   m    a    a )                                          ( d    d    m   m    a    a ) 
                          
Tipo de habitación:          (privada)       (2 camas)       (3 camas)        
(otro______________________) 
 
Hospital:        (SSA)        (IMSS)          (ISSSTE)         (Privado)       
           (Nombre:_________________________________________________________) 
 
Servicios consultados durante la admisión (marcar las necesarias) 
8. Neurología     
9. Cardiología     
10. Oncología     
11. Infectología     
12. Psiquiatría     
13. Medicina general/Interna   
14. Otros (especifique)    
____________________________________________ 
 
 
Calificación de Karnofsky en la admisión  
 
Causa de esta admisión (marcar todas las condiciones asociadas a NCC/convulsiones que se 
apliquen) 
 
29. Epilepsia (>1 convulsión no febril y no asociada a un proceso agudo del SNC)  
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30. Convulsiones agudas sintomáticas        
31. Convulsión única           
32. Demencia           
33. Hidrocefalia           
34. Vasculitis                                                                                                                     
35. EVC           
36. Hipertensión intracraneana         
37. Cefalea grave con duración mayor a 3 días       
38. Otra causa, especifique______________________________________________  
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Estudio de neurocisticercosis (NCC) 
Formato para costeo de consulta externa  
 
Identificación del encuestado 
 
Identificación del encuestador 
 
Hospital/Clínica:  (INNN)             (CMNSXXI)              (INPed)               (SSA Uruapan)  
                             (Otro)   (Nombre:_________________________________________________________) 
 
REGISTRO DE PACIENTE DE CONSULTA EXTERNA (del 2002 a la fecha de hoy) (Use 
una hoja separada para cada consulta externa) 
 
Fecha de consulta externa                                      
                                          ( d   d    m   m    a    a  ) 
 
Hospital o clínica visitada       (SSA)        (IMSS)          (ISSSTE)         (Privado)       
           (Nombre:_________________________________________________________) 
 
Número de la consulta externa (número secuencial de la consulta más vieja a la más nueva) 
______  
 
Servicios consultados (marcar las necesarias) 
1. Neurología     
2. Cardiología     
3. Oncología     
4. Infectología     
5. Psiquiatría     
6. Medicina general/Interna   
7. Otros, especifique______________  
 
Causa de la visita de seguimiento de hoy (marcar todas las condiciones asociadas a 
NCC/convulsiones que se apliquen) 
 
10. Epilepsia (>1 convulsión no febril y no asociada a un proceso agudo del SNC)  
11. Convulsiones agudas sintomáticas        
12. Convulsión única           
13. Demencia           
14. Hidrocefalia           
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15. Vasculitis                                                                                                                     
16. EVC           
17. Hipertensión intracraneana         
18. Cefalea grave con duración mayor a 3 días       
19. Otra causa, especifique______________________________________________  
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APPENDIX G 
 
 
Date: ______________________ 
 
Name of Respondent: _________________ 
 
Organization/Hospital of Respondent: ______________________ 
 
 
 
Cysticercosis in Mexico  
 
Questions for Michoacan Ministry of Health (or other Ministry of Health in an endemic 
region) 
 
For the questions below, please fill in the blank or circle your response.  
 
1. In rural areas, what proportion of epilepsy patients do you believe consult a traditional healer 
before consulting a physician? ________%  I DON’T KNOW 
 
 
2. Do you believe that some epilepsy patients that seek treatment by a traditional healer never 
see a doctor?  YES   NO    I DON’T KNOW 
 
a. If yes, what proportion of epilepsy patients do you think sees a traditional healer 
without ever consulting a modern doctor? ________%  I DON’T KNOW 
 
 
3. In rural areas, what proportion of severe chronic headaches patients do you believe consult a 
traditional healer before consulting  a physician?________%   I DON’T KNOW 
 
 
4. Do you believe that some patients with severe chronic headaches that seek treatment by a 
traditional healer never see a doctor?      YES   NO   I DON’T KNOW 
 
a. If yes, what proportion of patients with severe chronic headaches do you think sees a 
traditional healer without ever consulting a modern doctor? _______%       I DON’T 
KNOW 
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5. How much does a traditional healer typically charge to treat epilepsy? (The answer may 
include non-monetary payments such as a chickens, eggs, or services.) 
 
Monetary payment: ____________________________ 
 
Non-monetary payments: ___________________________________ 
 
I DON’T KNOW 
6. How much does a traditional healer typically charge to treat severe chronic headaches? (The 
answer may include non-monetary payments such as a chickens, eggs, or services) 
 
Monetary payment: ____________________________ 
 
Non-monetary payments: ___________________________________ 
 
I DON’T KNOW 
 
 
7. How many days of work (or school) do you think a person with untreated severe chronic 
headaches misses every month (you can provide a range of values)? ______________      
I DON’T KNOW 
 
 
8. How many days of work (or school) do you think a person with untreated epilepsy misses 
every month (you can provide a range of values)? ______________________  I DON’T 
KNOW 
 
 
9. What proportion of epilepsy cases do you believe is currently not receiving any treatment for 
their seizures?  
Between 0 and 10% Between 11% and 20% Between 21% and 30% 
 
Other:  ____________ I DON’T KNOW 
 
 
10. What proportion of severe chronic headaches cases do you believe is currently not receiving 
any treatment for their headaches?  
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Between 0 and 10% Between 11% and 20% Between 21% and 30%  
 
Other:  ____________ I DON’T KNOW 
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Date: ______________________ 
 
Name of Respondent: _________________ 
 
Organization/Hospital of Respondent: ______________________ 
 
 
 
Cysticercosis in Mexico  
 
Questions for physicians at a primary care clinic (preferably from a rural area where NCC is 
endemic) 
 
For the questions below, please fill in the blank or circle your response.  
 
1. What proportion of your patients with epilepsy consulted a traditional healer before coming 
to you? _________%  I DON’T KNOW 
 
 
2. Do you believe that some epilepsy patients that seek treatment by a traditional healer never 
see a doctor?  YES   NO   I DON’T KNOW 
 
a. If yes, what proportion of epilepsy patients do you think see traditional healers 
without ever consulting a modern doctor? _________%  I DON’T KNOW 
 
 
3. What proportion of your patients with severe chronic headaches consulted a traditional healer 
before coming to you?_________%  I DON’T KNOW 
 
 
4. Do you believe that some patients with severe chronic headaches that seek treatment by a 
traditional healer never see a doctor?       YES   NO   I DON’T KNOW 
 
a. If yes, what proportion of patients with severe chronic headaches do you think see 
traditional healers without ever consulting a modern doctor? _________% 
 I DON’T KNOW 
 
 
5. How much does a traditional healer typically charge to treat epilepsy? (The answer may 
include non-monetary payments such as a chickens, eggs, or services.) 
 
Monetary payment: ____________________________ 
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Non-monetary payments: ___________________________________ 
 
I DON’T KNOW 
6. How much does a traditional healer typically charge to treat severe chronic headaches? (The 
answer may include non-monetary payments such as a chickens, eggs, or services.) 
 
Monetary payment: ____________________________ 
 
Non-monetary payments: ___________________________________ 
 
I DON’T KNOW 
 
 
7. What proportion of epilepsy patients seeks medical attention at a primary care clinic?  
___________%     I DON’T KNOW 
 
 
8. What proportion of your patients with epilepsy is referred to a secondary care provider (for 
example, a neurologist)? _________%   I DON’T KNOW 
 
 
9. What proportion of your patients with epilepsy is referred directly to a tertiary care hospital?  
__________%   I DON’T KNOW 
 
 
10. What proportion of patients with epilepsy that seek treatment at your clinic is hospitalized at 
your clinic? _________%    I DON’T KNOW      THERE ARE NO HOSPITAL BEDS IN 
THIS CLINIC 
 
 
11. What are the principal drugs provided to/used by patients with epilepsy who are seen at your 
clinic? If possible, please include dosages. 
 
Prescribed drugs: 
Drug: _______________________ Dosage: ______________________________ 
Drug: _______________________ Dosage: ______________________________ 
Drug: _______________________ Dosage: ______________________________ 
 
Over the counter drugs: 
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Drug: _______________________ Dosage: ______________________________ 
Drug: _______________________ Dosage: ______________________________ 
Drug: _______________________ Dosage: ______________________________ 
 
 
12. How many times per year do you think patients with epilepsy consult medical doctors at a 
primary care clinic? _______________  I DON’T KNOW 
 
 
13. What proportion of patients with severe chronic headaches seeks medical attention at a 
primary care clinic? ________%          I DON’T KNOW 
 
 
14. What proportion of your patients with severe chronic headaches is referred to a secondary 
care provider (for example, a neurologist)? __________%     I DON’T KNOW 
 
 
15. What proportion of your patients with severe chronic headaches is referred directly to a 
tertiary care hospital? _________%    I DON’T KNOW 
 
 
16. What proportion of patients with severe chronic headaches that seek treatment at your clinic 
is hospitalized at your clinic? _____%   
 I DON’T KNOW  THERE ARE NO HOSPITAL BEDS IN THIS CLINIC 
 
 
17. What are the principal drugs provided to/used by patients with severe chronic headaches who 
are seen at your clinic? If possible, please include dosages. 
 
Prescribed drugs: 
Drug: _______________________ Dosage: ______________________________ 
Drug: _______________________ Dosage: ______________________________ 
Drug: _______________________ Dosage: ______________________________ 
 
Over the counter drugs: 
Drug: _______________________ Dosage: ______________________________ 
Drug: _______________________ Dosage: ______________________________ 
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Drug: _______________________ Dosage: ______________________________ 
 
 
18. How many times per year do you think patients with severe chronic headaches consult a 
medical doctor at a primary care clinic? _______________ I DON’T KNOW 
 
 
 
19. What tests are available at your clinic for the diagnosis of NCC?  (Circle all that apply)  
None  X-ray  CT-scan MRI  
ELISA test to detect antibodies  EITB test to detect antibodies    
 
 
20. How many days of work (or school) do you think a person treated at your clinic for severe 
chronic headaches misses every month (you can provide a range of values)? ____________  I 
DON’T KNOW 
 
 
21. How many days of work (or school) do you think a person treated at your clinic for epilepsy 
misses every month (you can provide a range of values)? ____________________ I 
DON’T KNOW 
 
 
22. What proportion of patients with epilepsy do you believe is currently not receiving any 
treatment for their seizures?  
 
Between 0 and 10% Between 11% and 20% Between 21% and 30%  
 
Other: _______________  I DON’T KNOW 
 
 
23. What proportion of patients with severe chronic headaches do you believe is currently not 
receiving any treatment for their headaches?  
 
Between 0 and 10% Between 11% and 20% Between 21% and 30% 
 
Other: ________________ I DON’T KNOW 
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Date: ______________________ 
 
Name of Respondent: _________________ 
 
Organization/Hospital of Respondent: ______________________ 
 
 
 
Cysticercosis in Mexico  
 
Questions for physicians at a secondary care clinic (for example, neurologists) 
 
For the questions below, please fill in the blank or circle your response.  
 
1. What proportion of epilepsy patients seeks medical attention at your clinic without 
previously consulting with a primary care provider? _________%        I DON’T KNOW 
 
 
2. What proportion of your epilepsy patients is referred to you by a primary care physician? 
_________%    I DON’T KNOW 
 
 
3. What proportion of your epilepsy patients do you refer to a tertiary care hospital?  
_________%   I DON’T KNOW 
 
 
4. What proportion of your patients with epilepsy is hospitalized at your facility? _____%  
I DON’T KNOW  THERE ARE NO HOSPITAL BEDS IN THIS CLINIC 
 
 
5. What are the principal drugs provided to/used by your epilepsy patients? Please provide 
dosages if available.  
 
Prescribed drugs: 
Drug: _______________________ Dosage: ______________________________ 
Drug: _______________________ Dosage: ______________________________ 
Drug: _______________________ Dosage: ______________________________ 
 
Over the counter drugs: 
Drug: _______________________ Dosage: ______________________________ 
Drug: _______________________ Dosage: ______________________________ 
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Drug: _______________________ Dosage: ______________________________ 
 
6. What are the principal drugs prescribed for your patients with NCC-associated epilepsy? 
Please provide dosages if available. 
 
Prescribed drugs: 
Drug: _______________________ Dosage: ______________________________ 
Drug: _______________________ Dosage: ______________________________ 
Drug: _______________________ Dosage: ______________________________ 
 
 
7. How many times per year do you think patients with epilepsy consult a medical doctor at a 
secondary care clinic?  _______________  I DON’T KNOW 
 
 
8. What proportion of patients with severe chronic headaches seeks medical attention at your 
clinic without previously consulting with a primary care provider? ___________%  I 
DON’T KNOW 
 
 
9. What proportion of your patients with severe chronic headaches is referred to you by a 
primary care physician? __________%   I DON’T KNOW 
 
 
10. What proportion of your patients with severe chronic headaches do you refer to a tertiary 
care hospital? ___________%   I DON’T KNOW 
 
 
11. What proportion of your patients with severe chronic headaches is hospitalized at your 
facility? ___________%   I DON’T KNOW THERE ARE NO HOSPITAL BEDS IN 
THIS CLINIC 
 
 
12. What are the principal drugs provided to/used by your patients with severe chronic 
headaches? Please provide dosages if available.  
 
Prescribed drugs: 
Drug: _______________________ Dosage: ______________________________ 
Drug: _______________________ Dosage: ______________________________ 
 169 
 
 
Drug: _______________________ Dosage: ______________________________ 
 
Over the counter drugs: 
Drug: _______________________ Dosage: ______________________________ 
Drug: _______________________ Dosage: ______________________________ 
Drug: _______________________ Dosage: ______________________________ 
13. What are the principal drugs prescribed for your patients with NCC-associated severe chronic 
headaches? Please provide dosages if available. 
 
Prescribed drugs: 
Drug: _______________________ Dosage: ______________________________ 
Drug: _______________________ Dosage: ______________________________ 
Drug: _______________________ Dosage: ______________________________ 
 
 
14. How many times per year do you think patients with severe chronic headaches consult a 
medical doctor at a secondary care clinic?  ___________  I DON’T KNOW 
 
 
15. What tests are available at your clinic for the diagnosis of?  
None  X-ray  CT-scan MRI  
ELISA test to detect antibodies  EITB test to detect antibodies    
 
 
16. How many days of work (or school) do you think a person treated at your hospital for severe 
chronic headaches misses every month (you can provide a range of values)?  
______________   I DON’T KNOW 
 
 
17. How many days of work (or school) do you think a person treated at your hospital for 
epilepsy misses every month (you can provide a range of values)? _________________
 I DON’T KNOW 
 
 
18. What proportion of patients with epilepsy do you believe is currently not receiving any 
treatment for their seizures?  
 
Between 0 and 10% Between 11% and 20% Between 21% and 30%  
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Other: _______________  I DON’T KNOW 
 
 
19. What proportion of patients with severe chronic headaches do you believe is currently not 
receiving any treatment for their headaches?  
 
Between 0 and 10% Between 11% and 20% Between 21% and 30% 
 
Other: ________________ I DON’T KNOW 
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